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Summary 
The human Hepatitis B virus (HBV) is a small hepatotropic DNA virus, which consists of a 
nucleocapsid and an envelope with three membrane-embedded surface proteins (large (L), 
middle (M), and small (S)). While the S protein is required for budding and is the major 
component of the envelope, the L protein is crucial for infectivity. Several infectivity 
determinants have previously been described: (i) The N-terminal myristic acid moiety together 
with aa 2-48 are indispensable for virus infectivity and specifically bind a yet unknown receptor. 
Consistent with this, a peptide HBVpreS/2-48myr, composed of a myristoyl group and the N-
terminal 47 residues of the L protein, inhibits HBV entry at picomolar concentrations. (ii) Amino 
acids 49-78 and the first transmembrane domain of the L protein are also required for virus 
infectivity. However, their function is not clear. (iii) Recently, it has been shown that the S-
domain, which is common to all three surface proteins, also contains an infectivity determinant 
in its antigenic loop. Currently, it is not fully understood how the virion orchestrates these 
infectivity determinants during entry process and how exactly the preS-derived peptide 
HBVpreS/2-48myr interferes with virus entry. The major obstacle, restricting such investigations 
for a long time, was the lack of easily accessible in vitro infection systems. A recently established 
human hepatoma cell line (HepaRG), susceptible for HBV infection upon differentiation in vitro, 
resolved this issue and allowed us to analyze the role of the HBV envelope proteins in virus 
entry. 
In the present work, several approaches were undertaken: (i) systematic optimization of HepaRG 
cells for HBV infection, (ii) establishment of a reverse genetics approach that allows production 
of virions with mutated envelope proteins, (iii) an extensive mutation analysis within the L and S 
protein to determine viral assembly and infectivity, (iv) infection-competition study using preS-
derived peptides, and (v) design of membrane-anchored inhibitory peptides by replacing the 
myristoyl group with a type II transmembrane protein.  
With an optimized infection assay, over 30% of differentiated HepaRG cells could be infected. 
The optimized infection assay facilitated further infectivity analyses of HBV virions generated by 
complementation, in which the L and S proteins were separately expressed. The following was 
observed in the present work: (i) Besides acting as a simple myristoylation signal, the N-terminus 
of the L-protein (aa 2-8) bears a more complex function for virus entry, since the substitution 
with heterologous myristoylation motifs abolished virus infectivity. This conclusion is 
strengthened by a complementary approach showing that the inhibitory potential of the peptide 
was also severely reduced when amino acids 2-8 were deleted or substituted. (ii) Expression of a 
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membrane-anchored peptide prevents HepaRG cells from HBV infection, probably due to an 
interference with virus receptor on the plasma membrane. (iii) Amino acids 49-78 of L protein 
do not tolerate insertions and point mutations at their conserved region, and the peptide 
comprising aa 49-78 did neither interfere with HBV infection nor inhibit the antiviral activity of 
HBVpreS/2-48myr. (iv) While the M protein is dispensable for both HBV assembly and 
infectivity, the preS2 domain as an internal domain of the L protein is needed for virion release 
in a length-dependent but sequence-independent manner. Notably, HBV with an L protein 
carrying a mostly scrambled preS2 domain fully supported virion formation and virus infectivity. 
(v) Cysteine mutations in cytosolic loop-I of L protein drastically reduced virus infectivity, 
indicating that a properly formed cytosolic loop-I is also required for HBV entry. (vi) The 
essentiality of the antigenic loops during virus entry is mainly contributed by those in the context 
of S protein, and is correlated with the binding activity of the virion to heparin. 
In summary, this data indicates that the myristoyl chain of the L protein provides an anchor into 
the hepatocyte membrane thereby allowing the subsequent interaction with a hepatocyte-specific 
receptor. The N-terminal amino acids 2-8 of the HBV L protein serve as an adapter between the 
myristoyl moiety and the receptor-binding domain that orients the essential receptor binding site 
into the right position. The preS2 domain is dispensable for the HBV infectivity in vitro. 
However, it acts as a linker within the L-protein during virus assembly. The S protein may 
participate in primary attachment of virion to hepatocytes via the antigenic loop, which is critical 
for virus infectivity. Last but not the least, the membrane-anchored inhibitory peptide presents a 
promising approach to identify the virus receptor and may be used in a gene therapy approach 
against HBV infection. 
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Zusammenfassung 
Das humane Hepatits B Virus (HBV) ist ein kleines hepatotropisches DNA Virus. Es besteht 
aus einem Nukleokapsid und einer Hülle mit drei membran-ständigen Oberflächenproteinen 
(groß (L), mittel (M), und klein (S)). Während das S-Protein Hauptbestandteil der Hülle und für 
das Budding des Virus notwendig ist, ist das L Protein für die Infektiösität entscheidend. 
Verschiedene Infektiösitätsdeterminaten wurden beschrieben: (i) Der N-terminale 
Myristinsäurerest zusammen mit den Aminosäuren 2-48 sind unverzichtbar für die 
Virusinfektiösität und binden spezifisch an einen bis jetzt unbekannten Rezeptor auf 
Hepatozyten. In Übereinstimmung mit diesen Erkenntnissen inhibiert ein HBVpreS/2-48myr 
Peptid, bestehend aus einer Myristolgruppe und den 47 N-terminalen Aminosäuren des L-
Proteins , die Eintritt von HBV bereits in picomolaren Konzentrationen. (ii)Die Aminosäuren 
49-78 und die erste Transmembrandomäne des L-Proteins sind für die Infektiösität des Virus 
ebenfalls essentiell. Der genaue Mechanismus ist jedoch noch nicht geklärt. (iii) Kürzlich wurde 
gezeigt, dass auch das S-Protein, das in allen drei Oberflächenproteinen vorkommt, eine 
Infektiösitätsdeterminate im „antigenic loop“ trägt. Bis heute ist noch nicht vollständig 
verstanden, wie das Virion die verschiedenen Infektiösitätsdeterminaten während des 
Eintrittsprozesses koordiniert und in welcher Weise das HBVpreS/2-48myr Peptid den Eintritt 
des Virus behindert. Das Haupthindernis, das solche Untersuchungen für lange Zeit 
eingeschränkt hat, war das Fehlen eines einfach zugänglichen in vitro Infektionssystems. Eine 
kürzlich etablierte humane Hepatomazelllinie (HepaRG), die nach  Differenzierung in vitro 
suszeptibel für HBV Infektionen wird, hat dieses Problem gelöst und erlaubt es die Rolle der 
HBV Hüllproteine während des Viruseintritts zu analysieren.  
In der vorliegenden Arbeit wurden verschiedene Ansätze unternommen: (i) Die systematische 
Optimierung von HepaRG Zellen für HBV Infektion, (ii) Die Etablierung eines 
Versuchsmodells, das mit Hilfe von  reverser Genetik die Produktion von mutierten 
Hüllproteinen erlaubt, (iii) eine detaillierte Mutationsanalyse der L- und S-Proteine um den 
viralen Aufbau und die Infektiösität zu bestimmen, (iv) Studien zur Infektionskompetition mit 
von preS abgeleiteten Peptiden und (v) die Entwicklung  von membran-verankerten 
inhibitorischen Peptiden bei denen die N-terminale Myristoylgruppe durch ein Typ-II-
Transmembranprotein ersetzt wurde.  
Durch die Optimierung des Infektionsassays konnten über 30% der differenzierten HepaRG 
Zellen infiziert werden. Der optimierte Infektionsassay ermöglichte Infektionsanalysen von HBV 
Virionen die durch Komplementation generiert wurden. Hierfür wurden das L- und das S-
Protein getrennt exprimiert. In der vorliegenden Arbeit wurden folgende Beobachtungen 
gemacht: (i) Neben der Aufgabe als einfaches Myristoylationssignal zu fungieren, hat der N-
Terminus des L-Proteins (Aminosäuren 2-8) auch eine Funktion für den Viruseintritt, da die 
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Substitution mit heterologen Myristoylationsmotiven zu Viren führt, die nicht mehr infektiös 
sind. Durch einen ergänzenden Ansatz, der zeigt, dass das inhibitorische Potential des HBV 
preS2-48myr Peptids durch Deletion oder Substitution der Aminosäuren 2-8 stark vermindert 
wird, konnte diese Beobachtung weiter untermauert werden. (ii) Die Expression eines 
membranständigen Peptides verhindert die Infektion von HepaRG Zellen mit HBV. Dies 
geschieht wahrscheinlich durch die Interferenz mit dem Virusrezeptor auf der Plasmamembran. 
(iii) In der Aminosäurensequenz 49-78 des L-Proteins befindet sich eine konservierte region. 
Innerhalb dieser Region werden keine Insertionen und Punktmutationen toleriert. Peptide die die 
Aminosäuren 49-78 enthalten können eine HBV Infektion nicht inhibieren. Diese Peptide 
beeinflussen die inhibitorische Aktivität von HBVpreS2-48myr Peptiden nicht. (iv) Während das 
M-Protein für den Viruszusammenbau und für dessen Infektiösität unwesentlich ist, ist die 
preS2-Domäne, als interne Domäne des L-Proteins, Längen-abhängig aber Sequenz-unabhängig 
unverzichtbar für die Freisetzung von Virionen. Bemerkenswert ist, dass ein HBV Virus, mit 
einem L-Protein dass eine beinahe vollständig randomisierte preS2 Domäne aufweist trotzdem 
keine Defekte bei der Formierung von Virionen oder eine Verminderung der Infektiösität 
aufweist. (v) Dagegen führen Cysteinmutationen im cytosolischen Loop-I des L-Proteins zu 
einer drastisch reduzierten Virusinfektiösität. Diese Beobachtung impliziert, dass ein genau 
geformter cytosolischer Loop-I für die HBV-Eintritt erforderlich ist. (vi) Die Bedeutung der 
„antigenic loops“  während dem Viruseintritt ist hauptsächlich auf die Loops im S-Protein 
zurückzuführen und korreliert mit der Bindungsaktivität der Virionen an Heparin. 
Zusammenfassend implizieren die vorliegenden Daten, dass die Myristoylkette des L-Proteins 
einen Anker in die Hepatozytenmembran darstellt und somit die folgende Interaktion mit dem 
Hepatozyten-spezifischen Rezeptor erlaubt. Die preS2-Domäne nicht essentiell für die 
Infektiösität von HBV in vitro,  fungiert aber als ein Linker im L-Protein beim Zusammenbau des 
Virions. Möglicherweise ist das S-Protein mit seinen für die Infektiösitöt essentiellen „antigenic 
loops“ an der Initialen Anlagerung eines Virions an die Hepatozyte beteiligt. Das in dieser Arbeit 
entwickelte membranständige Peptid, bei dem die N-terminale Myristoylgruppe durch eine Typ-
II-Transmembranprotein ersetzt wurde eröffnet neue Möglichkeiten bei der Indentifikation des 
HBV Rezeptormoleküls und eignet sich möglicherweise für die Verwendung in einem 
gentherapeutischen Ansatz zur Behandlung von chronischen HBV Infektionen. 
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1. Introduction 
1.1. Hepatitis B virus biology 
1.1.1 Classification of viruses within the Hepadnavirus family 
Hepatitis B virus (HBV) was discovered in the 1960s as a serum agent1-3. It is a DNA virus that 
requires reverse transcription in its life cycle4,5. HBV belongs to the family of Hepadnaviridae, 
which preferentially infect hepatocytes. Hepadnaviruses are subdivided into two genera, the 
Orthohepadnaviruses and the Avihepadnaviruses, according to their different host ranges, 
mammals and birds.  
HBV is the prototype virus of the orthohepadnaviruses and is genetically related to other species 
in this genus, such as woodchuck hepatitis virus (WHV), Ground squirrel hepatitis virus 
(GSHBV) and woolly monkey hepatitis B virus (WMHBV). Duck hepatitis B virus (DHBV), 
which is more distantly related, is the prototype virus of avihepadnavirus. Other members of this 
genus are heron hepatitis virus (HHBV)6, Snow goose hepatitis B virus (SGHBV)7,8, Crane 
hepatitis B virus (CHBV)9, and Stork hepatitis B virus (STHBV)10.  
1.1.2 Serotypes and genotypes 
HBV was first identified in serum of an individual as “Australian antigen” and has been divided 
into different serotypes according to their antigenicity for a long time. The different serotypes 
are defined by antibody recognition sites on the small surface protein. All known hepatitis B 
virus strains have a common epitope called determinant “a”. Four different serotypes can be 
distinguished by two pairs of mutually exclusive eptitopes, named “d” or “y” and “w” or “r”. 
Determinant “d” has a lysine at position 122 on the small surface protein, while “y” has an 
arginine at the same position; “w” has a lysine at position 160 while “r” has an arginine at that 
position11.  
The availability of molecular techniques, such as polymerase chain reaction and DNA 
sequencing, made it easy to obtain genetic information. This led to the division of HBV into 
different genotypes according to pair-wise differences greater than 8% and smaller than 17%12-14. 
So far, ten genotypes, A to H, and the newly proposed genotypes I15 and J16, have been 
identified. They can be further divided into subgenotypes and are correlated to the serotypes 
(Tab. 1). Different genotypes and subgenotypes show distinct geographic distributions (Fig. 1) 
and possibly distinct clinical behaviors. Previous reports indicate that hepatocellular carcinoma 
(HCC) is more frequent in the patients infected with genotype C than those infected with 
genotype B14,17. Treatment with interferon is more effective in patients infected with genotype B 
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than in those with genotype C (in Asia). The same was observed in patients infected with 
genotype A, which is more effectively treatable with interferon-alpha than genotype D (in 
Europe)18,19. 
HBV has also been found in chimpanzees20,21, gorillas22, orangutans23, and gibbons22. The isolates 
are closely related to human HBV and are considered to be subtypes of HBV. 
 
TAB. 1. Overview of the genotypes and the associated serotypes (modified from Stephen 
Locarnini24) 
 
Genotype  Serotype Genome length/nt preS1/aa pol/aa core/aa 
A adw2, ayw1 3221 119 845 185 
B adw2, ayw1 3215 119 843 183 
C adw2, adr, ayr 3215 119 843 183 
D ayw2, ayw3 3182 108 832 183 
E ayw4 3212 118 842 183 
F adw, ayw 3215 119 845 183 
G adw2 3248 108 842 195 
H adw 3215 119 843 183 
nt, nucleotides; aa, amino acids; pol, polymerase. 
 
 
 
 
FIG. 1. Geographic distribution of HBV genotypes (from the review by Stefan Schaefer25) 
The map shows the geographic distribution of the eight different HBV genotypes (A to H) and subgenotypes 
(numbers). 
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1.1.3 Virus structure 
HBV is an enveloped DNA virus. The infectious virion (Dane particle) has a diameter of 42 
nm26. In addition to Dane particles, sera of HBV-infected patients contain 1000-fold excessive 
amounts of subviral particles (SVP) that are either 22 nm spheres or 22 nm-diameter filaments 
with variable lengths. The SVPs do not contain nucleocapsids and are therefore non-infectious. 
The nucleocapsid of HBV has an icosahedral structure, with a diameter of ~28 nm. It was 
assembled by 120 core protein dimers. The nucleocapsid contains one copy of partially double-
strand viral DNA genome and probably one polymerase. There is also evidence for the presence 
of cellular proteins, including one or more serine kinases within the virus22,27. 
The nucleocapsid of HBV is surrounded by a virus envelope, which contains three different viral 
envelope proteins (L, M, and S). These proteins are estimated to be present in the virion with a 
molecular ratio of 1:1:4 (L:M:S). For subviral particles, this ratio is believed to be different. 
Spheres contain the M and S proteins in a ratio of about 1:2, but only traces of the L protein28. 
However, filaments contain approximately equal amounts of the M and L protein. 
The membrane topology of the M and S proteins is shown in Fig. 2, whereas the topology of the 
L protein is still not fully understood. The N-terminal myristoylation of the L protein is required 
for virus infectivity29. Since myristoylation takes place in the cytosol, the N-terminus of L protein 
is initially located inside the virion (i-preS). This is consistent with the fact that preS is 
responsible for binding the viral capsid during the viral assembly. On the other hand, the preS is 
also responsible for the interaction with the cellular receptors during virus entry. The fact that 
the virus can be immunoprecipitated and neutralized with antibodies against preS supports the 
notion that preS is in the outside of virus (e-preS). This paradox is explained by the commonly 
accepted translocation model for the L proteins: 50% of the L proteins, initially i-preS, 
translocate to e-preS, the other 50% of preS remain inside and interact with the capsid30. The 
detailed topology of the two different forms of L proteins is still not fully understood. For 
example, it is not clear where is the location of trans-membrane domain I (TM-I) in L protein 
with i-preS conformation.  
1.1.4 Genome structure and organization 
Coding regions in the genome of hepatitis B virus are organized in a highly efficient manner (Fig. 
3). Four overlapping or nested open reading frames (ORFs) are translated to yield seven 
different viral proteins. In this compact genetic organization, every nucleotide is at least present 
in one of the ORFs for coding a protein. In addition, crucial elements like a polyadenylation 
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signal, a packaging signal, two enhancer elements, and two direct repeats, are also present within 
the coding regions.  
 
 
FIG. 2. Schematic diagram of hepatitis B particle (picture kindly provided by Stefan Seitz) 
Top left: Illustration of the infectious viral particle of HBV. Capsid, envelope, polymerase, preS1, preS2 and S are 
labeled as black, green, pink, orange and red respectively. RT, reverse transcriptase; TP, terminal protein.  
Top right : The envelope of HBV contains three viral proteins (L, M and S protein). Note that the L protein is 
thought to have two different topologies (Li-preS, Le-preS).  
Bottom: Proposed membrane topology of the three HBV envelope proteins. The preS1, preS2, S region are labeled 
with pink, orange, red bars. Four transmembrane domains (I, II, III, IV) are shown in yellow box. glycosylation, ; 
partial glycosylation, [ ] myristoylation,        . 
 
Within virions, relaxed circular DNA (rcDNA) represents the major form of the viral DNA. In 
rcDNA the minus-strand is complete, spans the entire genome and is covalently linked to a viral 
polymerase.  In contrast, the plus strand extends to about two-thirds of the genome length and 
has variable 3’ ends31,32. Due to an aberrant plus-strand priming in virus maturation, a small 
fraction (5%-20%) of virus particles contains double-stranded linear DNA (DSL) instead of 
rcDNA33. The virions with DSL DNA are infectious but can lose important sequences from 
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their ends during initiation of infection and therefore appear to only play a minor role in 
hepadnavirus replication34,35.  
                            
FIG. 3. HBV genome organization (picture kindly provided by Stephan Urban) 
The HBV genome consists of a circular partially double-stranded DNA (black bold circles). The (-) strand is 
associated with the viral polymerase (Δ) and the 5´end of the (+) strand consists of an RNA-oligonucleotide (       ). 
Two direct repeats (small circles) are located at the ends of the strand. The genome comprises four different ORFs 
(centre), the preC/C-ORF, preS/S-ORF, the X-ORF and the P-ORF which encodes the pre-core/core protein, the 
surface proteins, the X-protein and the polymerase, respectively. During transcription, 4 mRNAs (outer lines) are 
produced with a 5´cap (small triangles) and contain a 3’ poly-A- tail. The genomic RNA bears the endcapsidation 
signal (ε) at the 5´ end.  
 
1.1.5 Primary attachment and receptor mediated binding 
Identification of virus receptor(s), in most case, is not an easy task and the virus-receptor 
interactions are often complex. The criteria for identification of virus receptors are quite 
stringent. Evidence should be provided for direct interaction between receptor and the viral 
surface protein. Additionally it must be demonstrated that permissive cells gain virus-binding 
activity and can be infected, if receptor molecules are provided to the cells. Moreover, it is 
important to show that infection can be inhibited with  antibodies or soluble receptors, and that 
the receptors are expressed on the surface of susceptible cells or organs36.  
Virus-host cell interaction is often a process which involves the interaction with multiple 
receptors with different affinities. This multivalent binding is common in many viruses37. Upon 
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interaction with the first binding partner, viruses usually bind to a second molecule that mediates 
a virus-specific interaction. During this scenario, the virus might bind weakly to the abundant 
first receptor in order to move over the surface of a cell, while the interaction with a second 
receptor could be more specific, with higher affinity, and induce endocytosis or fusion. This 
multi-step binding is beneficial for the virus, since the binding to the cell surface allows 
movements in only two dimensions instead of three. To understand the viral entry process, it is 
important to distinguish between the abundant receptor with low affinity and the specific 
receptor with high affinity, both co-existing on the cell surface. 
The described scenario could be true for HBV entry. It has been known that the viral infectivity 
determinant is located in the N terminus of the L protein (preS1). A second epitope involved in 
cell attachment outside the preS1 region has been suggested. Paran et al. showed that beads 
conjugated with particles containing the all three surface proteins bind to HepG2 cells better 
than preS1 alone38. This “second epitope” might interact with heparan sulfate proteoglycans 
(HSPG), which has been described as the primary attachment site for many virus such as HSV, 
HIV-1 and flavivirus39-41. Indeed, it also plays an important role in HBV entry. This conclusion is 
based on the following observation. Heparin can bind specifically to infectious virus particles 
and prevents virus binding to and infection of susceptible HepaRG cells. Enzymatic removal of 
defined acidic carbohydrate structures from the cell surface using heparinase I/III inhibits HBV 
infection and leads to a reduction of virus binding to the cell surface42. A recent study using 
hepatitis delta virus (HDV), a satellite virus of HBV requires envelope proteins to infect 
hepatocytes, provided evidence that the antigenic loop of the S domain is required for the 
infectivity of HDV43. However, the binding partner of the antigenic loop has not been linked to 
HSPG. Nevertheless, it is apparent that HBV contains at least two separate determinants that 
synergistically act to mediate effective cell attachment. 
It is commonly believed that there is a specific receptor for HBV preS1 domain on the surface of 
hepatocytes, but it has not yet been identified. A lot of candidate receptors have been reported 
and are summarized in Tab. 2, but all of them were not commonly accepted as the specific 
receptor of HBV. 
 
TAB. 2. Described binding partners for HBV preS1-domain. 
(modified from the review by Dieter Glebe44).  
Domain aa  Described interaction partners/binding factors for HBV Ref. 
preS1 10-36 
Binding of hepatoma cells HepG2 to HBsAg (subtype ad) 
can be inhibited by synthetic peptide aa 21-47 and antisera 
against aa 21-47 45 
Introduction 11 
 
  16-38 
Binding of highly purified virion to plasma membrane 
extraction of human liver. Inhibition by anti-preS1 aa16-38 46 
  10-36 
PreS1-peptide binding not limited to liver cells, also on 
extrahepatic sites 47 
  10-36 
Partial homology of preS1 aa10-36 with IgA. HBV entry via 
IgA-binding receptor? 48 
  10-21 
PreS1 aa10-21 crossreact with IgA alpha-1 chain, IgA and 
HBV use related receptors? 49 
  10-36 PreS1 aa10-36 binding to 31 kDa protein on HepG2 cells 50 
  10-36 
PreS1-peptide aa10-36 binds to Interleukin 6 (IL6) but not 
IL3, IL5 and IL7 51 
  10-36 
CHO cells transfected with IL6 cDNA acquire binding sites 
for preS1 peptide aa10-36 52 
  10-36 
Isolation of a 44 kDa protein (HBV-BP) from HepG2 
plasma membranes. Homology to SCCA1, human squamous 
cell carcinoma antigen 1 (human serpin) 53 
  preS1-GST 
Isolation of p80 binding protein from human hepatocytes. 
Needs preS1 aa12-20/82-90 for binding. p80 binding also to 
rat hepatocytes 54 
  preS1 
Anti-idiotypic antisera of antibody inhibiting binding of 
HBV to HepG2. 35kDa protein homology to 
Glycerinaldehyde-3-phoshate-dehydrgenase (GAPDH) 55,56 
  preS1/preS2 
50 kD serum glycoprotein interferes with binding of preS1 
and preS2 mAbs. Soluble form of plasma membrane protein 
on human hepatocytes 57 
  preS1 
Yeast two-hybrid assay I: preS1 domain and human liver 
cDNA library. Isolation of an unidentified protein and a 
mitochondrial protein. 58 
  preS1 
Yeast two-hybrid assay II: preS1 domain and human liver 
cDNA library. Isolation of cytoplasmic "nascent 
polypeptide-associated complex alpha polypeptide" (NACA) 59 
  
HBV 
particles 
Asialoglycoproteinreceptor (ASGPR) I: preS1-but not preS2-
mabs inhibited binding of HBV to ASGPR. SHBs did not 
bind to ASGPR 60 
  
HBV 
particles 
Asialoglycoproteinreceptor (ASGPR) II: HBV uptake by 
HepG2 and HuH-7 (ASGPR+), but not CHO (ASGPR-) 61 
  
HBV 
particles 
Asialoglycoproteinreceptor (ASGPR) III: Desialylated HBV 
only binds to HepG2. Uptake only by susceptible primary 
human hepatocytes 62 
  
HBV 
particles 
Asialoglycoproteinreceptor (ASGPR) IV: Increased HBV 
uptake by HepG2 after desialyation results in HBV infection 63 
Numbering of amino acids (aa) is given for HBV genotype D.  
 
Introduction 12 
 
1.1.6 Fusion with the cellular membrane 
In order to release the nucleocapsid into cytoplasma during virus entry, the enveloped virus has 
to get rid of its envelope. This is thought to happen by fusion with the cellular membrane. 
Depending on where the fusion occurs, two modes of fusion have been described. One is pH-
independent fusion mostly happen at the plasma membrane, as the fusion of human 
immunodeficiency virus (HIV) triggered by association with a second receptor. Another is fusion 
following endocytosis triggered by acidification in the endosome. 
Endocytosis is required for various different functions that are essential for the cells. It is the 
process by which cells take up material from outside by engulfing them with their cell 
membrane. It is not surprising that viruses, in order to deliver themselves into cells for 
replication, take advantage of this process to mediate their entry. Virus binding to receptor is 
mostly followed by receptor mediated endocytosis. Even the well-accepted dogma for 
endocytosis independent entry of HIV, had recently been challenged by visualization of the virus 
movement in living cells64. 
As an enveloped virus, HBV could also be endosome-dependent for virus entry. The close 
related virus, DHBV, uses endocytosis for the virus uptake65,66. Infection of duck hepatocytes 
with DHBV is a slow process that can take up to 16 hours67. It hints that internalization rather 
than binding to the receptor appears to be the rate-limiting step because the binding occur 
rapidly at 4ºC. Additionally, exposure of DHBV particles to low pH was shown to induce a 
conformational change in the viral large surface protein resulting in increased hydrophobicity of 
the virus surface68. Entry of HBV is thought to be pH independent, but the entry could be 
inhibited by hypernonic medium (supplemented with sucrose) which inactivate endocytosis 
(Schultz A and Glebe D, unpublished data from). It is not clear which endocytosis pathway the 
HBV particles take advantage after binding to the receptor. 
1.1.7 Nucleocapsid transportation 
There is little information on the post-fusion events in HBV entry. It is believed that after 
uncoating of virions, nucleocapsids have to be transported to the cell nucleus69 in order to form 
cccDNA, a prerequisite for transcription. It has been shown that HBV capsid can be lipid-
mediated “transfected” into the hepatocytes and leads to genome expression70. Additionally, the 
core protein contains nuclear localization signals (NLSs) and has been shown to bind the 
hepatocyte nuclear membrane71 in a core phosphorylation and importin-dependent manner72. 
Although the mechanism of this process is poorly understood, the transport of nucleocapsids 
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brings the virions rcDNA to the nucleus, where it is converted into covalently closed circular 
DNA (cccDNA to serves a template for the transcription. 
1.1.8 cccDNA formation 
Ten hepatitis B virions entering the blood of chimpanzee are enough to establish a chronic 
infection. However, it is still an open question, how many virions successfully entering the 
hepatocytes could eventually convert their rcDNA into cccDNA. This is partially due to the 
lacking of detection methods to quantify both events, i.e., quantification of engulfed viruses and 
cccDNA at the single-cell level. Referring to the cccDNA as the endpoint of successful entry, 
uptake of virus particle might lead to “abortive entry”, which is a phenomenon described in 
viruses like HIV-173 and HCMV74. The kinetics of cccDNA formation shows that the conversion 
of rcDNA to cccDNA in the liver is established within the first 24 hours post-infection. In 
DHBV, in a simulating one-step growth kinetics studies, it was determined that internalization 
and transportation to the nuclear membrane required a period of approximately 4 hours75. The 
subsequent step of uncoating/transfer into the nucleus is measured by the appearance of the 
cccDNA, which happens within 48 hours. In contrast, by using a sensitive PCR assay selective 
for the detection of cccDNA derived from input viral DNA and not through replication, it had 
been shown that transfer into the nucleus required only 20 hours65,76. It is still unclear if the 
model for DHBV can be applied to that of HBV. 
The mechanisms of DNA repair involved in this conversion are also not fully understood, but 
the rcDNA must be deproteinized to remove the covalently bound polymerase from the 5’ end 
of minor-strand. Consecutively, a capped RNA oligomer present at the 5’ end of plus-strand 
DNA must be removed, while DNA synthesis at the 3’ end makes the entire molecule double-
stranded. The ends of each strand are then ligated to form cccDNA. It is still a matter of debate 
whether the viral polymerase plays a role in this process, although most of these modifications 
are performed by host enzymes.  
1.1.9 Transcription  
cccDNA serves as the template for all viral transcripts. The initiation of transcription is 
suggested to be dependent on viral X protein (Kuhn C and Sonnabend J, unpublished results). 
All transcripts are capped and polyadenylated due to a unique polyadenylation signal in the viral 
genome, these transcripts have the same 3’ end but differed in the 5’ end, as found in Northern 
blot as 3.5, 2.4, 2.1 kb and 0.7 kb length products. These mRNA are called pre-C/C, pre-S, S and 
X, respectively65,76-80.  
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Since most of HBV promoters do not contain the TATA box, different products exist with 
slightly heterogenous 5’ end within each size of mRNA band. For example, the 2.1 kb transcripts 
actually contain mRNA covering the start codon of PreS2 (the transcript for the M protein) or 
mRNA only with the start codon of S-ORF (the transcript for the S protein). Another example is 
the 3.5 kb product, which differs according to the absence or presence of the preC start codon. 
The longer transcript with the preC start codon is used only for the translation of e-antigen. The 
short one without the preC start codon can be transcribed into core protein, polymerase and 
used as the pregenomic RNA (pgRNA)81. The 5’ end of X mRNA is also heterogeneous82. 
The 3.5 kb RNA product is longer than the circular 3.2 kb cccDNA. Thus, this product has to 
be transcribed by ignoring the first polyadenylation signal in the viral genome. Studies on DHBV 
indicated that it is facilitated by a sequence named PET (positive effector of transcription), which 
is located between the transcription initiation site and the poly(A) signal83. 
1.1.10 Translation of viral proteins and co/post-translational modification 
The translation of viral proteins is depicted in Fig. 3. In the common scenario, the mRNA is 
scanned for the first start codon to initiate the translation, except for the translation of the 
polymerase. The start codon of the Pol ORF is downstream of the core protein together with 
several other possible start codon. For the translation of the HBV pol, it appears that the 
ribosome bypasses the upstream start codons by ‘leaky scanning’. Another model suggests that 
ribosomes bind at the 5’ end, but are then shunted to the initiation codon of the pol without 
scanning the codons in between84. By any of these mechanisms, much more core proteins are 
translated than pol, which makes sense for the ratio requirement in the assembly of the virus 
capsid (240 core proteins and 1 polymerase per nucleocapsid). 
Some of the viral proteins undergo a co-translational or post-translational modification. HBeAg 
is translated from the longer subset of the 3.5 kb mRNAs including the start codon for the 
preC/C ORF. A signal sequence in the N-terminus of the newly translated product directs the 
translation of HBeAg to ER membranes. As a consequence, the protein enters the secretory 
pathway, where it undergoes a second cleavage event, in which the proximal 34 aa from the C-
terminus are removed before it is secreted85-89. All three envelope proteins are partially 
glycosylated in their common antigenic loop. While the preS2 region of the M protein is fully 
glycosylated, the L protein is not glycosylated in the preS2 region but is myristoylated at the N 
terminus. It has been found that myristoylation of L is not required for virus assembly but 
required for the virus infectivity29,90.  
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When the L protein is translated, the N terminus is located in the cytosol and gets myristoylated. 
However, after translation, the N-termini of a potion of the L proteins have to be translocated 
into the lumen side of ER membrane to form the two distinct topologies. It is not clear when 
and how this translocation takes place, but it is thought that the cell heat shock protein Hsc70 
plays a role in this process via the interaction with the preS1 region of the L protein91.  
1.1.11 Genome Replication  
Although cccDNA in the nucleus of infected hepatocytes exists as a mini chromosome, the 
hepadnavirus uses a unique replication strategy, i.e., transcription of pregenomic mRNA 
(pgRNA) followed by intracellular reverse transcription to form genomic DNA. 
As mentioned above, the 3.5 kb mRNA transcript, which does not contain the start codon of 
PreC, acts as the template for DNA synthesis. At the same time, it is also used for the translation 
of the P protein. It has been shown that the polymerase binds to an RNA stem-loop structure (ε, 
epsilon) at the 5’ end of the pgRNA,  and that this event triggers the packaging of pgRNA and 
polymerase into RNA-containing capsids92,93. It has also been shown that the polymerase 
preferentially binds to its cognate mRNAs to ensure the integrity of pgRNA to be packaged.  
The genome replication inside the capsid proceeds as the following. Initially a 4-nucleotide 
minor-strand DNA complementing the ε-sequence is synthesized and then transferred to a 
complementary sequence in DR1 near the 3’ end of the pregenome. DNA synthesis continues 
towards the 5’ end of the pregenome template. The RNase H activity of the P protein degrades 
the pregenome RNA from the RNA/DNA duplex. The RNA is removed except for a remnant 
of 15–18 bases including the cap. The –OH group at the 3’ end of the RNA remnant acts as the 
primer for the synthesis of the plus-strand DNA. During plus-strand DNA synthesis 
nucleocapsids can either migrate to the nucleus to increase the pool of cccDNA or undergo 
maturation that enables it to bud through a membrane containing virus envelope proteins.  
1.1.12 Assembly and virus release 
To secret a Dane particle, a nucleocapsid must be formed first. The core dimer forms an 
isohedral capsid when the polymerase binds to pregenomic RNA. The mature nuleocapsid can 
thereafter interact with the preS domain of the L protein and also interact with the cytosolic loop 
of the S protein. This conclusion is supported by two facts: (1) Mutation in a linear stretch of 
preS domain (aa 93-113) or in the CYL-I of S domain (aa 56-59) do not interfere with subviral 
particle formation but block virion formation94,95. (2) Synthetic peptides identical to aa 96-116 of 
the L protein and aa 56-80 of the S protein bind efficiently to core particle in vitro96. This 
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process is believed to happen in a compartment between the endoplasmic reticulum and the 
Golgi complex. Virions are thought to be transported within vesicles and released from the cell 
by exocytosis97.   
A distinguished characteristic of HBV infection is the formation of excessive amount of subviral 
particles, secreted irrespective of viral nulcleocapsid, compared to infectious Dane particle. A 
similar phenomenon is also found in the foamy virus. It is suggested that the robust self-
secretion of subviral particles might use a different pathway compared to the secretion of 
infectious Dane particles. Patient et al. has shown that subviral particles are formed by the S 
protein self-assembly into branched filaments in hamster kidney cells. This takes place in the 
lumen of the endoplasmic reticulum and then transported to the ER-Golgi intermediate 
compartment (ERGIC)98. Several study on DHBV or HBV showed that Dane particle are 
secreted via multi vesicle bodies (MVB) by EM study. By introducing dominant negative form of 
AIP1 and Vps4B, both of which are MVB protein, Watanabe et al. also showed that virions, 
subviral particles and naked nucleocapsids were released by distinct pathways99-101.  
As a summary, the life cycle of HBV from entry to virus release is depicted in Fig. 4. 
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FIG. 4. The replication cycle of hepatitis B virus (adapted from the review of Stephan Urban102) 
(1) Reversible attachment to HSPG. (2) Specific binding to an unknown hepatocyte-specific preS1-receptor. (3) Two 
different entry pathways have been proposed: endocytosis or fusion at the plasma membrane. (4) Release of the viral 
nucleocapsid containing rcDNA. (5) Transport of the nucleocapsid along microtubules. (6) Possible trapping of the 
nucleocapsid in the nuclear basket and release of rcDNA into the nucleoplasm. (7) ‘‘Repair” of the incoming 
rcDNA: Completion of the plus strand of the rcDNA by the viral polymerase. (8) cccDNA formation by covalent 
ligation of both DNA strands. (9) Transcription of the subgenomic RNAs which encode the surface proteins and 
the X-protein and the pregenomic (pg) RNA, which encode the polymerase and the core-protein. (10) All 4 major 
mRNAs utilize a single common polyadenylation signal. (11) Translation of the pregenomic RNA (pgRNA) to the 
core protein and the viral polymerase. (12) Complex formation of the pgRNA (via its epsilon stem loop structure) 
with the core protein and the polymerase and self-assembly of an RNA-containing nucleocapsid. (13) Reverse 
transcription of the pgRNA followed by plus-strand DNA-synthesis within the nucleocapsid. (14) DNA-containing 
nucleocapsids can be either re-imported into the nucleus to form additional cccDNA molecules or can be enveloped 
for secretion. (15) Re-import of nucleocapsids increases the cccDNA population. (16) Compared to virions, 
spherical and filamentous SVPs are secreted in a 103–106-fold excess into the blood of infected individuals.  
 
1.2 The HBV entry inhibitor: Myrcludex B 
There are 7 FDA approved drugs and several drug candidates in the pipeline for Hepatitis B 
treatment103. According to the different steps they interfere with virus infection, they can be 
divided into three catalogs: (1) immunomodulating agents like interferon-α, (2) reverse 
transcriptase inhibitors like nucleoside analogue Lamividine, (3) Non-nuleoside antivirals 
interfering with viral protein during replication, e.g., Bay 41-4109. Another drug candidate, 
Myrcludex B, is coming in the pipeline addressing a different stage of HBV infection. Similar to 
the Fuzeon against the entry of HIV, Myrcludex B is an entry inhibitor for the HBV and HDV 
infection. Now it is in the preclinical stage and towards the phase I clinical trials in 2010.  
The concept of developing Myrcludex B came from the characterization of a peptide, original 
described as HBVpreS/2-48myr, bearing the same sequence and N-myristoylation as the N-
terminal 47 residues of the L protein. It potentially inhibits HBV entry in vitro and in vivo in an 
efficient and specific manner, and was further optimized with respect to the length, N-terminal 
modification, and genotype usage104. To summarize these results, the following characteristics are 
found: (1) the N terminal modification is necessary since the activity of unmyristoylated peptide 
decreases 1000-fold in vitro; (2) based on the sequence of genotype D, the length of peptide was 
optimized to the N-terminal 47 aa, since the shorter or longer peptide reduces the potency of 
inhibition; (3) by comparing the preS1 sequence between genotype C and genotype D, the 
optimal peptide come from the consensus sequence based on genotype C. Following this 
observation, a peptide was produced for the clinical trial and was named as Mycludex B. It has a 
potent inhibition activity with IC50 of 25-800 pM (unpublished data). 
Toxicity tests of Myrcludex B in rats and dogs showed the possibility of this drug to be applied 
in a high dose. This paves the way towards the Phase I clinical trials. However, the discovery and 
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characterization of Myrcludex B did not only lead to a promising clinical application, but also 
gave some hints for the mechanisms of HBV entry.  
Firstly, the presence of the peptide during inoculation inhibits the virus entry, and the pre-
incubation of the hepatocytes with the peptide also lead to abolishment of the entry event. This 
indicates that the peptide addresses to a cellular factor, where it interferes with the virus-cell 
interaction. Apparently, this cellular factor might be the receptor of HBV. 
Secondly, an interesting observation is that the peptide at the concentration for 90% inhibition 
can not inhibit the binding of virus to hepatocytes. Indeed, the HBV infection can be inhibited at 
extremely low concentration of Myrcludex B (25-800 pM). These facts indicate that either the 
virus binding to hepatocytes is a multivalent event (see section 1.1.5), or the peptide might not 
simply compete the binding of virus but interfere with a critical step afterwards. However, it 
should be taken into account that the unusual efficacy of the peptide might be due to the N-
myristoylation, which enhances the membrane association of peptide and facilitate the 
interaction of the peptide and its binding partner at a two dimension level of cellular membrane. 
Indeed, in vitro data have suggested that the peptide can highly specifically bind to the surface of 
differentiated hepatocytes, and this binding is myrsitoylation dependent (Anja Meier, 
unpublished data). 
In addition, the peptide shows a compelling liver tropism in vivo. This observation is based on 
study with radioactively labeled peptide, when subcuterously injected, quickly addressed to and 
accumulated in the liver (within 20 minutes) and were retained in the liver for 24 to 48 hours. 
The C-terminus shortened peptide HBVpreS/2-20myr still showed the liver tropism (Alexa 
Schieck, unpublished data). These results explained the organ tropism of HBV infection and 
pinpointed the determinant of liver tropism to the very short sequence in the N-terminus of the 
L protein. Moreover, it suggested for further applications of Mycludex B as a vehicle to 
specifically deliver drug to the liver. 
In the end, the essential elements of the peptide were narrowed down to the N-myristoylation 
and the aa 9-15. Both of them are very critical for the inhibitory activity, hepatocyte binding and 
liver tropism. Considering that these two elements are very close to each other, it is reasonable 
that the hydrophobic myristic group and aa 9-15 might form a complex before or during the 
virus-receptor interaction, and this conformation is crucial for the virus infectivity. 
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1.3 Host and organ tropism of hepadnaviruses 
So far, HBV can only infect primates. The host determinant of HBV has been identified in the 
preS region. Studies comparing DHBV with HHBV showed that the host determinant of DHBV 
lies within aa 22-37 of preS region. Similarly, the study comparing the infectivity of WMHBV 
and HBV in PHH showed that the N-terminal aa 1-30 of the L protein determine the species 
specificity of WMHBV and HBV105. 
The assumption that the specific host tropism of HBV is due to the specific binding receptor 
was challenged. It has been shown that mouse hepatocytes, although mice are not susceptible to 
HBV infection, can very efficiently interact with the peptide HBVpreS/2-48myr (Anja Meier, 
unpublished data). This peptide has been shown to inhibit HBV infection and is supposed to 
bind to the unknown receptor on the surface of human hepatocytes. More importantly, this 
peptide is specifically tropic to the mouse liver in vivo (Alexa Schieck, unpublished data). Thus, 
mice actually bear the preS1-specific receptor but the bound viruses are probably restricted in 
(one of) the post-binding steps so that they are not able to establish cccDNA in the cell nucleus. 
It is believed that some cell types other than hepatocytes could also support viral replication. In 
DHBV, infection of bile duct epithelial cells of the liver also occurs106, and studies with primary 
cell cultures suggest that they may be sites of DHBV reproduction in vivo107. cccDNA and typical 
DNA replication intermediates, with abundant single-stranded DNA, are found not only in liver, 
but also in pancreas and kidney of chronically infected ducks108. Extrahepatic infection has also 
been studied in chronically infected woodchucks. Typical DNA replication intermediates have 
only been found in the liver and, at a ~10-fold lower level, in spleen. The evidence of 
extrahepatic infection in the woodchuck was obtained from studies with peripheral blood 
lymphocytes (PBLs) of WHV-infected woodchucks. Although WHV did not replicate in PBLs in 
vivo, they produced typical viral DNA replication intermediates and released viruses when 
stimulated with lipopolysaccharide in vitro, and thus appear to be latently infected109,110. 
Nevertheless, the importance of the “nonhepatocyte infection” on virus pathogenesis is still not 
clear. 
1.4 Cellular factors needed for infection  
While a preS-specific receptor of DHBV had been identified as the Duck Carboxypeptidase D 
(dCPD, gp180), the exploration for the HBV receptor has had limited success. During the last 25 
years, numerous reports on a variety of possible cellular preS-binding partners have been 
published (Tab. 2). They were identified via a variety of approaches, such as biochemical 
identification of the binding partners from the membrane exacts of hepatocytes, or from phage 
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display library using the viral particles, subviral particles, or peptides. None of these potential 
preS-binding partners have so far been convincingly proved to be the receptor of HBV111. The 
most important evidence, which is still lacking, is the conversion of permissive cells to 
susceptible cells when these candidates are expressed. 
The myristoylated peptide, HBVpreS/2-48myr, could prevent the binding of purified preS1-
containing subviral particles to PTH, whereas preincubation with the myristoylated preS peptides 
from avian hepadnaviruses could not112. However, inhibition of the binding required micromolar 
concentrations of the peptide, rather than picomolar concentrations needed for the inhibition of 
infection112. This difference suggested the presence of an abundant low-affinity receptor for viral 
and subviral particles. This low affinity receptor might be heparan sulphate proteoglycans 
(HSPG). It has been shown that binding of HBV to HepG2 cells and PHH are both inhibited by 
sulphated polymers113. Furthermore, HBV binds to heparin in vitro and could be purified from 
the plasma of HBV infected patients by heparin-sepharose columns114. Unfortunately, these two 
reports could not clarify the relevance of binding to HBV infection. Recently, it has been shown 
that HBV infection could be specifically blocked by preincubation of purified virus with heparin, 
or by treatment of PTH and HepaRG cells with heparinase42,115. Since heparan sulphate 
proteoglycanes (HSPGs) are enriched in the liver within the space of Dissé, one may speculate 
that HBV is trapped by liver specific HSPGs, serving as low-affinity receptors similar to the 
interaction and entry of apolipoprotein E lipoprotein remnants by liver HSPGs116. Specific entry 
of the virus may subsequently require a yet undefined high affinity receptor(s), which can be 
blocked by the acylated preS1-derived peptides. 
1.5 The HBV envelope and known viral infectivity determinants 
If the “virus infectivity determinant” was defined here as the particular sequence in the envelope 
protein that is necessary for virus infectivity, the following scheme summarizes all the available 
information so far regarding the preS1 region (Fig. 5). In short, the N-myristoylation, 
consecutive 5 aa of the N-terminal 77 amino acids of the L protein, are known to be critical for 
the infectivity of either HBV or HDV. 
In line with the finding that preS1 contains critical determinants responsible for virus infectivity, 
the myristoylated peptide comprising the N-terminal 47 aa of preS1 can inhibit HBV infection. 
The non-myristoylated peptide can only inhibit HBV infection at >1000-fold higher 
concentration than the myristoylated one. More interestingly, there are some difference between 
the sequence requirement of peptides and the infectivity determinants of preS1 (Fig. 5).  
Generally, the N-terminus of peptide is more important than the C-terminus104. The essential 
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elements are the aa 9-15 and the N-terminal myristic group. The peptide containing the aa 49-78 
does not increase but weakens the activity112,117, which indicates that aa 49-78 may have a 
different function compared to aa 2-48. 
Besides the information from the study on virus infectivity and inhibitory peptides, some other 
evidence has suggested preS1-domain contains the receptor binding site. It has been reported 
that a synthetic preS1 peptide, aa 10-36 (in genotype D) without N-terminal myristoylation, 
binds to the surface of HepG2 cells and also inhibits HBV binding45. Furthermore, antisera 
raised against this peptide compete with the binding of HBV particles to HepG2 cells. 
Additionally, the neutralizing activity of monoclonal antibodies (mAb) MA18/7118, KR359119, 
KR127120 with epitopes encompassing the aa 20-23, aa 19-26, aa 37-45 hint that these regions are 
involved in the entry process. Using an in vitro binding assay based on peptide-coupled beads 
mimicking the virus particle, it could be shown that the aa 18-23, motif QLDPAF, is important 
for binding to HepG2 cells38. 
 
 
 
 
 
FIG. 5. Schematic illustrations of the infectivity determinants within the N-terminus of preS1 domain 
The N-terminus of preS1 is strongly required for the virus infectivity. For HBV, the abolishment of myristoylation 
or deletion of the consecutive 5 aa in this region completely abrogates the virus infectivity29,121. In consistence, the 
abolishment of myristoylation or partially substitution of the consecutive 5 aa in the aa 11-75 also abrogates the 
infectivity of HDV43,122. 
The sequence required for the inhibitory peptide derived from the N-terminus of preS1 has been mapped to 
detail104,112,117. Although the myristoylation (red line) and the aa 9-15 (red bar) are as essential for the peptide as for 
the virus infectivity, the aa 49-78 do not increase but impair the activity of peptide (yellow bar). While the flanking 
sequences comprising the aa 2-8 and the aa16-20 drastically increase the activity of peptide (orange bar), the aa 21-33 
do not show significant effect (green bar). 
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The envelope of HBV contains three envelope proteins, L, M and S, and all three envelope 
proteins have a common C-terminal S-domain. Beside the preS region, the domain structure of 
three proteins and the regions necessary for virus infectivity are depicted in Fig. 6. It had been 
pointed out that some regions are dispensable for the infectivity of HBV or HDV. The C-
terminus of preS1 (aa 78-87)121 and the C-terminus of preS2 (aa 114-163)123 are not important. 
The matrix-domain critical for HBV assembly94 covering aa 87-113 is not important for HDV 
infectivity, thus is also unlikely involved in HBV entry122,124. The absence of M protein in the 
virion has no effects on HBV infectivity125. A systematic mutation analysis has demonstrated that 
all assembly-competent HDV with mutation in cytosolic loop-I (aa 24-80 of S domain) are 
infectious and also minimize a possible role of cytosolic loop-II (aa 193-202) in entry process126. 
Interestingly, using peptide-coupled beads, the second binding partner in the envelope was 
identified within the S protein38. In consistence with this result, it was known that the antibodies 
against the S-domain, generated by current vaccines containing solely S-protein, could neutralize 
infection in vivo and in vitro127-129. Moreover, in patients positive for anti-HBs, the presence of 
escape mutants (commonly found G145R and D144A mutation in the S-domain) also suggests 
that the antigenic domain is involved in the infection process in vivo130-135. The data from HDV 
infectivity studies in vitro confirmed the assumption that S-domain contains an infectivity 
determinant, which is further narrowed down to the antigenic loop. Virions with the S domain 
lacking the residues between 119 and 128 showed reduced infectivity on PHHs and HepaRG 
cells. A further study pinpointed aa 119 to 124 (GPCRTC) as the most important sequence 
required for HDV infectivity136. This domain contains a CXXC motif, known to be the substrate 
of protein disulfide isomerase (PDI), which catalyzes disulfide-bridge exchanges. For non-
enveloped virus like SV40, it has been reported that the isomerase is involved during virus entry 
to disassemble the viral capsid137. For the enveloped virus like murine leukemia virus, the 
receptor-binding subunit (SU) in the surface proteins contains a CXXC motif that is activated 
after receptor-binding of the envelope transmembrane (TM) subunit. This leads to isomerisation 
of SU-TM disulfide bonds and fusion-activation within the TM subunit138,139. All this evidence 
led to an attractive assumption that CXXC motif in the S domain play a similar role in HBV, i.e., 
a signal for disassembly. However, the infectivity of HDV was not impaired when the CXXC 
motif was mutated into CXXXC or CXC motifs that can not be recognized by the PDI. 
Nevertheless, it could not be ruled out that the S-S disulfide bridge(s) within the AGL plays an 
important role in HBV entry. 
Introduction 23 
 
The third infectivity determinant in HBV entry can be ascribed to the first transmembrane 
sequence of the S-domain, which has a sequence similarity to type I fusion peptides. The 
replacement of the fusion peptides of influenza virus hemagglutinin (HA) with this first 
transmembrane sequence of HBV lead to the hemifusion activity of the resulting chimeric HA 
protein140. Consistent with this, transmembrane domain I (TM-I) of the L protein but not the S 
protein is critical for DHBV entry. This scenario might also be applied to HBV because the 
common putative fusion peptides are found in both viruses141. 
A debate was triggered regarding to a so-called translocation motif (TLM) in the preS2 region 
presenting in both L and M proteins. It was described that a fusion preS2 protein is able to 
translocate itself into the cell and evenly distributed in the cytosol. Detailed analysis revealed that 
cell-permeability is mediated by an amphipatic a-helix between amino acids 41 and 52 of preS2, 
which was named as translocation motif (TLM)142. Two homologous motifs were found in the 
preS domain of DHBV, and lacking of these two motif in DHBV lead to the loss of virus 
infectivity143. Therefore, it was suggested that TLM is an essential infectivity determinant for 
hepadnavirus to translocate virions into cytosol for establishment of productive infection. 
However, accumulating evidence from the study on HDV and HBV showed that TLM is not 
necessary for virus infectivity. 
 
        
 
FIG. 6. Schematic representation of the domain structure of the three HBV surface proteins and the 
regions critical for virus infectivity 
The HBV envelope consists of the L, M and S surface proteins. All three proteins are encoded by the nested open 
reading frame and share the common S-domain (red bar). The hydrophobic S-domain contains four trans-
membrane domains (I, II, III and IV; yellow box), that help to form three loop structures in the S-domain, cytosolic 
loop-I (CYL-I), antigenic loop (AGL) and a small cytosolic loop-II (CYL-II). The M protein consists of an N-
terminal extension of S by 55 aa (preS2, orange bar), while L protein (genotype D) contains an additional N-terminal 
108 aa (preS1, pink bar). All three envelope proteins are partially glycosylated ( ) in their S-domain. The M protein 
is fully glycosylated at Asn 4 of preS2, while the L protein is not glycosylated at this site but is myristoylated at the 
glycine 2 of preS1 domain (       ). There are three critical regions for the virus infectivity (underground with blue box): 
the N-terminal 77 residues of the preS1 domain, the first trans-membrane domain of the L-protein, and the S-
domain. 
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1.6 Animal and cellular models for HBV infection 
Due to the strict host tropism, HBV can only infect humans and primates such as chimpanzee, 
but not the woodchuck (host of WHV) and Duck (host of DHBV). WHV and DHBV are 
comparable to some extent to the HBV. This led to extensive studies using woodchuck and duck 
as the animal models. These studies showed the particular advantage of these animal models and 
brought us invaluable information regarding immune response and viral pathogenesis. The 
infection of newborn woodchuck by WHV develops chronic infection and presents the most 
feasible model, so far, to investigate carcinogenesis induced by chronic hepdnavirus infection. 
Duck is a small animal infection model with ready availability and low expense. Along with the 
well established primary duck hepatocytes culture for efficient infection and chicken hepatoma 
cell line for the study of viral replication in vitro, DHBV offers the full range of experimental 
approaches. 
Nevertheless, these two animals are not susceptible to HBV infection. Due to poor homology of 
preS region, WHV and DHBV are very likely to address different cellular receptors compared to 
HBV. Therefore, in the following text, we prefer to describe infection models on chimpanzee, 
tree shrews hepatocytes (Tupaia belangeri) and the modified mice that can be experimentally 
infected by HBV. 
The chimpanzee, in particular, has been employed periodically to study virus transmission, host 
response and vaccination. Although the hepatitis in chimpanzee infected by HBV appears to be 
mild, there are serologic evidences of chronic infection together with persistent liver 
inflammation144,145. It was shown that inoculation with 1-10 virions could lead to chronic 
infection, in contrast to that the high dose leads to transient infection and viral clearance. The 
chimpanzee is not proven as a model for hepatocellular carcinoma but has been used to illustrate 
the immunological response in the course of viral infection146-148. 
Mice are one of the most commonly used animal models, since they are easy to maintain in the 
laboratory and have a short breeding cycle. However, mice are not the natural host for HBV and 
they can neither be experimentally infected by HBV nor other hepadnavirus. Mouse hepatocytes 
are also not susceptible to HBV infection in vitro, but they are competent of HBV replication. 
Therefore, HBV transgenic mouse has been generated149. This mouse contains a chromosomally 
integrated 1.3-mer over-length HBV genome and produces substantial amounts of viral antigens 
and infectious virions. In contrast to cell lines with integrated HBV genome, such as 
HepAD38150,151, there is no evidence that the cccDNA, a critical marker for HBV infection, is 
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formed in mice152. The transgenic mice are immunologically tolerant to HBV infection, but 
fundamentally new insights into the immune response against HBV infection have been gained 
by adoptive transfer of lymphocytes153-155. Apparently, the HBV transgenic mice are not suitable 
for entry studies. It must be mentioned that transgenic mice producing HBV proteins, e.g., 
HBeAg, core and X, has also been generated to examine the pathologic effects of viral 
proteins156,157. 
Another elegant model is the immuno-incompetent mice, uPA-SCID, xenotransplanted with 
primary hepatocytes from either humans 158, woodchucks159, or tupaias160. These chimeric mice 
maintain transplanted hepatocytes for a long time and allow the investigation of the full life cycle 
of HBV infection including the virus entry158,161. As a small animal model, it was used to 
demonstrate the efficacy of an HBV entry inhibitor in vivo162. The disadvantage of these chimeric 
animals is the technical difficulty to generate them. Moreover, sine these mice are 
immunodeficient, they are not ideal for immunological investigations. 
Since in vitro infection systems were not available for long time, several surrogate systems have 
been established. The ability of certain human hepatoma cell lines, such as HepG2 and HuH-7, 
to support HBV replication after transfection of cloned HBV DNA, makes them highly valuable 
tools to investigate replication steps downstream the entry pathway. Most of our current 
knowledge of HBV replication is derived from these systems. The subsequently developed 
HepG2.2.15 cells with an integrated HBV genome163, and the HepAD38112,150,151,164 cells with tet-
inducible viral replication are extensively used to investigate reverse transcription, virus assembly, 
secretion and the sensitivity to RT-inhibitors. 
To study the early events of virus infection, or to evaluate the mechanism of HBV entry 
inhibitors, primary human hepatocytes (PHH) have been used exclusively for a long time. The 
infection of PHH with HBV was irreproducible and insufficient at the beginning. As shown by 
immuno-staining, intracellular HBcAg was present in only 2-3% of the PHH post infection165, 
12% of the primary fetal hepatocyte166 and less than 0.1% of cryopreserved PHH167. Gripon et al. 
demonstrated that the addition of 1.5% dimethyl sulfoxide (DMSO) to the culture markedly 
enhanced the infection efficiency168. Consistent with this observation, the addition of 2% DMSO 
to the culture of primary duck hepatocytes (PDH) also increases DHBV infection67,169. This 
effect is contributed by two reasons: (1) DMSO prolongs the susceptibility of PDH to allow the 
virus spread via repeated cycle of infection. (2) DMSO enhances the expression of core antigen 
and viral DNA in PDH. In addition, the work from Gripon demonstrated that, besides the 
adding of 2% DMSO, the infection of PHH could be greatly enhanced by addition of 
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polyethylene glycol (PEG) during inoculation. This effect is mediated by enhanced attachment of 
virions to PHH170. The role of PEG was further suggested to enhance the binding of HBV to 
cell-surface glycoaminoglycans (GAG)42. 
Established in 2002, the HepaRG cell line is the first cell line supporting HBV infection. It was 
obtained from liver tumor tissue of a female patient suffering from hepatitis C virus (HCV) 
associated hepatocellular carcinoma (HCC)171. Subsequently, HepaRG cells were shown to be 
HCV-free and to behave as bi-potent progenitor cells that can be differentiated into hepatocyte-
like cells and biliary-like cells under a certain condition172. In similar to primary hepatocytes, 
HepaRG cells can only be infected by HBV in a differentiated state. The selection procedure for 
establishment of HepaRG cells was heavily dependent on the combination of hydrocortisone 
(5×105 M) and 2% DMSO, two differentiation inducers for hepatocytes. It was observed that the 
continuous presence of hydrocortisone in culturing cells keeps the phenotypic stability. The 
adding of DMSO differentiates the cells into hepatocyte clusters and the removal of DMSO 
trans-differentiates the cells into an active proliferate state171. Therefore, to promote a maximum 
morphological differentiation level, culture conditions were defined as 2 weeks in the presence of 
5×105 M hydrocortisone followed by 2 weeks of exposure to both hydrocortisone and DMSO. It 
must be pointed out that HepaRG cells start to differentiate when they reach the confluency, 
probably due to the presence of hydrocortisone. After seeding, the transcription levels of 
haptoglobin, albumin and aldolase B on HepaRG cells increase over time in absence of DMSO. 
However, in the presence of DMSO, the transcriptions of cytochrome P450 (CYP) family, such 
as CYP 1A2, 2C9, 2E1 and 3A4, are significantly up-regulated173. In two independent 
observations on HepaRG cells, the expression of hepatocyte nuclear factor (HNF)-4α was 
drastically increased in the presence of DMSO172,174. HNF-4α is known to be essential for HBV 
replication, since knock-down of HNF-4α has a significant negative effect on pgRNA 
transcription, intracellular core protein expression, replicative intermediates and even the size of 
cccDNA pool174. In similar to infection of PHH, infection of HepaRG cells by HBV is also 
significantly enhanced by the presence of PEG during virus inoculation171. 
In 2001, primary tupaia hepatocytes (PTH) from tree shrews (Tupaia belangeri) were shown to 
be susceptible to HBV and WMHBV infection175. However, the infection in vivo by HBV is mild 
and self-limited. The cell culture model is useful for investigations on mechanism of HBV entry 
112,164 and studies on the pathogenesis of clinical HBV isolates from patients with fulminant 
hepatitis176. However, the optimal culture condition for infection of PTH is quite different from 
that for the infection of PHH and HepaRG cells. In short, optimal infection on PTH is obtained 
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in the absence of DMSO, PEG and serum, while the optimal infections on PHH and HepaRG 
both require the presence of 2% DMSO, 4% PEG and 10% serum. In addition, PEG-
precipitated viruses are as infectious as the sucrose-gradient purified virus in PHH and HepaRG 
cells, but they are significantly less infectious in PTH (Sonnabend J and Glebe D, unpublished 
data). 
1.7 Aims of this work 
The mechanism of virus entry is still largely unknown and remains one of the most interesting 
questions in the field of HBV study. In the present work, HepaRG-cell-based infection system 
was optimized in order to characterize infectivity determinants of the envelope proteins of 
hepatitis B virus. 
1. HepaRG-cell-based infection system is available in our lab, but with a fluctuated 
efficiency. Recombinant virion bearing mutation is a useful tool to study the role of viral 
proteins in virus entry. To test the infectivity of recombinant virion, normally with a low 
yield, is a technically challenging task. Therefore, we were asking for an optimal infection 
system and a sensitive read-out for HBV infection. To optimize HepeRG cells with 
respect to reliable susceptibility and robust virus replication is the first aim in the present 
study. To this purpose, we defined the HepaRG cell passages with a comparable 
susceptibility, and systematically study the effect of culture condition including the usage 
of DMSO, the concentration of PEG, EGTA treatment, spin-down inoculation. In 
addition, to quantify the infection events, especially those with a low infection rate, we 
developed a quantitative immunofluorescent method and compare its sensitivity and 
linearity to commercial assay measuring secreted viral markers. 
2. The integrity of the N-terminal 78 amino acids of preS1 is required for the infectivity of 
Hepatitis B virions. It is known that aa 2-48, with an essential sequence at aa 9-15, is 
responsible for binding to an unknown virus receptor. However, the role of aa 2-9 and aa 
49-78 remains unclear. To answer this question, recombinant virions, bearing mutation in 
aa 2-9 and aa 49-78 of the L protein, were produced and analyzed for their infectivity. In 
addition, a panel of preS1-derived peptides was tested for their inhibitory activity against 
HBV infection.  
3. It is still unclear what the role of myristoylation is in viral L protein and in the preS-
derived inhibitory peptide. With a hypothesis that myristoyl chain of peptide (and viral L 
protein) is inserted into cellular membrane during interaction with an unknown receptor, 
we replaced the myristoyl chain of peptide with a type II transmembrane protein. This 
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membrane anchored peptide was expressed in differentiated HepaRG cells via lentiviral 
transduction system and was characterized for its effect on the oncoming HBV infection. 
4. The preS2 region in the L protein and the M protein has been shown to be dispensable 
for virus assembly and infectivity. A so-called TLM motif in the preS2 region triggered 
the debate on the role of preS2 domain. With a system to produce M-protein-free 
recombinant virion, we tried to answer the role of preS2 by comprehensive mutations on 
the preS2 region of L protein. 
5. The cysteine residues in the S-domain have been shown to be critical for the infectivity 
of HDV, a satellite virus carrying envelope proteins of HBV. However, it is not clear if 
these cysteine residues are also important for the infectivity of HBV. Since the S-domain 
is present in all three envelope proteins (L, M and S), the importance of S-domain in 
different envelope proteins is not well-understood. To answer this question, in the 
present study, we mutated the cysteine residues in the L and S proteins and further 
determined virus assembly and infectivity. Moreover, a previous work has suggested that 
HSPG is the primary attachment site for HBV. We tried to correlate the infectivity of 
viruses bearing cysteine mutation with their binding activity to heparin, and explore the 
role of the S-domain in virus entry of HBV. 
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2. Results 
2.1 Optimization of HBV recombinant virus production and infection assay 
2.1.1 Optimization of the viral production by transfection of complementary expression 
plasmids 
In order to dissect the role of envelope proteins for the virus infectivity, it is important to 
establish a virus production system that allows production of virus carrying mutated envelope 
proteins. Since the ORFs of the viral polymerase and envelope genes overlap, mutations 
introduced into the envelope genes in cis change the sequence and possibly the function of the 
viral polymerase. Complementation is commonly used to avoid such interference through 
expression of envelope protein(s) from a helper construct. 
To produce HBV particles, the SacI fragment (3381bp) of pCHT-9/3091177 containing 1.1-mer 
HBV genome (genotype D) was inserted into the pcDNA3.1 zeo(-) vector for introducing the 
selection marker and some useful restriction sites. This construct is designated HBV (kindly 
provided by Kerry Mill). Like its parental construct pCHT-9/3091, this plasmid support HBV 
replication and virus secretion. To prevent the expression of L protein, a point mutation was 
introduced at the start codon of the L-ORF (ATG to ACG). This construct was designated HBV 
L- (kindly provided by Kerry Mill). The introduced mutation remains silent in the overlapping 
reading frame of the viral polymerase. A helper construct was generated by insertion of the L 
ORF into NheI-HindIII sites of pcDNA3.1/Zeo(-) vector to express the wild type HBV L 
protein (genotype D), designate as wt L (kindly provided by Kerry Mill).  
It has been shown that the N-terminus of L protein contains a retention signal, which retains the 
S protein in the ER membrane and inhibits the secretion of subviral and viral particles178. Thus 
the expression level of the L protein might interfere with virus production. Therefore, the ratio 
of genomic construct (HBV L-) to the helper construct (wt L) has to be optimized for virus 
production. HuH-7 cells were co-transfected with different ratio of these two plasmids and the 
supernatants of cell cultures day 3-8 post transfection were applied to the CsCl density gradient 
centrifugation, and fractions of the gradient were analyzed by HBV specific DNA dot-blot. In 
addition to subviral particles and virions, free capsids are secreted into the supernatant by an 
unknown mechanism, but they have a higher density compared to the enveloped capsids, i.e., 
virus particles. As expected, the lacking of L protein abrogated virus production and the 
complementation with helper construct rescued virus production. The ratio of 5:1 (genomic : 
helper) facilitated the virus production up to a level in which the L proteins are intrinsically 
expressed (Fig. 7).  
Results 30 
 
 
      
 
FIG. 7. Titration of the genomic construct and helper construct for complementary viral production 
HBV-DNA specific Dot-blot of fractions of analytical CsCl density gradients obtained from supernatants of 
transfected HuH-7 cells, which have been transfected with different ratios of genomic construct (HBV L-) and 
helper construct (wt L). The parental construct (HBV) supporting HBV replication was also included. Linearized 
pCHT-9/3091 at the indicated copy numbers were used as the standard. Note that transfection with the HBV 
genomic construct and the helper construct expressing L-protein resulted in secretion of both viral particles (VP) 
and free nucleocapsids (FC).  
 
Based on thess result, in the following experiments, co-transfections were consistently 
performed with 10µg of genomic construct and 2µg of the helper construct (ratio of 5:1) for a 
10-cm dish of HuH-7 cells to produce virus particles. 
2.1.2 Kinetics of virus production following co-transfection 
To quantify the kinetics of particle production in HuH-7 cells following co-transfection, the 
supernatant was collected at different time points post-transfection, and virus production was 
determined by CsCl gradient centrifugation and DNA dot-blot analysis. 
As shown in Fig. 8, the production of free capsids dropped more rapidly than the production of 
virions, which kept relatively constant for 2 weeks. Considering that both constructs are driven 
by the CMV-promoter, it is possible that the decline of free capsids reflects the kinetics of CMV-
promoter-driven transcription of pregenomic RNA and the formation of subsequent capsids. 
The limiting factor for virus secretion in this scenario could be the L protein, which might 
accumulate at the ER membrane for a relatively long period. 
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Based on these result, in the following experiments, the supernatant of days 3-8 (or mixed with 
supernatant of days 8-13) post-transfection were routinely collected for subsequent 
quantification of the virus assembly and infectivity. 
 
                                 
 
FIG. 8. Kinetics of recombinant viral production 
HBV-DNA specific Dot-blot of fractions of an analytical CsCl density gradient of the supernatants of HuH-7 cells 
transfected with a mixture of genomic construct (HBV L-) and helper construct (wt L) at a ratio of 5:1. These 
supernatants were collected at diffent time points post-transfection and concentrated by PEG-precipitation before 
applying them to a CsCl density gradient (row 1-5). Also included was the supernatants obtained from cultivated 
HepAD38 cells in the absence of tetracycline (row 6). Linearized pCHT-9/3091 with indicated copy numbers was 
used as the standard (row 7). FC, free nucleocapsid; VP, viral particle. 
 
2.1.3 Anti-core IF staining of infected HepaRG cells  
To detect infection events on the single-cell level, it is important to select an antibody that 
specifically binds to an intracellular viral marker. Since the recombinant virus is deficient for L 
protein expression, the anti-core antisera were chosen to perform the IF staining. 
Several polyclonal antibodies were tested against the core protein (#158, #312 and H363) for the 
IF staining (Fig. 9A). All of them were suitable for the IF staining, judged by the following 
observations: (1) infection could be seen only in a subset of HepaRG cells, i.e., differentiated 
hepatic cells; (2) the IF signal was specific and in marked contrast to uninfected cells; (3) single-
cell-staining patterns showed that the core protein was associated with nuclei and speckle-like 
structures in the cytoplasm, especially profound with antibody H363. Thus, H363 was used as 
the antibody for anti-core staining in the following studies, if not specified otherwise. 
To optimize the IF assay, the HepaRG cells were infected with a concentrated virus stock from 
the supernatant of HepAD38 cells. The cells were fixed at different time points and stained for 
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the presence of the core protein (Fig. 9B). As shown, the overnight inoculation of virus with 
HepaRG cells led to a strong core-staining (Day 1) although the cells had been intensively 
washed for 3 times with PBS before the IF staining. The signals were specific but it was hard to 
distinguish between membrane-associated viral particles and free capsids. Irrespective of this, the 
signal decreased quickly afterwards and the specific staining of the expressed core protein of 
infected cells (as mentioned above) emerged and became dominant over time. In the cells with 
the typical staining patterns as described above, a few infection events were identified at day 4 
post-infection. However, the strongest signal from the infected cells was obtained at day 13. 
In the following experiments, the IF-staining was routinely performed at day 13 post-infection.  
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FIG. 9. Anti-core immunofluorescence analysis of the HBV infection in the HepaRG cells 
A. HepaRG cells 13-days post-infection were stained with the polyclonal rabbit antiserum (H363) or polyclonal 
mouse antiserum (#158, #312) against HBV core protein (the first column from the left). The higher magnification 
of the selected region (dashed box) is shown in the second column. The identical regions with nuclei-staining 
(DAPI, column 3), phase-contrast graph (PC, column 4) and the merged pictures (column 5) are shown as well.  
B. Kinetic of core-protein expression in HepaRG cells post-infection with virus prepared from HepAD38 cells. 
HepaRG cells were washed and fixed before the infection (Day 0), or after the infection at the indicated time points 
(Day 1, 4, 6, 7, 8, 9 and 13).  Then the cells were subjected to the IF analysis by polyclonal anti-core antiserum H363 
(green) and the cell nuclei were stained by DAPI (blue).  
 
2.1.4 Quantification of the infection by secreted viral markers and the number of infected 
cells 
HBV infection can be quantified by secreted viral proteins such as HBsAg and HBeAg. To 
explore the possibility to quantify infection by more sensitive IF staining at a single cell level, the 
number of infected cells was quantified and correlation with the secreted HBsAg and/or 
HBeAg, which is measured by microparticle enzyme immunoassays (MEIA), was evaluated.  
HepaRG cells were infected with a virus stock prepared from HepAD38 cells (Fig. 10A) or virus 
preparation following co-transfection of HuH-7 cells with HBV L- and wt L (Fig. 10B).  In 
addition, the infection was performed in the presence of inhibitory peptide at different 
concentration (Fig. 10C). In all of the cases, the number of infected cells correlated with the 
secreted viral marker independent of the source of the virus. This correlation was also observed 
when the infection was inhibited by the peptide, HBVpreS/2-48myr, in a dose-dependent manner. 
The anti-core staining of the cells post-infection are also shown in Fig. 10D.  
The data indicates that the infection events can be quantified by counting infected cells even 
when the HBsAg and HBeAg have decreased below the cut-off value of MEIA. Therefore, 
counting of infected cells after IF staining is a more sensitive method than the commercial 
HBsAg and HBeAg assay we used.  
More importantly, the two read-out of infection based on the number of infected cells and the 
secreted HBsAg both showed a linear correlation with the virus input in a broad range. This fact 
demonstrates the possibility to compare the infectivity of virus without infecting cells with the 
same amount of virions. Instead, both of the read-outs (HBsAg and cell number) can be 
normalized to the amount of virus input after infection to calculate the specific infectivity. 
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FIG. 10. Correlation of the secreted viral marker and the number of infected cells  
A. HBsAg (red line) secreted from day 8-13 post-infection of HepaRG cells with concentrated virus from cell 
culture supernatants of HepAD38 cells. The amount of virus used for infection varied from 0.05 µl to 50 µl, which 
resulted in a multiplicity of 10 to 10000 genome equivalents per cell. Quantification on the single cell level was 
performed by counting HBcAg-positive cells 13 days post-infection (green line).  
B. HBsAg (red line) secreted from day 8-13 following infection of HepaRG cells with concentrated virus from cell 
culture supernatants obtained from HuH-7 cells, which were co-transfected with HBV L- and wt L. The amount of 
virus used for infection varied from 2 µl to 32 µl. Quantification on the single cell level was performed by counting 
HBcAg-positive cells 13 days post-infection (green line).  
C. HBsAg (red line) secreted from day 8-13 following infection of HepaRG with concentrated virus from HepAD38 
cells in the absence (0 nM) or in the presence of different concentration (1, 5, 25, 100, 2000 nM) of inhibitory 
peptide. Quantification on the single cell level was performed by counting HBcAg-positive cells 13 days post-
infection (green line). 
D. HBcAg-specific immunofluorescence (green) of HepaRG cells 13 days post-infection with concentrated virus 
from HepAD38 cells in the absence (0 nM) or in the presence of different concentration (1, 5, 25, 100, 2000 nM) of 
the inhibitory peptide, HBVpreS/2-48myr. 
 
2.1.5 Optimization of the infection-the effect of DMSO 
It has been shown in DHBV infection assay169, that the addition of DMSO to the culture 
medium could maintain the differentiation state of duck hepatocytes and dramatically prolong 
the susceptibility to DHBV infection. During the cultivation of the HepaRG cells, it has also 
been shown that DMSO could differentiate the progenitor HepaRG cells into epithelial-like cells 
and hepatocyte-like cells, which are susceptible to HBV infection. It is recommended that the 
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HepaRG cells are grown for 2 weeks, and then cultivated with 2% DMSO to be differentiated 
for additional 2 weeks before they can be used for HBV infection171. Since the concentrations of 
DMSO have a significant influence on cell differentiation and consequently susceptibility, the 
effect of DMSO was therefore systematically evaluated to optimize virus infection. 
For this purpose, the effect of DMSO on virus infection was evaluated during three different 
time periods (Fig. 11A), i.e., 2 weeks before the inoculation, the overnight inoculation, and post 
inoculation. The effect of DMSO on the infection assay 2 weeks before the inoculation was 
investigated, during which period the DMSO was considered to accelerate the differentiation 
process. Surprisingly, the absence of DMSO during “differentiation period” yielded a higher 
HBsAg compared to 2% DMSO, which was recommended (Fig. 11B). Further titrations 
revealed that constant 0.5% DMSO resulted in the optimal infection (Fig. 11C, Fig. 11D).  
Next the effect of DMSO during inoculation was investigated. The HepaRG cells pretreated 
either with 0.5% or 2% DMSO were infected in the presence of 0, 0.5, 1.0, 1.5 and 2.0% DMSO. 
Additionally, the necessity of fetal calf serum (FCS) during this period was tested. The results 
showed that 2% DMSO and the presence of FCS (10%) during the inoculation led to the highest 
values of secreted HBsAg (Fig. 11E). Finally, the effect of DMSO post-inoculation was 
investigated. Based on the information from previous results, two batches of HepaRG cells were 
treated with 0.5% DMSO for 2 weeks prior to infection and then inoculated with virus in the 
presence of 2% DMSO. The cells were further cultivated in medium with different 
concentrations of DMSO. The maximal infection was achieved with 2% DMSO post-
inoculation (Fig. 11F). The infection of HepaRG cells with an optimized DMSO concentration 
largely improve the efficacy of infection, as demonstrated by the secreted HBsAg in 1:4 diluted 
supernatant (S/N: ~100).  
To summarize the results, the optimized DMSO recipe for the infection assay is the following: 
The HepaRG cell should be grown for 2 weeks without DMSO, and further treated with 0.5% 
DMSO for 2 weeks, and then the cells should be infected and further cultivated in the presence 
of 2% DMSO.  
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FIG. 11. The effect of DMSO on HBV infection of HepaRG cells. 
A. Schematic illustration of the cultivation and the infection of HepaRG cells. The detailed procedure is described in 
the “Material and Methods”. Note that DMSO is present in three periods defined as pre-infection, inoculation and 
post-inoculation. 
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B-D. The influence of DMSO during the pre-infection period on infection. During the pre-infection period of 2 
weeks, HepaRG cells were treated with 0%, 1.2%, 1.4%, 1.6%, 1.8% or 2% DMSO (B), or with 0%, 0.5%, 1%, 
1.5%, 2% or 2.5% of DMSO (C). In addition, the cells were treated with gradually increased concentration of 
DMSO from 0.5%, 1.0%, 1.5% to 2% (0.5-1.0-1.5-2.0) or from 0.5%, 0.5%, 2.0% to 2% (0.5-0.5-2.0-2.0) during this 
period. Similarly, gradually decreased or constant concentration of DMSO (2.0-2.0-0.5-0.5, 2.0-1.5-1.0-0.5, 0.5-0.5-
0.5-0.5, 2.0-2.0-2.0-2.0) were used during this period (D). Infection was performed using standard procedure. The 
supernatant of cells were collected at the indicated time points and the amount of HBsAg or HBeAg was 
determined. 
E. The influence of DMSO during inoculation on HBV infection. HepaRG cells were treated with 0.5% or 2.0% 
DMSO for two weeks before infection. During the overnight inoculation period, indicated amount of DMSO (from 
0% to 2.0%) were presented. The supernatant of cells between day 7-11 post-infection were collected and the 
amount of HBsAg was determined. 
F. The influence of DMSO post-inoculation on HBV infection. HepaRG cells were treated with 0.5% DMSO 
before infection and incubated with virus in the presence of 2.0% DMSO. After infection, the cells were further 
cultivated at the indicated concentration of DMSO. The diluted cell supernatant (1:4) of days 7-11 post-infection 
were analyzed for the amount of HBsAg. For this experiment, two different passages, P29 (white bar) and P30 
(black bar), of HepaRG cells were used. 
 
2.1.6 Optimization of the infection-the effect of “spin inoculation” 
It has been shown that heparan sulfate proteoglycans (HSPG) on the surface of hepatocytes can 
facilitate the attachment of HBV to the cells and the addition of PEG during the inoculation 
improves the infection by increasing the primary attachment via HSPG42. Based on these 
observations, HBV infection strongly relies on a close contact between the virus and cells. Spin 
inoculation has been used for some viruses, such as the lentivirus, to improve the efficiency of 
infection179. Thus, next question was: does the centrifugation also improve the infection of HBV 
in HepaRG cells? 
To answer that, HepaRG cells was inoculated with virus and subsequently centrifuged at 
different speeds and for different periods. Fig. 12 A showed that efficiency of infection was 
enhanced slightly in an input-dependent and specific manner when centrifugation was performed 
at 280g for 5 minutes. When the speed and time of centrifugation was increased, the efficiency of 
infection was further elevated. A maximal elevation of 50% was observed when the virus/cells 
were centrifuged at 1200g for 90 minutes (Fig. 12). Indeed, the HepaRG cells tolerate these 
centrifugation procedures. 
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FIG. 12. The influence of centrifugation on the infection assay 
A. HBeAg secreted from day 4-7 following infection of HepaRG cells by 5 µl or 25 µl virus stock without (no 
centrifugation) or with spin-inoculation. For spin-inoculation, HepaRG cells with inocula were centrifuged at 280 g 
for 5 minutes immediately after the inoculation (280 g/5 min). To control the specificity of infection, virus 
inoculation was performed in the absence (black bars) or presence of 100 nM HBVpreS/2-48myr (white bars). 
B. HBsAg secreted from day 8-13 following infection of HepaRG cells by virus stock without (no centrifugation) or 
with spin-inoculation at different parameter (280 g/5 min, 1200 g/5 min, 1200 g/90 min). 
C. Immunofluorescence staining 13 days following infection of HepaRG cells without or with spin-inoculation 
(1200 g/90 min). The infected cells were visualized by staining with polyclonal rabbit antiserum (H363) against HBV 
core protein (green).  
 
2.1.7 Optimization of the infection-the effect of PEG 
For in vitro infection of primary human hepatocytes (PHH) and HepaRG cells, PEG was 
commonly added during the inoculation with HBV to increase the efficiency. 
To infect HepaRG cells, the viral inoculum diluted in culture medium were mixed with PEG 
(final concentration of 4%) before it was incubated with the cells. In order to investigate the 
stablity of virus inoculum in the presence of PEG, the mixture of virus with PEG was 
immediately used to inoculate the cells or was incubated for different time periods before the 
inoculation. There is no significant difference on infection (Fig. 13A), suggesting that inoculum 
containing PEG is quite stable for at least 6 hours. 
Furthermore, two concentrations of PEG commonly used for the HBV/HDV infection assay 
were compared. Two batches of HepRG cells were infected in the presence of 4% or 5% of 
PEG, there is no significant difference as shown by IF staining (Fig. 13B). 
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In summary, the virus inoculum containing PEG is quite stable, and 4% or 5% of PEG can both 
be used for HBV infection. 
 
                     
 
FIG. 13. The influence of PEG on the infection assay 
A. HBsAg (day 7-11) secreted from HepaRG cells post-infection. Concentrated virus from HepAD38 cells were 
mixed with 4% PEG for the indicated time periods before the incubation with HepaRG cells.  
B. HBcAg-specific immunofluorescence of HepaRG cells 13 days post-infection. Concentrated virus from 
HepAD38 cells was inoculated with two different passages of HepaRG cells (Passage 28 and Passage 30) in the 
presence of 4% or 5% PEG. The infected cells were stained with polyclonal rabbit antiserum (H363) against HBV 
core protein. The identical region with nuclei-staining (DAPI), or phase-contrast (PC) is shown as well.  
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2.1.8 Optimization of the infection-the effect of EGTA  
The previous results in our lab (Kerry Mills and Andreas Schulze, unpublished results) showed 
that EGTA treatment of HepaRG cells could enhance the infection, and suggested that EGTA 
treatment might open the tight junction between cells and make a subset of differentiated cells 
accessible and thus susceptible to virus infection. Here this observation was confirmed again in 
the optimized infection procedure. 
                          
FIG. 14. The influence of EGTA on the infection assay 
A. HBsAg secreted from day 7-11 following infection of HepaRG cells with concentrated virus from HepAD38 
cells. Prior to infection, the HepaRG cells were treated with EGTA of indicated concentration (0, 125, 250, 500, 
1000 µM) for 5 minutes.  
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B. Immunofluorescence staining 11 days following infection of HepaRG cells pre-treated with EGTA as described 
in (A). The infected cells were visualized by staining with polyclonal rabbit antiserum (H363) against HBV core 
protein (the left column). The identical regions with nuclei-staining by DAPI (the middle column), phase-contrast 
graph (PC, the right column) are shown as well.  
 
The HepaRG cells were treated with the optimized DMSO recipe as mentioned above, and then 
treated with different concentrations of EGTA for 5 minutes. The virus inoculum was incubated 
with HepaRG cells and then centrifuged at 1200 g for 90 minutes. The EGTA treatment slightly 
increases the infection as shown by secreted viral markers (Fig. 14A) or IF staining of cells (Fig. 
14B). However, the enhancement of infection was not concentration-dependent at least in the 
tested range.  
With all the optimized procedures tested so far, the infection efficiency of HBV on HepaRG 
cells can be significantly increased to achieve ~30% infection of differentiated cells (Fig. 14B). 
2.1.9 The effect of passage number on HBV infection  
The HepaRG cell line derived from a patient with hepatocellular carcinoma. Interestingly, these 
cells exhibit an undifferentiated morphology (characterized by active dividing) when seeded at 
low density, and after having reached confluence they formed typical hepatocyte-like colonies 
surrounded by epithelial-like cells172,173,180. Similar phenomenon was observed in the present study 
that the cells formed hepatocyte-like and epithelial-like cells one week after seeding in the 
absence of DMSO. This hinted that they already differentiated to some extent when they reach 
confluence. However, when they were passaged at low cell density, they again acquired the 
undifferentiated morphology and divided actively as described172. The reversible differentiation 
raised a question: how often they can be differentiated and dedifferentiated during the cell 
passaging without loss of their susceptibility to perform the infection assay. 
To answer the question, HepaRG cells with two different passage numbers, passage 27 (P27) or 
38 (P38), were seeded and further differentiated. The same amount of inoculum was used to 
infect the cells at the same time and the secreted viral markers were measured at day 11. 
Additionally, the cells were stained for the core protein (d13 post-infection) and a differentiation 
marker, multidrug resistance-associated protein 2 (MRP2). MRP2 has been characterized as an 
ATP-dependent membrane transport protein, which is responsible for the biliary excretion of a 
diverse range of substrates, including glutathione and organic anions. It is located exclusively on 
the canalicular membrane (apical membrane) of the hepatocytes181 and, thus, is a marker for 
differentiation and polarization. The morphologies of two passages of HepaRG cell were 
different. While P27 cells displayed small but abundant hepatocyte islands, the older passage 
(P38) formed large but connected hepatocyte region. The patterns of MRP2 staining also 
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support their different morphology (Fig. 15A). In both cases, only the hepatocyte regions were 
infected, although the infection on the early passage (P27) was slightly higher than on the late 
one (P38) (Fig. 15B). The anti-core staining and different cell morphologies were also shown in a 
higher magnification (Fig. 15C). As observed previously (Kerry Mills and Andreas Schulze, 
unpublished data), most infected HepaRG cells were well-polarized as shown by the MRP2 
staining. 
Collectively, the HepaRG cells can be cultivated, differentiated and dedifferentiated extensively 
for a long time without loss of their susceptibility to HBV infection. For most of the following 
experiment, infection assay was performed with HepaRG cells between passage 27 and 38. 
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FIG. 15. The effect of passage number on the infection assay 
A. Two passages of HepaRG cells (Passage 27 and Passage 38) 13-days post-infection were stained with mouse anti-
core antiserum (Core) and rabbit anti-MRP2 antiserum (MRP2). The identical regions with nuclei-staining (DAPI) 
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and phase-contrast graph (PC) are shown as well. The higher magnification of the selected regions (dashed box) is 
showed in next column to the right.  
B. HBsAg secreted from day 7-11 following infection of two passages of HepaRG cells (Passage 27 and Passage 38). 
C. Staining pattern and morphology of two passages of HepaRG cells (Passage 27 and Passage 38). For each 
passage, the staining of core protein (red), MRP2 (green) and nuclei (blue) are merged in the left column, while the 
phase contrast graph (PC) was shown in the right. The higher magnification of selected regions (dashed box) is 
shown below. 
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2.2 The N-terminus of preS1 domain serves a critical function for virus infectivity 
It has been shown that the preS1 domain of the L protein play different roles in the HBV life 
cycle. Present inside of the virus particle, the preS1 domain contains elements crucial for virus 
assembly94, and other activities such as binding to heat shock proteins, of which the biological 
function remains unclear91. The preS1 is also known to be important for virus infectivity when it 
is present outside of the virus particle121. The region critical for virus infectivity is located within 
the N-terminal ~77 amino acids of preS1 domain (numbered according to genotype D). 
Mutagenesis analyses within this region in both HBV and HDV showed that deletion or 
substitution of 5 amino acids in this region abrogated virus infectivity121,122. This region consists 
of three distinguishable elements, which is summarized according to currently available 
knowledge in Fig. 16. The first is the myristoyl group, which is covalently linked to the second 
amino acid (glycine) of preS1 domain. Secondly, concluded from characterization on inhibitory 
peptide, the N-terminal 47 amino acids of preS1 with essential region (aa 9-15) and accessory 
region (aa 28-48) are responsible for the binding of L protein to an unknown hepatocyte-specific 
receptor.  The third is a region encompassing aa 49-78, which is also required for virus 
infectivity.  
 
 
FIG. 16. Schematic representation of preS-domains from different genotypes 
The HBV L-protein is myristoylated (Myr) at Gly-2 of the N-terminus of the preS domain. The potential receptor 
binding site (brown dashed line) within the preS1-domain is shown with an essential region (aa 9-15) and two 
accessory regions (aa 28-39 and 39-48). The cytosolic anchorage determinant (red dashed line), HSP (HSc70) 
binding site (blue dashed line), capsid binding site (green dashed line) are indicated as well. The sequence is 
numbered according to genotype D (108 aa), in comparison with other genotypes (alignment produced with Vector 
NTI 11.0, highly conserved residues are labeled with yellow background). The preS1 and preS2 domains are 
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indicated (black dashed line below). Three conserved regions are shown (yellow dashed line below). aa 2-77 are 
known to be necessary for viral infection (black dashed line below), but aa 49-78 have an unknown function (black 
dashed line below).  
 
The role of myristoylation is not fully understood. Although unmyristoylated preS1-derived 
peptide binds to hepatocytes to some extent (e.g. aa 2-48112, aa 10-3645, and the QLDPAF 
motif38), the modification with myristic acid drastically increases the binding activity of 
HBVpreS/2-48myr to hepatocytes (Anja Meier, unpublished results) and confer the peptide an 
inhibitory activity at nM concentrations. It seems that the myristoyl group plays a role by 
increasing the hydrophobicity of the N-terminus of L-protein, since the inhibitory activity of 
peptide are correlated with the length of hydrocarbaon chain (C18,C16>C14>C8>c5)117. Thus it 
is reasonable to assume that the myristoyl group might increase the affinity of virus to the 
unknown receptor in a hydrophobicity-dependent manner. What the exact role of myristoylation 
is in the viral L protein and in the inhibitory peptide is one of the questions we address in this 
section.  
Myristoylation is a post-translational modification processed by the cellular N-
Myristoyltransferase (NMT) during or early after protein synthesis via recognition of the 
myrisitoylation motif, which is located in the N-terminus of the L-protein. The well known motif 
for N-myristoylation is MGXXXS/T182, which is present in the L proteins of all genotypes of 
HBV irrespective of their diverse N-terminal sequences. The diversity of N-terminal residues 
suggested that the sequence of aa 1-8 might just function as provider for a myristoylation signal. 
This is consistent with the loss of virus infectivity when 5 amino acids within this region are 
deleted121. Since a myrisoylated peptide made up of aa 2-8 can not inhibit HBV infection, the 
suggestion from this observation is that aa 2-8 are not important for inhibitory peptide112. 
However, our following studies showed that the activity of peptide, HBVpreS2-48myr, was more 
drastically impaired when it was truncated at the N-terminus than at the C-terminus104. This 
observation raised one of the questions that we want to answer in this section: do aa 1-8 just 
serve as myrisoylation signal or are they required for virus infectivity? 
Beside the well-defined binding site within the N terminus of preS1, the role of residues 49-78 is 
still enigmatic. Although it is apparently that aa 49-77 is also critical for virus infectivity121,122, the 
peptide encompassing this region, HBVpreS/2-78myr, has a reduced inhibitory activity compared 
to HBVpreS/2-48myr 117. This difference indicates that aa 49-78 may have a different function 
other than binding. The alignment of preS1 domain with L proteins from different genotypes 
shows that there is a conserved sequence as 57-TPPHGGIGWSPQ-68 within aa 49-78, beside 
the other two conserved regions in the receptor binding site (9-NPLGFFP-15) and capsid 
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binding region respectively (Fig. 16). Therefore, mutation analysis and infection-inhibition assay 
were also described in this section to address a possible role of aa 49-78.  
2.2.1 Infectivity of genotypically L-protein pseudotyped HBV particles 
As mentioned above, there are several conserved sequences in the viral L proteins of different 
genotype. Diverse regions can also be found, especially in the N-terminus of preS1 domain. The 
preS1 domain of genotype D encodes 108 aa while genotypes A, B and C encode 11 additional 
residues (MGGWSSKPRKG) in the N-terminus. The preS1 of genotype F also encodes 11 
residues (MGAPLSTTRRG), while genotype E and G encode only 10 additional residues 
(MGLSWTVPLE) and the downstream methionine is substituted with tryptophan (M1W). 
Therefore, the first question was: can L proteins from other genotypes replace the function of 
genotype D L protein. 
To answer this question, the L-ORF of genotype B, E and G were inserted into the NheI-
HindIII site of pcDNA3.1 Zeo(-) vector. The difference in their N-terminus is shown (Fig. 17A). 
These constructs were verified by DNA sequencing (data not shown) and the L protein 
expressions were confirmed by Western blot (Fig. 17B). HuH-7 cells were co-transfected with L-
deficient genomic construct, HBV L-, (genotype D) without or with genotypically different 
helper constructs in order to produce pseudotyped virus. As shown, all these L proteins can 
rescue virus production as efficient as the L protein of genotype D (Fig. 17C). The infectivity of 
these pseudotyped viruses was quantified by measuring the secreted HBsAg and counting of 
infected cells. It was evident that the infectivity of these L-protein pseutotyped viruses was 
similar to the authentic genotype D virus. Moreover, in the presence of genotype-D derived 
peptides, HBVpreS/2-48myr, the infections were inhibited to a comparable level (Fig. 17D-F).  
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FIG. 17. Assembly and infectivity of pseudotyped genotype-D virus carrying genotype-specific L proteins 
A. Amino acid sequences of the N-terminus of L proteins of genotypes D, B, E, and G. The letters in red indicate 
the aa that differ from genotype D. The assembly and infectivity of virus with these L proteins are summarized on 
the right. 
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B Western blot of cellular extracts of HuH-7 cells 2 days post-transfection without (/) or with the genotype-specific 
L expression constructs (D, B, E and G).  
C. Analysis of assembly and secretion of the pseudotyped virus bearing genotype-specific L proteins post-
transfection. HBV-DNA specific Dot-blot of fractions of an analytical CsCl density gradient was obtained from 
concentrated supernatants of HuH-7 cells, which were transfected with a mixture of the genomic construct (HBV L-
) and helper constructs expressing genotype-specific L-proteins (D, B, E and G). As a control, the HuH-7 cells 
transfected without the helper expressing L-protein (/) was included. 
D. HBsAg secreted from HepaRG cells day 8-13 p.i. by the pseudotyped virus bearing genotype-specific L protein. 
The concentrated supernatant was obtained from HuH-7 cells transfected with a mixture of genomic construct 
(HBV L-) and helper constructs expressing genotype-specific L-proteins (D, B, E and G). To test their sensitivity 
against inhibitory peptide, virus inoculation was performed in the absence (black bars) or presence of 5 nM (grey 
bars) or 25 nM (white bars) HBVpreS/2-48myr. As a negative control, the concentrated supernatant from HuH-7 
cells transfected without the helper (/) was also incubated with HepaRG cells. 
E. Quantification on the single cell level was performed 13 days post-infection by counting HBcAg-positive 
HepaRG cells infected with pseudotyped virus as described in (D). 
F. HBcAg-specific immune fluorescence (green) of HepaRG cells 13 days post-infection with pseudotyped virus. 
Identical regions with nuclei-staining (DAPI) are shown in the right column.  
 
This data demonstrates that L proteins from other genotypes can replace that of genotype D 
without losing viral assembly and infectivity. Because the envelope of these pseudo-particles is a 
mixture of genotypically different S- and L-protein, it can be concluded that neither genotype-
specific interaction between L and S protein is required for both viral assembly and infectivity. 
Finally, the cross-inhibition of these pseudotyped viruses with a genotype-D derived peptide 
suggests that the peptide could be clinically used as an entry inhibitor for all genotypic HBV 
infections. 
2.2.2 Infectivity of HBV carrying chimeric L proteins from genotypes D and B 
Since the chimeric envelope (mixture of genotypically different S- and L-protein) does not 
interfere with virus assembly and infectivity, it is interesting to examine the influence of chimeric 
L proteins on assembly and infectivity. Although no genotype-specific interactions between L 
and S proteins are required, as shown previously, a possibility for interactions within L proteins 
still exists, e.g., interaction between that the preS and the S domain. If this interaction does exist 
and is genotype-specific, the chimeric L protein could become nonfunctional for assembly or 
infectivity. 
Helper constructs expressing a panel of chimeric L proteins of genotype D and B (Fig. 17A) 
were produced according to the sequence alignment of these two L proteins. These constructs 
were verified by DNA sequencing and protein expressions were confirmed by Western blot (data 
not shown).  The virus assembly was then determined by CsCl density gradients of concentrated 
virus obtained from transfected HuH-7 cells (Fig. 17B). The virus infectivity was tested in 
HepaRG cells (Fig. 17C). None of the chimeric L proteins interfered with virus assembly. Most 
chimeric L proteins did not impair the virus infectivity, suggesting that there is no genotype-
specific interaction required between preS and S domain, and between preS1 and preS2 domain. 
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Intriguingly, the N-terminal 11 amino acids of genotype-B L-protein fused to that of genotype-D 
(B11-D) abolished viral infectivity to the background level. In contrast, 8 amino acid longer 
replacements (B19-D) restored the virus infectivity. Therefore, it is possible that, to keep the 
virus infectious, the additional N-terminal 11 amino acids of L protein of genotype B 
(numbering as aa -11/-1) have to be adjacent to its own downstream 8 amino acids. This result 
argued that there is a genotype-specific interaction within the N-terminus, i.e., between the N-
terminal 11 amino acids and the following 8 amino acids.  
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FIG. 18. Assembly and infectivity of pseudotyped virus carrying chimeric L proteins of genotype D and B 
A. Schematic illustration of the L proteins from HBV genotypes D (black) and B (red), and the produced chimeras. 
The assembly and the infectivity of the pseudotyped viruses with these L proteins are summarized on the right. To 
highlight the differences between B11-D and B19-D, the N-terminal residues are depicted below, in which the 
genotype-B specific amino acid are shown in red. Note that three residues differ between the N-terminus of B11-D 
and B19-D and result in different virus infectivity. 
B. Analysis of assembly and secretion of the chimeric pseudotyped virus. HBV-DNA specific Dot-blot of fractions 
of an analytical CsCl density gradient were obtained from supernatants of HuH-7 cells, which were transfected with 
a mixture of L-deficient genomic construct and helper constructs expressing L proteins of genotype D (row 1 and 
7), genotype B (row 2), or the chimeras (row 3-6 and row 8-10). 
C. HBsAg secreted from day 8-13 following infection of HepaRG cells with the pseudotyped virus bearing L 
proteins of genotype D, genotype B, or the chimeras. The infection was performed in the absence (black bars) or 
presence of 100 or 500 nM HBVpreS/2-48myr to block the preS1-receptor-mediated entry pathway of HBV (white 
bars). 
 
It is noteworthy to point out that these 8 amino acids of genotype-B L protein (aa 1-8) are not 
responsible for the myristoylation, but the corresponding sequence in genotype-D L-protein is 
commonly thought as myristoylation recognition signal. This raised a question: what is the role 
of these 8 amino acids in the L protein? 
2.2.3 Infectivity of HBV carrying chimeric L protein with His-6 tag 
To further confirm that this 8 amino acids are critical for the virus infectivity,  the His-6 tag 
(HHHHHH) was used to partially substitute this region (Fig. 18A, gt B/14H6) in the context of 
genotype-B L protein, together with other substitutions in near positions (gt B/8H6, gt 
B/11H6). 
The results clearly showed that three chimeric L proteins were correctly expressed (Fig. 19B), did 
not interfere with virus assembly (Fig. 19C), but abolished virus infectivity (Fig. 19D). 
Therefore, it can be comfirmed that these 8 amino acids (aa 1-8) are critical for virus infectivity 
in genotype-B L proteins, although they are not used as a myristoylation signal. It is likely that 
the conformation of N-terminus is changed when these amino acids are replaced by His-6 tag, 
which subsequently abolishes virus infectivity by interfering with the receptor-binding. 
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FIG. 19. Assembly and infectivity of pseudotyped virus carrying L proteins with substituted His-6 tag at 
the N-terminus 
A. N-terminal sequences of L proteins from genotype-D (D), genotype-B (B), and the mutants with substitutions 
with His-6 tag (8H6, 11H6, 14H6). The letters in red indicate aa that differ from genotype D. The assembly and 
infectivity of virus with these L proteins are summarized on the right.  
B. Western blot of cellular extracts of HuH-7 cells 2 days post-transfection with helper constructs expressing the 
wild-type (genotype D and B) or the mutant L-proteins as shown in (A).  
C. DNA Dot-blot analysis of assembly and secretion of the pseudotyped virus bearing mutated L proteins. The 
HBV-DNA specific Dot-blot of fractions of an analytical CsCl density gradient were obtained from supernatants of 
HuH-7 cells, which were transfected with a mixture of L-deficient genomic construct and helper constructs 
expressing L proteins of genotype B (row 1), or the mutated L protein bearing His-6 tag at different position (row 2-
4). 
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D. HBsAg secreted from days 8-13 following infection of HepaRG cells by the virus bearing L proteins of genotype 
B, or the mutants. The infection was performed in the absence (black bars) or presence of 100 nM HBVpreS/2-
48myr (white bars). 
 
2.2.4 Infectivity of HBV with different myristoylation motifs 
In the genotype-B L protein, aa 1-8 are important for virus infectivity. It is therefore reasonable 
to assume that the corresponding sequence in genotype-D L-protein also serve an specific 
function aside from being a myristoylation recognition signal, i.e. the sequence itself is also a 
determinant for virus infectivity. If this hypothesis held true, heterologous myristoylation motifs 
should not be able to replace this region although N-myristoylation occured. The N-terminal 9 
amino acids (MGAQVSSQKV) of poliovirus VP4 protein is a well-defined myristoylation motif. 
It has been demonstrated that these 9 amino acids are sufficient to confer the myristoylation of 
green fluorescence protein (GFP) when it was fused to the N-terminus of GFP183. Therefore, the 
VP4 myristoylation motif was used to replace aa 1-8 of HBV L protein (Fig. 20A, VP4-8), 
together with some replacements shown in Fig. 14 (VP4-5, Vp4-D). Assembly and infectivity of 
pseudovirus with these chimeric L proteins were determined (Fig. 20B-C, upper panels). These 
chimeras did not interfere with the virus assembly, but the all the pseudoviruses including VP4-8 
lost its infectivity, supporting the hypothesis that aa 1-8 of genotype-D L-protein does not 
simply serve as myristoylation motif. Interestingly, the VP4-D, in which the VP4 myristoylation 
motif was fused N-terminally to Gly-2 of the L protein, did also abolish virus infectivity. This 
result is similar to our previous observation that the myristoylation motif of L protein of 
genotype B (within the N-terminal 11 amino acids) has to be adjacent with its own downstream 
8 amino acids in order to keep virus infectivity (Fig. 18, mutants B19-D and B11D). 
To strengthen the previous finding, the myristoylation motifs of other well-defined myristoylated 
protein were fused to the N-terminus of D-genotype L protein (Fig 20A, lower panel). These 
myristoylation motifs include the N-terminus of LCMV µ1 protein (LCMV), Vac8p, Fyn and 
Yes protein184,185. The correctness of the depicted constructs was verified by DNA sequencing 
and the protein expression was confirmed by Western blot (data not shown). All chimeric L 
proteins can be expressed, did not interfere with viral assembly, but abolished the virus 
infectivity (Figure 20B and C, lower panels). Apparently, although aa 1-8 were intact, the 
infectivity of virus was lost when the aa 1-8 were N-terminally fused to other myristoylation 
signals, suggesting that a highly strict sequence in the N-terminus is required for virus infectivity. 
In conclusion, the 8 amino acids at the N-terminus of D-genotype L protein serve not only as a 
myristoylation signal, but might also be directly involved in virus entry.  These results suggest a 
highly strict sequence requirement within the N terminus of L protein for virus infectivity. 
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FIG. 20. Assembly and infectivity of pseudotyped virus carrying L proteins with heterologous 
myristoylation signals. 
A. N-terminal preS1 sequences of chimeric L proteins with myristoylation signal from Poliovirus VP4 protein (VP4-
D),  µ1 protein of LCMV (LCMV-D), Vac8 (Vac8-D), Fyn (Fyn-D) and Yes (Yes-D). The letters in red indicate the 
heterologous myristoylation signals. Assembly and infectivity of the respective viruses with these chimeric L 
proteins are summarized on the right. 
B. Analysis of assembly and secretion of the pseudotyped viruses. HBV-DNA specific Dot-blots of fractions of 
analytical CsCl density gradients were obtained from supernatants of HuH-7 cells, which were transfected with a 
mixture of L-deficient genomic construct and helper constructs expressing L proteins of genotype D (row 1 and 5), 
or the chimeras (row 2-4 and row 6-9). 
C. Infectivity of the pseudotyped viruses in the presence or absence of the inhibitory peptide. Infectivity of the 
pseudotyped viruses was measured by quantification of secreted HBsAg day 11 p.i.. The infection was performed in 
the absence (black bars) or presence of 100 nM HBVpreS/2-48myr (white bars). 
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2.2.5 Infectivity of HBV carrying chimeric L protein of different genotypes 
Apparently, aa -11-1 of genotype-B L-proteins can not be fused N-terminally to the genotype-D 
L-proteins. However, compared to L-protein of genotype-B, the genotype E and G contain 10 
additional aa (MGLSWTVPLE) that differ from genotype B, while the genotype F has different 
11 aa (MGAPLSTTRRG). In addition, there is isolated HBV genome of genotype C in which 
preS1 only encode 108 aa, i.e., naturally truncation of N-terminal 11 aa186. These diverse 10 or 11 
amino acids triggered our interest to look into the compatibility of the N-termini of different 
genotypes. 
A set of helper plasmids expressing mutant L protein with chimeric N-terminus were 
constructed (Fig. 21A), including fusion of genotype-D L protein with the N-terminal 10 aa of 
the genotype E or G (E/G10-D), 11 aa of genotype F (F11-D), as well as the G2A mutation to 
prevent the myristoylation (D G2A). A truncated genotype-B L protein (Bt), or further fused 
with 10 aa from the genotype E or G (E/G10-Bt) were also included. As a control, the VP4 
myristoylation motif was fused to the truncated genotype-B L protein (VP4-Bt). 
The sequence of these constructs were verified by DNA sequencing (data not shown) and the 
protein expression was confirmed by Western blot (Fig. 21B). None of these chimeric L proteins 
interferes with viral assembly (Fig. 21C). However, the infectivities of viruses were different (Fig. 
21D). The F11-D mutation abolished virus infectivity similar to the previously shown B11-D 
and the myristoylation-deficient control (D G2A). E/G10-D partially remained infectivity. 
Interestingly, Bt showed a higher infectivity compared to the that of genotype D, although they 
have the same length of preS1 (108 aa). The fusion of additional 10 amino acids from genotype 
E/G showed also an increased infectivity (E/G10-Bt). In contrast, when it was fused to the 
heterologous VP4 myristoylation motif, virus infectivity was abolished (VP4-Bt).  
Taken together, these results suggest that the genotype D L-protein can hardly be prolonged 
with N-terminal sequence, while the corresponding sequence from genotype B (Bt) seems more 
tolerable except for the heterologous myritoylation signal. These results confirm again that a 
stringent sequence is required in the N-terminus of L protein and further indicats that this 
sequence is genotype-dependent.  
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FIG. 21. Assembly and infectivity of pseudotyped virus carrying L-proteins with chimeric N-termini of 
different genotypes 
A. N-terminal sequence of L proteins with chimeric N-termini. The N-termini of the L proteins of different 
genotypes, i.e., 11aa from genotype B, 10aa from genotype E or G, 11aa from genotype F were fused to the N 
terminus of the genotype D L-protein as depicted as B11-D, E/G10-D, F11-D respectively. As a control, the G2A 
mutation to prevent the N-myristoylation of L protein was also included. In addition, The L proteins of genotype B 
with the 11 aa truncation or further fused with the N-terminal 10 aa from genotype E/G or with VP4 myristoylation 
motif were depicted as Bt, E/G-Bt, VP4-Bt, respectively. The letters in red indicate aa that differ from genotype D. 
The assembly and infectivity of virus with these L proteins are summarized on the right. 
B. Western blot of cellular extracts of HuH-7 cells 2 days post-transfection with helper constructs expressing the L-
proteins of genotype D, or the chemeric L proteins as decribed in (A). 
C. Analysis of assembly and secretion of the pseudotyped virus bearing chimeric L proteins. HBV-DNA specific 
Dot-blot of fractions of an analytical CsCl density gradient were obtained from supernatants of HuH-7 cells, which 
were transfected with a mixture of L-deficient genomic construct and helper constructs expressing L proteins of 
genotype D (row 1), or the chimeric L proteins as decribed in (A) (row 2-8). 
D. HBsAg secreted from days 8-13 following infection of HepaRG cells by the virus bearing L proteins of genotype 
D, or the mutated L proteins as described in (A). The infection was performed in the absence (black bars) or 
presence of 100 nM HBVpreS/2-48myr (white bars). 
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2.2.6 Characterization of inhibitory peptides with muations in the N-terminus 
To summarize all the mutagenesis analyses of pseudovirus, the N-terminal sequence, between 
the myristoyl group and the downstream receptor binding site, is highly critical in the following 
manner. (1) In genotype D, this sequence is relatively short (aa 1-8) but has a dual function as a 
myristoylation motif and an infection determinant. It does not tolerate N-terminal fusion with 
foreign myristoylation sequence. (2) In genotype B, it consists of two short sequences: the 
additional aa -11/-1 and the following aa 1-8. The aa -11/-1 can be deleted but can not be 
replaced by heterologous myristoylation signal either, and the sequence needs to be adjacent to 
its own downstream sequence aa 1-8.  
Based on these results, it could be proposed that this short sequence in the N-terminus acts as an 
“adapter” to connect its N-terminal essential myristic group and C-terminal receptor binding 
domain. Instead of being flexible, this sequence should be able to form a special secondary 
structure, which coordinates two essential groups in both ends to implement receptor binding. 
In order to prove this hypothesis, reconstruction of the 3D-structure of the preS1 domain is 
extremely valuable. Unfortunately, the preS1 domain is a natively unstructured protein without a 
unique tertiary structure187, and the X-ray crystallographic structure of the preS1 domain has not 
been successfully studied yet.  
However, to test the hypothesis that a very short stretch of the N-terminus of the L protein acts 
as an “adapter”, the inhibitory peptides derived from HBV preS1 provide a complementary tool 
to the infectivity assay of HBV mutants. The preS1 derived peptides can inhibit virus infection 
by interference with receptor-binding. This conclusion is supported by the following facts. (1) 
Pre-incubation of susceptible cells with peptide for 30 minutes inhibits virus infection. (2) The 
peptide has been visualized to specifically bind to the surface of differentiated hepatocytes117. (3) 
The mutated peptide without essential aa 11-15 or lacking of N-myristoylation lost their activity 
to bind with hepatocytes and inhibit virus infection. The virus carrying single-point mutations in 
this region lost their infectivity188. Considering these strong correlations between the activity of 
peptide and the infectivity of virus, the characterization of the peptides bearing N-terminal 
mutation would be an additional method to test our hypothesis, at least to estimate the binding 
of preS to the virus receptor. This approach also has some intrinsic advantages. (1) It is 
technically easy to introduce mutations during the peptide synthesis. (2) The peptides can be N-
myristoylated regardless of the presence of NMT recognition motif. (3) More important, its 
inhibitory activity is useful to estimate the binding of preS1 to the virus receptor.  
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Peptides with two types of modification (N-myristoylation or N-stearoylation) derived from the 
genotype C (C preS/-11-48myr, C preS/-11-48stear) and its truncated mutant (C preS/2-48myr, C 
preS/2-48stear) were synthesized (Fig. 22A). Since the peptide derived from genotype D can 
inhibit the infection of virus pseudotyped with different genotypic L-proteins (Fig. 17), it was 
also interesting in a vice versa experiment to compare the activity of peptides derived from 
different HBV genotypes. More important, since the virus with N-terminal 11 aa truncated 
genotype-B L-protein was more infectious than that with genotype-D L-protein (Fig. 21), it 
would be interesting to compare the activity of intact with N-terminally shortened peptide. 
According to the “adapter” hypothesis, it could be possible that the truncated peptide form a 
better secondary structure to coordinate two essential groups in its two ends to implement 
receptor binding. If this scenario hold true, the genotype C derived peptide (the preS1 sequence 
of genotype A, B and C are actually quite similar as shown in Fig. 16) truncated at the N-terminal 
11 aa should inherit this better conformation. Thus it can bind to the receptor and inhibit virus 
infection more profoundly than that of genotype D. 
To test that, these 4 peptides were incubated at different concentration with virus inoculum 
during infection to measure their inhibitory activity (Fig. 22). Consistent with previous results117, 
the stearoylated peptides showed an enhanced inhibitory activity compared to the myristoylated 
peptides. Moreover, the genotype-C derived peptides were more competent than those of 
genotype D. When the N-terminal 11 aa of genotype-C derived myristoylated peptides were 
truncated, it was more active for inhibition of HBV infection, with an IC50 less than 1 nM. This 
phenomenon can also be observed by comparing stearoylated peptides. The similarity of 
inhibitory activity of peptide and the infectivity of virus bearing the same N-terminal truncation 
demonstrated that the “adapter” sequence, when truncated at aa -11/-1, is more efficient in 
coordinating two essential groups in both ends to bind to virus receptor and thus implement 
virus entry. 
 
Results 60 
 
 
 
Results 61 
 
FIG. 22. Inhibition of genotype D HBV entry by genotype C derived peptides 
A. Peptide sequences used for the inhibition assay. The letters in red indicate the amino acids that differ from 
genotype D. All the peptides are either myristoylated (blue zigzag line) or stearoylated (green zigzag line) at the N-
terminus.  
B. HBsAg secreted from day 8-13 following infection of HepaRG cells in the absence (0nM) or in the presence of 
increasing concentration (1, 5, 25, 100, 2000 nM) of the peptides shown in (A).  
C. HBcAg-specific immunofluorescence (green) of HepaRG cells 13 days post-infection in the absence (0 nM) or in 
the presence of different concentrations (5 nM and 100 nM) of inhibitory peptides shown in (A).   
 
Second, to get an insight into the role of downstream aa 1-8, deletions and substitutions within 
this region was introduced. These mutant peptides include gradually truncations of N-terminal aa 
1-8 or substitutions with alanines to keep the overall length of peptide (Fig. 23A). Their 
inhibitory activities were measured on the susceptible HepaRG cells infected with HBV.  
In contrast to the deletion of aa -11/-1, which increases the peptide activity, the length-
increasing N-terminal truncation of aa 1-8 resulted in a progressive loss of the inhibitory 
activities. Since those peptides were highly purified and fully myristoylated in the absence of 
myristoylation motif, they provide invaluable information that virus might also gradually loose its 
infectivity with N-terminally deleted L protein. This can not be tested by introducing the 
corresponding mutations into virus particle because it would abolish the myristoylation. 
When aa 1-8 were deleted (preS9-48stear), the activity of the peptides decreased by about 1000-
fold. This again proves the conclusion that aa 1-8 is not solely a myristoylation signal. Instead, 
the presence of this sequence is fundamental to maintain the activity of peptide, thus, is also 
fundamental for the binding of myristic group and receptor binding site to the unknown 
receptor.  
The loss of activity by the N-terminal deletions can not be rescued by introducing alanines to 
keep the length of N-terminus (preS/A2-8/9-48stear). This indicates that aa 1-8 do not serve as a 
spacer, coinciding with previous results showing the loss of infectivity of VP4-8 mutant (Fig. 20). 
Furthermore, the substitution of Asn9 (preS/A2-9/10-48stear) results in a complete loss of 
inhibitory activity, suggesting that Asn9 is an essential residue for the binding of the peptide to 
the virus receptor. 
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FIG. 23. Inhibition of HBV infection by preS peptides with N-terminal truncations or substitution 
A. Schematic illustration of the sequence of peptides used for the inhibition assay. The letters in red indicate the 
amino acids that differ from genotype D. All the peptides are stearoylated (green zigzag line) at the N-terminus.  
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B-C. HBeAg secreted from day 4-7 following infection of HepaRG cells with concentrated virus in the absence (0 
nM) or in the presence of indicated concentration of inhibitory peptides described in (A).  
D. The IC50 (concentration of substance lead to 50% reduction of virus infection) of inhibitory peptides 
 
Previous results indicate that L proteins with chimeric N-termini have a profound influence on 
the virus infectivity. It was therefore interesting to test the inhibitory peptides consisting of the 
same chimeric N-termini. We selected two mutants that result in lost infectivity, B11-D and 
VP4-D, and synthesized the corresponding chimeric peptides, B-Dmyr and VP4-Dmyr (Fig. 24). 
HepaRG cells were infected with virus in the presence of these two peptides at varying 
concentrations in order to determine their inhibitory activities. 
Indeed, the inhibitory activities of both peptides were drastically reduced. Compared to the wild-
type peptides (IC50 of ~5nM), the IC50 of peptide B-Dmyr is 25-fold higher (~125 nM). Moreover, 
the peptide VP4-Dmyr can not inhibit HBV infection in concentration up to 125nM, which is 
consistent with our observation that the myristoylation signal from VP4 strongly abolishs both 
genotype-B and genotype-D L protein (VP4-D and VP4-Bt) mediated infection when it is fused 
to the N terminus (Fig. 20 and Fig. 21). 
 
 
 
FIG. 24. The inhibitory activities of myristoylated peptides with chimeric N-termini 
A. Sequence of peptides used for the inhibition assay. The letters in red indicate the amino acids from genotype-B 
L-protein or VP4. All the peptides are myristoylated (blue) at the N-terminus. The inhibitory activities of these 
peptides against HBV infection were summarized at the right. 
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B. HBeAg secreted from days 4-7 following infection of HepaRG with concentrated virus in the absence (0nM) or 
presence of inhibitory peptides described in (A) at different concentration (1, 5, 25, 125nM).  
 
Taken together, variations in the N-terminus of the peptide have a significant effect on their 
inhibitory activities. This effect is correlated with the infectivity of virus carrying corresponding 
mutations. This complementary evidence from myristoylated peptide minimize the possibility 
that the lost infectivity of virus with N-terminal chimera of preS1 (e.g. B11-D, VP4-D) is due to 
the interruption of myristoylation signal. Last but most important, these results show that the N-
terminus of the L protein (aa-11/-1 and aa 1-8) was a subtle but critical function for virus 
infection, which is probably mediated by the interference of the binding of preS to the virus 
receptor. 
2.2.7 The role of myristoylation in HBV entry 
The myristoyl moiety of L protein is critical for HBV entry. G2A mutation of L protein 
abolishes the myristoylation and also abolishes HBV/DHBV infection. Consistently, the non-
myristoylated HBV preS-dereived peptide can only inhibit infection at a much higher 
concentration (>1000 fold). While the presence of myristloyl group is known to be important for 
several years, the role of myristloylation is still unknown. The most commonly described 
function of myristoyl group is the targeting of modified proteins to membranes by inserting the 
hydrophobic C14 carbon chain into the lipid bilayer from the cytoplasmic side189. We ask if the 
myristoyl chain of HBV particle or the peptide, from the outside, addresses to and even inserts 
into the cellular membrane during interaction with receptor. If that is the case, one could 
speculate that the myristoyl chain of peptide could be functionally replaced by a transmembrane 
domain, which anchors the peptide and orientates the N-terminus of peptide to the membrane. 
To test this possibility, a type-II transmembrane protein (Us9) was fused to the N-terminus of 
HBV preS2-48. The Us9 protein is derived from pseudorabies virus and well characterized with 
respect to its trafficking and function. It is located in both trans-Golgi network (TGN) region 
and plasma membrane190. When GFP is fused to the C-terminus of US9 (US9-GFP), topology of 
the fusion protein keeps identical to that of Us9 (single-pass transmembrane protein with an 
extracellular C-terminus)191. Since the size of HBV preS2-48 is much smaller than GFP, one 
could speculate that the fusion of preS2-48 to the C-terminus of US9 do not change the 
topology either. Considering that the important “adapter” sequence between the myristoylation 
group and receptor binding site might be important for such a fusion peptide, we chose aa 2-48 
and aa -11-48 of the preS from genotype B to construct fusion peptides Us9-B48 and US9-B59 
respectively (Fig. 25A). The preS sequence of genotype B was used because pseudotyped virus 
with wide-type and truncated L protein from genotype B are both infectious (Fig. 17 and Fig. 21). 
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Moreover, the peptide B-preS/2-48myr and B-preS/-11-48myr are both active to inhibit HBV 
infection (data not shown). The Us9 protein alone was used as a control. All these three proteins 
were introduced into a lentivirus transduction system, where GFP is co-expressed with the target 
protein. 
First, lentiviruses expressing these three membrane-anchored peptides were produced, and used 
to transduce differentiated HepaRG cells. Three days post-transduction, the expression of Us9-
B48 and US9-B59 was analyzed by IF against HBV preS. An unspecific staining was observed in 
the control (Us9), but it is not localized in the transduced cell (expressing GFP). In comparison, 
the staining of Us9-B48 and US9-B59 is mostly localized in the transduced cells. More important, 
the fusion protein is mainly expressed on the plasma membrane and trans-Golgi compartment-
like structures, which is consistent with the described localization pattern of Us9 and US9-GFP 
fusion protein191,192. 
 
 
 
FIG. 25. Design of membrane anchored peptides and their expression in HepaRG cells 
A. Schematic illustration of the membrane anchored peptides. The aa 2-48 and aa -11-48 (red bars) of L protein 
from genotype B were fused to the C-terminus of Us9 protein (black bar), which contain a transmembrane domain 
within its C-terminus (TMD). The Us9 protein alone was also included as a control.  
B. Expression of membrane anchored peptides in differentiated HepaRG cells. 3 days post transduction, the 
expression of Us9-B48 and Us9-B59 was analyzed by IF with an anti-preS antibody as shown in the upper panel 
(red). The expression of GFP in transduced cell (green) and nuclei (blue) are shown in the lower panel. Lentiviral 
production in the absence of transfer vector was also used for the transduction (mock). 
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In order to investigate the influence of fusion peptides on oncoming HBV infection, the 
differentiated HepaRG cells were transduced 4 days prior to HBV infection. Indeed, there was a 
clear drop of infection when Us9-B48 and US9-B59 were expressed (judged by secreted HBsAg) 
(Fig. 26A). Since the hepatocytes were apparently not fully transduced, it was important to 
analyze at a single-cell level if the transduction could inhibit HBV infection. Therefore, IF was 
performed to identify HBV-infected cells (anti-core staining) and transduced cells (anti-GFP 
staining). It is clear that the Us9-B48 and US9-B59-transduced cells did not allow for a following 
HBV entry, showing an exclusive red core-staining in the single-cell level. In comparison, there 
are significant superinfection events (red core-staining co-existed with green GFP-expression in 
the same cell) in Us9 transduced cell (Fig. 26B).  
 
FIG. 26. Infection of HepaRG cells transduced with lentivirus expressing membrane-anchored peptide 
A. Secreted viral markers following infection of transduced HepaRG cells. Non-transduced HepaRG cells were 
infected with HBV in the absence (/) or presence (/+peptide) of 500 nM HBVpreS/2-48myr. HepaRG cells 4 days 
post-transduction were also infected with HBV (Us9, Us9-B48, Us9-B59). Lentiviral production in the absence of 
transfer vector (mock) and the HepaRG cells without transduction and infection (neg) were included. At the 
indicated time points, the secreted viral markers in the supernatant of HepaRG cells were determined by MEIA.   
B. IF analysis of transduced and infected HepaRG cells. Us9 and Us9-B48 transduced HepaRG cells were infected 
with HBV 4 days post-transduction. The infected cells are showed in red (Core) and the transduced cells are shown 
in green (GFP). The merged pictures are shown (Merged). The cells both transduced and infected are indicated with 
arrow. The merged pictures with low magnification (Merged-Low) are representative of four randomly selected 
pictures.  
 
Results 67 
 
In summary, functional membrane-anchored inhibitory peptides were designed by fusion of N-
terminal preS to a type-II transmembrane protein. These fusion peptides obviously do not 
contain myristoyl group, but remarkably inhibit HBV infection. The effectiveness of these fusion 
peptides indicates that the myristoyl chain of HBVpreS/2-48myr play its role by insertion into 
cellular membrane. Moreover, it illustrates the topology of HBVpreS/2-48myr during inhibition: 
the N-terminus towards the cellular membrane. Apparently, this interaction scenario could be 
applied to the L protein during its interaction with the cellular receptor. 
2.2.8 A possible role of preS aa 49-78 in virus entry 
As mentioned before, the role of aa 49-78 is still unclear during virus infection. However, this 
region is required for the infectivity of HBV and HDV. Interestingly, there are antibody 
responses to both conserved regions in the infectivity-determining region in some patients 
recovered from the hepatitis B infection (Abd EI Wahed, unpublished data, Gottingen), 
indicating that these could be neutralizing antibodies. Both sequences must be exposed on the 
surface of virus particle so that it is able to induce antibody responses. To explore the possible 
role of this region, mutations were introduced into this conserved region and the infectivity of 
these mutants were determined (Fig. 27). Firstly the two prolines in the conserved sequence (57-
TPPHGGLLGWSPQ-69) were substituted with alanines, PP58/59AA, and this mutant was 
compared to a substitution of proline outside this region, P36A. In contrast to P36A, the mutant 
PP58/59AA lost virus infectivity, indicating that proline within this conserved region indeed 
plays an indispensible role in virus entry. Secondly, two additional repeats were inserted into this 
conserved region leading to a triple aa57-67 (Tri 57-67). The triple conserved sequence 
introduced into L protein did not increase but again abolish virus infectivity. 
If this region (aa 49-78) in viral L protein contains a cellular binding site critical for virus 
infection, a synthetic peptide comprising aa 49-78 might interfere with HBV infection. 
Additionally, if aa 49-78 in viral L protein interact with upstream aa 2-48 during virus entry, a 
synthetic peptide aa 49-78 might also impair the activity of HBVpreS/2-48myr. Therefore, this 
peptide was synthesized (HBVpreS/49-78), and its influence on HBV infection and inhibitory 
peptide HBVpreS/2-48myr was further determined.  
The result clearly showed that it does not have an influence on HBV infection and the activity of 
preS2-48myr up to a concentration of 10µM. This result again suggests that this region is probably 
not involved in receptor binding, and it does not interact with the upstream aa 2-48 directly (Fig. 
28).  
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This data is not sufficient to make a conclusion about the role of aa 49-78, but it supports the 
notion that this region does not function as a binding site and that this region is not able to 
directly interfere with the upstream region, aa 2-48. 
 
 
FIG. 27. Expression, assembly and infectivity of pseudotyped virus carrying L-proteins mutated in 
conserved region (aa 57-69) 
A. Schematic illustration of the N-terminal sequence of chimeric L proteins carrying indicated mutation. The letters 
in red indicate the amino acids that are different from that of genotype D.  
B. Western blot of cellular extracts of HuH-7 cells 2 days post-transfection with helper constructs expressing the L-
proteins of of genotype D (wt), or the mutant L proteins as decribed in (A). 
C. Analysis of assembly and secretion of the pseudotyped virus bearing chimeric L protein. HBV-DNA specific 
Dot-blot of fractions of an analytical CsCl density gradient were obtained from supernatants of HuH-7 cells, which 
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were transfected with a mixture of L-deficient genomic construct and helper constructs expressing L proteins of 
genotype D (row 3 and 5), or the mutant (row 1, 2 and 4). 
D. HBsAg secreted from day 8-13 following infection of HepaRG cells by the virus bearing wild type genotype-D L 
proteins (wt) or the mutant (P36A, P58/59A, Tri57-67). 
 
 
 
 
 
FIG. 28. The activity of peptides HBVpreS/49-78 on infection and the inhibitory peptide 
A. Sequence of HBVpreS/49-78 and HBVpreS/2-48myr in compared to the N-terminus of L protein. These peptides 
are myristoylated (blue zigzag line) at the N-terminus.  
B. HBeAg secreted from days 4-7 following HBV infection of HepaRG in the presence of synthetic HBVpreS/49-
78 at indicated concentrations without (0 nM) or with 100 nM HBVpreS/2-48myr (100 nM).  
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2.3 Using M protein-free virus to dissect the role of preS2 for assembly and infectivity of 
Hepatitis B virus 
Due to the overlapping ORFs, the preS2 domain is present in both the L and M protein. It has 
been demonstrated that the M protein and the preS2 domain of the L protein are not essential 
for both assembly and infectivity123,125,193. However, a so-called translocation motif (TLM) was 
found in the preS2 domain, which could permeabilize cells and translocate protein into 
cytosol142. The following study suggested the translocation is a critical step during HBV entry, 
with the evidence that the deletion of TLM in DHBV led to the loss of virus infectivity. In 
contrast, different approaches from independent groups demonstrated that the absence of TLM 
in the viral envelope does not impair with infectivity of HBV and HDV122,124,194. Nevertheless, it 
is still not clear what the role of preS2 is in HBV life cycle. To answer this question, a systematic 
mutation analysis in preS2 of L protein in an M protein-free system is desirable.  
Therefore, M-protein free viruses were produced in this study where the L protein is separately 
expressed by the helper constructs. A panel of deletion or substitution was introduced to the 
preS2 domain of L protein, and viral assembly and infectivity of these mutants were further 
determined. 
2.3.1 M-free system with independent expression of S and L-protein without loss of 
infectivity 
To knock out M-protein in virion, we constructed a plasmid termed HBV L-M-, which derived 
from parent plasmid HBV L-, allowing the transcription of all known viral factors except for the 
L and M proteins. In this construct, expression of the L and M proteins are suppressed by 
mutations in the start codons of the preS1 and preS2 ORF respectively (Fig. 29A). These point 
mutations remain silent for the overlapping polymerase. Indeed, shown by L-protein Western 
blot and HBsAg assay, HBV L-M- do not express L protein but still allow secretion of HBsAg as 
its parent plasmid HBV L- (Fig. 29B). Similar to previous approach, HBV L-M- was 
complemented with the helper construct wt L, which express wild-type L protein (Fig. 29B) 
under the CMV promoter. When the helper plasmid was co-transfected with HBV L-M-, virus 
assembly and secretion was determined by DNA dot blot analysis of CsCl gradients. As expected, 
the complementation of HBV L-M- with wt L was enough to rescue the viral production (Fig. 
29D), indicating that the M protein is not essential for viral assembly.  
To exclude the possibility that the S-protein might also be expressed by the helper construct wt 
L, which contains an intact S ORF, we co-transfected a previously characterized construct (data 
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not shown), HBV L-M-S-, which cannot express any of the envelope proteins (L, M and S) but 
allows the assembly and secretion of free capsid (Fig. 29A, 29B, 29C), together with the helper 
wt L. Then we measured the secreted HBsAg post-transfection, and quantify the assembly of 
secreted viral particle. There is no detectable HBsAg of day 3 to day 5 post transfection (Fig. 29B, 
HBV L-M-S-+L), suggesting that the S-protein can not be expressed by the helper construct wt L. 
This conclusion can be further supported by DNA dot blot showing that no detectable viral 
particles were secreted (Fig. 29D, HBV L-M-S-+L). 
To exclude the possibility that the M-protein was expressed by the helper construct wt L, we 
introduced a point mutation into the start codon of PreS2 ORF (ATG to ACG) in the helper 
construct, designated LM109T (Fig. 29A). Then the expression of LM109T was confirm by Western 
blot (Fig. 29B). The ability to rescue viral secretion was determined by DNA dot blot, which 
showed reduced but profound virus particle secretion (Fig. 29D). The reduction might be due to 
the substitution of the first amino acid (methionine with threonine) of the preS2 domain of the 
L-protein, which is located in the capsid-binding region. Nevertheless, this result demonstrates 
that the M-protein is not necessary for viral assembly.  
To quantify the infectivity of these recombinant viruses, we inoculated the HepaRG cells with 
the concentrated virus from transfected or co-transfected HuH-7 cells as quantified in Fig. 29C. 
For HBV, HBV L-M-+L, HBV L-M-+ LM109T, equal genome equivalents of viral particles (ranging 
from 22-185 µl) were used for inoculation. For HBV L-M-, HBV L-M-S- and HBV L-M-S-+L that 
only produce free capsids but not viral particles, 185 µl preparation of concentrated supernatant 
was used for inoculation. We then collected the supernatant from day 7 to day12 post infection 
to quantify HBsAg and then fixed the cells for the subsequent immonofluoresence staining 
against HBV core protein. The secreted viral marker and the number of infected cells (Fig. 29D) 
both clearly showed that HBV L-M-+L, HBV L-M-+ LM109T were infectious, indicating that M-
protein is not essential for viral infectivity. The inoculation of HepaRG cells with HBV L-M-, 
HBV L-M-S- or HBV L-M-S-+L did not result in any infection, even judged by the sensitive IF 
staining (Fig. 29E). The results demonstrate the potency of the infection assay and confirm that 
the infectivity of M-free virus is not impaired. 
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FIG. 29. Expression, assembly and infectivity of M-protein-deficient hepatitis B viruses  
A. Schematic illustration of the genomic (HBV, HBV L-, HBV L-M- and HBV L-M-S-) and the subgenomic plasmids 
(L, LM109T) used for the production of M-protein deficient HBV. Start codons of the viral proteins (C = core 
protein, P = polymerase, L = L-protein, M = M-protein, S = S-protein, X = X-protein) are marked by arrows. The 
preS1-, preS2- and the S-domains of the L-protein are highlighted in pink, orange and red, respectively. The 
positions of point mutations introduced to abolish initiation of translation of L-, M-, and S-protein are depicted by a 
cross. 
B. Analyses of secreted HBsAg (MEIA of supernatant from day 3-5) and intracellular L-protein (Western Blot at day 
2 using mAb Ma18/7) post-transfection of HuH-7 cells with the plasmids indicated below. Note that despite the 
fact that endogenous promoter driven expression of L-protein (HBV) is significantly lower than ectopic co-
expression controlled by the CMV-promoter (L), HBsAg secretion remains similar. 
C. HBV-DNA specific Dot-blot of fractions (indicated 2-9) of an analytical CsCl density gradient obtained from 
concentrated supernatants of transfected HuH-7 cells. Note that transfection with the HBV genomic construct with 
L expression in cis or in trans both result in secretion of viral particles (VP, fractions 6-8) and free nucleocapsids (FC, 
fractions 3-4). Constructs lacking either L- or S-expression only form free nucleocapsids. 
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D. Infection of HepaRG-cells with comparable amounts concentrated cell culture supernatants of HuH-7 cells after  
transfection/co-transfection  with HBV, HBV L-M-, HBV L-M- + L, HBV L-M- + LM109T, HBV L-M-S- and HBV L-
M-S- + L. HBsAg secreted during day 7-11 post-infection was determined (black bars above). A control infection 
was performed in the presence of 100 nM HBVpreS/2-48myr to block the preS1-receptor-mediated entry pathway of 
HBV (grey bars above). 
E. HBcAg-specific immunofluorescence (green) and nuclei specific DAPI-staining (blue) of HepaRG cells 13 days 
post-infection with the concentrated cell culture supernatants of transfected HuH-7 cells indicated in the picture. 
Quantification of the number of HBcAg-expressing HepaRG cells (bar chart below) was done by single cell 
counting. The number of HBcAg-positive cells correlates to the secreted HBsAg depicted in Fig. 1D. 
  
2.3.2 No specific sequence in preS2/114-163 is needed for virus infectivity but a length 
dependent linker within this region is important for viral assembly 
The established M-protein-free viral production and infectivity assay endow us the capacity to 
investigate the role of preS2 of L-protein in the in the absence of M-protein. Considering the 
fact the preS2 might function in a length dependent but not sequence dependent manner, we 
constructed serial mutants to dissect the role of preS2 in the context of L-protein. In brief, we 
cloned the mutant L-protein expression construct as following: (1) the serial deletion started 
from aa 114 with increasing length, (2) shift mutations keeping the overall length of preS2 but 
substituting the residues with the corresponding ORF of polymerase which overlaps with the 
PreS2 ORF, (3) direct deletion of the TLM motif or the 20 residues in the carboxyl terminal 
region of preS2 which contains the TLM motif along with a control construct delete the first 20 
amino acids of the S domain in the L-protein (Fig. 30A). Again, the protein expression (Fig. 
30B), viral assembly (Fig. 30C) and virus infectivity (Fig. 31) were examined. 
We show that a deletion of 20 amino acids of the N-terminus of preS2 is tolerated for the 
assembly. However, a deletion of longer than 30 amino acids completely abolishes viral 
assembly. Interestingly, substituting these 30 amino acids with the exactly corresponding part of 
the polymerase sequence rescues the assembly, suggesting that the first 30 amino acids in preS2 
are important for viral assembly in a length dependent but not sequence specific manner. 
Meanwhile, the longer substitutions of 50 or 70 amino acids again abolished the assembly, but 
that was reasonable due to the marginal L-protein expression of S114-163 and undetectable 
expression of S114-183. The difference between the expression level of S114-143 and S114-163 
does not come to the conclusion that the last 20 amino acid are crucial for the L-protein 
expression, since the deletion of last 20 amino acid do not harm the L-protein expression and 
viral assembly, but suggest that the corresponding sequence in the polymerase probably lead to 
unstable conformation of L-protein, which might be degraded quickly. 
The last, we showed that the TLM is not necessary for the HBV infectivity since the deletion of 
TLM (Δ149-160), even a longer deletion of the last 20 amino acid (Δ144-163) do not impair viral 
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infectivity. In contrast, the deletion of 20 aa in the S domain of L-protein completely abolish the 
infectivity since it destroy the first trans-membrane domain (TM-I). This result shows the role of 
preS2 for the virus is not for their infectivity but for the viral assembly in length-dependent but 
not sequence specific manner. 
 
 
FIG. 30. Protein expression and assembly competence of M-protein-deficient HBV with deletions and 
frame shift mutations in the preS2-domain of the L protein.  
A. Schematic illustration of the HBV L-protein (top) with its preS1- (pink), preS2- (orange) and S- (red) domains 
and the enlarged preS2/TM-I-domain (below). The numbers in the in the line drawings refer to the amino acid 
positions of the beginning and the end of the deletions (thin lines) and the onset and the ending of the polymerase 
frame-shift (thick lines). The trans-location motif (TLM) mapped to amino acids 149-160142 and the first 
transmembrane domain (TM-I, amino acids 171-191) of the S-domain are boxed.  
B. Western blots of cellular extracts of HuH-7 cells 2 days post-transfection with the different preS2-deletion L-
constructs. Note that the L-protein mutants encoding the two longest polymerase frame-shifts (S114-163 and S114-
183) are barely or even not expressed while all other mutants show the unglycosylated and the mono-glycosylated 
forms at the expected molecular weights.   
C. HBV-DNA specific Dot-blot of fractions of analytical CsCl-density gradients of the concentrated supernatants of 
HuH-7 cells which have been co-transfected with the genomic construct HBV L-M- and the respective 
deletion/frame-shift mutation indicated at the left. Fractions containing the non-enveloped nucleocapsids are 
labeled FC, virions are labeled VP. 
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FIG. 31. Infectivity of M-protein-deficient HBV with mutations in the preS2-domain of the L-protein 
A. HBsAg secreted from day 7-11 following infection of HepaRG cells with concentrated virus from cell culture 
supernatants of transfected HuH-7 cells. Equal genome equivalents (as judged from the CsCl-density gradient) of 
M-deficient viral particles containing wild type L (L) or the L- mutations Δ114-133, S114-143, Δ144-163, Δ149-160 
and Δ164-183 were used (black bars). To control specificity of infection virus inoculation was also performed in the 
presence of 100 nM HBVpreS/2-48myr (white bars). 
B. Single cell analysis of infection by the respective M-protein free L-mutants by quantification of HBcAg-
expressing HepaRG cells. 
C. HBcAg-specific immunofluorescence (green) and nuclei specific staining (blue) of HepaRG cell 13 days post-
infection with the M-protein-deficient HBV mutants L, Δ114-133, S114-143, Δ144-163, Δ149-160 andΔ164-183. 
 
2.3.3 M-protein-deficient HBV with a randomized preS2-sequence in its L-protein 
properly assembles and is infectious in HepaRG cells and PHH 
In the previous results we showed that the most of peS2 is not needed, since both the first 20 
amino acid deletion and the last 30 amino acid substitution did not abolish the viral assembly and 
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infectivity. However, S114-163 could no be expressed well, which might due to the instablilty of 
L-pol chimeric protein. To strengthen the notion that the majority of preS2 act solely as linker 
between the preS1 and trans-membrane region, we tried to replace aa 114-163 with scramble 
amino acids instead of the sequence from pol. We synthesize overlapping oligoes endoding 
scrambled amino acid sequence of preS 114-163 but keep the codon usage except for an 
introducing of a Pst I site in the 3’ end of PreS2 (Fig. 32A). This mutated L-protein (114-
163Scramble) could be expressed although with a decreased amount (Fig. 32B). Importantly, this 
mutant supports viral assembly as well as the wild-type L protein (Fig. 32C).  
Since this mutant allows a functional L-protein expression and viral assembly, we are interested 
to explore the infectivity of recombinant virus. Firstly, the HepaRG cells were used to determine 
the infectivity of 114-163Scramble. The infectivity is marginally affected as demonstrated by the 
secreted HBsAg post-infection and the number of infected cells (Fig. 32D). The infectivity of 
this pseudovirus was further illustrated using PHH, which is a more authentic infection system. 
The result is highly in line with that from the HepaRG cells (Fig. 32E). The increasing amount of 
secreted HBsAg and HBeAg indicates an ongoing viral replication, which could be visualized by 
the IF staining (Fig. 32F). Importantly, the specificity of infection could be well manifested by 
co-inoculation the pseudovirus with the myristoylated inhibitory peptide. This result clearly 
showed that virtually the entire preS2 in the L-protein act solely as a linker for assembly. Since 
this M-protein-free mutant, 114-163Scramble, is almost as infectious as the wide-type, it again 
exclude any sequence-specific role of preS2 in HBV entry, such as translocation or fusion. 
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FIG. 32. Analysis of assembly and infectivity of an HBV-mutant containing a scramble preS2 sequence.  
A) Sequence of the HBV preS2-domain (genotype D) as part of the L-protein (top) and the scrambled preS2 
sequence encompassing amino acid 114-163 (below). Note that the very N-terminal five amino acids remained 
unchanged in order to sustain nucleocapsid envelopment. The algorithm for scrambling amino acids 114-117 (YINI) 
differed from the one used to randomize amino acids 118-163.  
B) HBV-preS1-specific Western blot (mAb Ma18/7) of cellular extracts of HuH-7 cells transfected with wide-type L  
and 114-163Scramble.  
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C)  HBV-DNA specific Dot-blot of fractions from analytical CsCl-density gradients of the concentrated 
supernatants of HuH-7 cells after co-transfections with HBV L-M- + L and HBV L-M- + 114-163Scramble. Fractions 
containing non-enveloped nucleocapsids are labeled FC, fractions containing virions are labeled VP. Note that 
although expression the preS2-scrambled L-protein was lower, virion formation was virtually unaffected.  
D). Infection of HepaRG cells using comparable amounts of concentrated virus preparation obtained from HuH-7 
cells, co-transfected with HBV L-M- + L and HBV L-M- + 114-163Scramble. HBsAg (above) secreted between day 7-
11 post-infection was quantified by MEIA (black bars). Quantification on the single cell level was performed by 
counting HBcAg-positive cells 12 days p.i. (below). Control infections were performed in the presence of 500 nM 
HBVpreS/2-48myr (white bars above).  
E) Infection of PHH using equivalent amounts of concentrated virus preparation obtained from HuH-7 cells, co-
transfected with HBV L-M- + L and HBV L-M- + 114-163Scramble.  HBsAg (above) and HBeAg (below) secreted 
between day 4-6 and day 7-9 were quantified. Control infections were performed in the presence of 500 nM 
HBVpreS/2-48myr.  
F) HBcAg-specific immune fluorescence (green) of PHH 9 days post-infection with the concentrated virus 
preparation obtained from HuH-7 cells co-transfected with HBV L-M- + L (left panels designated with L) and HBV 
L-M- + 114-163Scramble (right panels designated with 114-163scramble). Note that infection by both viruses is blocked by 
500 nM HBVpreS/2-48myr. 
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2.4 Analysis of the role of the S domain in the L protein and the S protein for assembly 
and infectivity of HBV 
As mentioned above (1.1.3), both the S and L protein, bearing the S-domain, are present in the 
envelope of Dane particle and dispensable for virion morphogenesis. The S-domain contains 
four trans-membrane domains (TM) and three loop structures, designated cytosolic loop-I (CYL-
I), antigenic loop (AGL), and cytosolic loop-II (CYL-II).  
The short N- and C-terminus of the S protein, as well as the 60-aa AGL, the main recognition 
site for the antibody response, intrude into the ER lumen and are thus present at the outside of 
the virus particle (Fig. 2). The two cytosolic loops (CYL-I and CYL-II) face toward the cytosol 
and are present in the inside of the virus particle.  
The S-domains in the S and the L protein have different topologies and functions. The CYL-I of 
the S-protein but not of the L protein is important for virus assembly, due to its interaction with 
the HBV capsid96. Whereas, the first trans-membrane domain (TM-I) of L protein probably does 
not cross the membrane and acts as a fusion peptide141. 
It has been shown that three cysteine residues (C48, C65 and C69) in the CYL-I are required for 
the SVP and virus secretion126. It has also been shown that the importance of these cysteine 
residues on the viral assembly is due to its context in the S protein, since the substitutions in the 
S protein abolish the secretion of 22nm spherical particle195. Except for these cysteine residues, 
virtually all residues in the CYL-I can be substituted without interference with the infectivity of 
HDV126. It is noteworthy to point out that these introduced substitutions affected all three 
envelope proteins, and it is still unclear whether the three cysteine residues in the context of 
CYL-I of L protein affect the viral assembly and infectivity.  
It has been shown that the AGL in the S-domain is required for the infectivity of HDV136. 
Further mutation analysis showed that the cysteine residues (C121, C124, C137, C138, C139, 
C147 and C149) in the AGL are essential for the infectivity of HDV. Again, since these 
introduced mutations were present in all three envelope proteins, it is not clear in which context 
of envelope protein the mutation interfere with virion infectivity. The underlying mechanism 
remains unclear since a possible role of protein-disulfide isomerase (PDI) as a cellular factor is 
excluded by modification of the PDI-recognition motif (see 1.4)43. Thus, the following questions 
were addressed in this study: (1) Is the AGL required for the infectivity of HBV? (2) Do the 
AGLs in the L protein and the S protein actually play different roles? (3) What is the role of 
AGL in the HBV entry? 
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Two advantages we have, as shown in the previous section, enable us to answer these questions. 
First, we have shown that the M protein is not important for infection. Since we have set up a 
method for the production of M-free virus, we can focus solely on the L and S protein. Second, 
in the envelope of the M-free virus, we showed that the L and S protein can be expressed 
separately by two different constructs, which enable us to selectively introduce mutations into 
the L or the S protein. Based on these advantages and the previous results shown in the HDV 
system, cysteine residues of CYL-I or AGL were substituted independently in either the S or the 
L protein to determine the viral assembly and infectivity. As the preS-outside topology and the 
HSPG-binding activity of virus particle are considered as prerequisites for the virus infectivity, 
the topology of L protein and heparin-binding activity of mutant virus were analyzed 
correspondingly. 
2.4.1 The effect of cysteine mutations in the S protein and the L protein on protein 
expression and secretion 
To dissect the role of cysteine residues, we selectively addressed three cysteine residues (C48, 
C65, and C69) in the CYL-I of L or S and three cysteine residues (C124, C139 and C149) in the 
AGL of L or S. these cystenies were known to be important for viral assembly and infectivity 
respectively. In the CYL-I, these cysteine residues were individually substituted with alanines 
(C48A, C65A, and C69A), and in the AGL, the cysteine residues were individually substituted 
with serines (C124S, C139S, and C149S). All the mutations were introduced either into the 
helper construct (expressing the L protein) or genomic construct (expressing the S protein) (Fig. 
33A). 
To check the expression of the L protein, HuH-7 cells were transfected with wild-type or mutant 
helper constructs, and the cells were lysed 2 days post-transfection. All the L-proteins 
(p39/gp42) were detectable by Western blot using the preS1-specific monoclonal antibody mAb 
Ma18/7 (Fig. 33B). Although the expression level of CYL-I mutated L-protein was considerably 
lower compared to the wild-type L-protein, the glycosylation pattern of both proteins was similar 
(p39 and gp42).  
To check the secretion of S-protein, the HuH-7 cell were transfected with genomic and helper 
constructs at a ration of 5:1 as established before. The supernatants of cell culture at day 3-5 
post-transfection were collected to quantify HBsAg by MEIA. Compared to the transfection 
with S-protein expression constructs, the co-transfection of S and L protein expression 
constructs resulted in 50% reduction of secreted HBsAg, which is probably due to the retention 
potency of the L protein. Nevertheless, secreted HBsAg after co-transfection with all mutant L-
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proteins was comparable to that with wild-type L-protein, suggesting that these mutant L 
proteins allowed subviral particle secretion as efficiently as the wild-type L protein. As expected, 
the cysteine mutation introduced into CYL-I of S protein abolished the S-protein secretion, 
which is consistent with previous data196. However, we could not evaluate the secretion of 
HBsAg when the cysteines in AGL of S protein were substituted with serine, since the 
commercial HBsAg test against antigenic loop probably also can not detect these mutants as 
described previously43.  
2.4.2 The effect of cysteine mutations in the S protein and the L protein on virus 
assembly 
To answer the question whether the cysteine residues in either L protein or S protein have 
different influence on HBV assembly, HuH-7 cells were co-transfected with the respective 
genomic and helper constructs as described before. The virus present in the culture supernatant 
was concentrated for DNA dot-blot analysis of viral assembly. 
Substitution of one of the cysteines in the CYL-I (C48, C65 and C69) of the S protein resulted in 
a completely abolished assembly (Fig. 34). This is consistent with the observation that these 
mutations also abolished the secretion of HBsAg (Fig. 33C), suggesting that the CYL-I is crucial 
for the interaction between S proteins to form the viral envelope as it was shown previously196, 
Notably, the corresponding mutation, when selectively introduced into the L protein context, did 
not significantly reduce the level of viral formation and secretion. This indicates that the 
interaction between L and S proteins for the envelope formation might be distinct from 
interactions between S proteins. 
In contrast,  all the cysteine mutations introduced into the AGL of the S proteins did not 
diminish viral secretion, although there is a considerable difference (e.g. ~5 fold decrease in the 
case of the C149S mutant) with regarding to the amount of secreted particle judged by DNA 
dot-blot (Fig. 34). The corresponding mutations introduced into the context of L protein did not 
lead to significant difference in the viral assembly.  
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FIG. 33. Expression of the L and S protein bearing cysteine mutations 
A. Schematic illustration of introduced cysteine mutations in the envelope of M-free virus. The 6 cysteine residues 
(C48, C65, C69, C124, C139, C149) in the CYL-I or AGL of the S protein (left) were individually substituted by 
alanine or serine as indicated. The corresponding cysteine in the L protein was also individually substituted by 
alanine or serine as indicated (right). The AGL and CYL-I are assumed to be located on the outside and inside of 
the virus particle respectively. The preS1-, preS2- and the S-domains are highlighted in pink, orange and red. Note 
that the L protein with “preS-outside topology” was shown.  
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B. Western blots of cellular extracts of HuH-7 cells 2 days post-transfection without (neg) or with the wild-type L-
constructs (wt), or with L construct bearing mutation in the CYL-I (C48A, C65A, C69A) or AGL (C124S, C139S, 
C149S). 
C. Analyses of secreted HBsAg (MEIA of supernatants from day 3-5) post-transfection of HuH-7 cells with the 
plasmids indicated below.  
 
 
 
 
FIG. 34. Analysis of assembly and secretion of M-protein-free HBV with mutated cysteines in either the S 
or L protein 
HBV-DNA specific Dot-blots of fractions of analytical CsCl density gradients obtained from supernatants of HuH-
7 cells, which have been transfected with a mixture of L and M-deficient genomic construct expressing S protein, 
and helper constructs expressing L proteins. These M-protein-free viruses contain wild-type S and L protein, or the 
indicated mutated cysteines in the CYL-I in S proteins or L proteins, or mutated cysteine in the AGL of S proteins 
or L proteins. Virus production was quantified using Quantity One, and the relative production compared to the 
wild-type is shown in the right panel with horizontal black bars. 
 
2.4.3 The effect of cysteine mutations in the S and the L protein on HBV infectivity  
The nine assembly-competent mutant viruses with mutation in the CYL-I or AGL allowed us to 
investigate the impact of individual cysteine substitutions in the S and L protein on virus 
infectivity. HepaRG cells were infected with comparable genome equivalents of the mutants, and 
the infection was quantified by the secreted viral marker or the number of infected cells (Fig. 35). 
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When any of 3 cysteines in the CYL-I of L protein was substituted, the virus infectivity was 
drastically lost, as judged by the secreted viral marker and the number of infected cells. This 
indicates the existence of an infectivity determinant in the CYL-I of L protein. Since cysteines 
are important for the formation of disulfide bonds, it is probably not the cysteine residue per se 
but the conformation of CYL-I formed by inter or intra-molecualr disulfide bonds197, which is 
critical for the virus infectivity. 
When the mutation was introduced into the AGL of the S protein, but not into the L protein, 
HBV infectivity was drastically reduced to the background level judged by co-incubation with 
100nM inhibitory peptide HBVpreS/2-48myr. This indicates that HBV infection relies largely on 
the AGL of the S protein as HDV. It must be mentioned that the infectivity of viruses with 
mutated cysteine in the S-protein is not suitable for the MEIA of secreted HBsAg, since the 
commercial HBsAg test relies on the antibody recognizing the wild-type AGL. 
The data above demonstrates the distinct roles of the CYL-I and AGL in the S and L proteins of 
HBV for infection. The CYL-I in the L protein but not S protein allows proper viral assembly 
but severely impairs the infectivity of virions. The cysteines in the AGL of the S protein, but not 
of the L protein are critical for HBV infectivity, suggesting that the observed impact of the AGL 
on HDV infectivity43 might also be resulted from the AGL in the S protein.   
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FIG. 35. Infectivity of M-protein free HBV with cysteine mutations in either S or L protein 
A. Infectivity of the cysteine mutants on HepaRG cells. The infectivity was determined by the number of infected 
cells and the amount of secreted HBsAg into the supernatant between days 8-13 post-infection. The infection was 
performed in the absence (black bars) or presence of 100 nM HBVpreS/2-48myr (white bars).  
B. IF staining of HepaRG cells using the HBcAg-specific antibody 13 days post-infection. Infected cells with virus 
containing cysteine mutations (S/L) were visualized by staining with polyclonal rabbit antiserum (H363) against 
HBV core protein (green).  
 
2.4.4 The effect of cysteine mutations on the topology of the L protein 
It was important to understand the mechanism that the virus assembly and infectivity differ 
when the mutations were differentially introduced into the S protein and the L protein. It is 
thought that the L protein have two different topologies. In one of the topology, preS is inside 
and is necessary for nucleocapsid binding, while another with preS outside is critical for receptor 
interaction. We next asked whether these mutations introduced into the CYL-I of the L protein, 
and the AGL of S protein and L protein affect the L-protein topology during virus assembly.  
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Two techniques were used to analyze the L protein topology. One is based on the assumption 
that the anti-preS antibody can only recognize viral and subviral particles with preS orientated 
outside. An rabbit polyclonal antiserum was raised against the myristoylated N-terminal 47 
residues of the L protein, HBVpreS/2-48myr. Therefore this antibody was used to immuno-
precipitate both viral and subviral particles from the supernatant of co-transected HuH-7 cells in 
the presence or absence of 0.5% NP-40. As a control for efficiency of the IP, the same amount 
of material was precipitated with PEG. Western blot analysis was performed with all three 
precipitates to determine the amount of L protein. Our result showed that the L protein-
enriched particles can be precipitated in the absence of NP-40, suggesting that all mutant viruses 
bear the preS1-domain accessible on the surface of virus particle. The use of NP-40, which 
disrupts virus membrane and increase the accessibility of the preS-inside L protein, increase the 
efficiency of IP to some extent, supporting the model of two topology of the preS-domain. More 
importantly, the amount of L protein-enriched particles correlated to the total amount, the PEG-
precipitate (Fig. 36A), indicating that mutant viral particles and subviral particles were recognized 
by the anti-preS antibody as efficiently as the wild-type. This suggests that the introduced 
mutations in the envelope protein do not significantly change the preS-outside topology of the L 
protein in viral and subviral particles. Change in their infectivity therefore did not resulted from a 
changed preS-accessibility. 
A trypsin digestion assay was used as the second method to quantify the ratio of preS-inside and 
preS-outside L protein (Fig. 36B). This method was established in previous study since trypsin 
can only hydrolyze the arginine or lysine residues in the preS domain on the outside the virus  
particle198. As a control, NP-40 was added to expose the inside preS and makes them accessible 
to trypsin digestion. Therefore, the PEG-precipitated virus was treated with trypsin in the 
presence or absence of NP-40. Following trypsinization, L protein was detected by Western blot 
with Ma18/7. Our result showed that when wild-type S and L proteins are present in the particle, 
a proportion of L protein is trypsin-resistant compared to the undigested control. The results 
favored the two topologies of L protein and validated the used digestion assay. As the wild-type, 
all cysteine mutants showed a similar trypsin-digestion pattern, supporting again the notion that 
the L proteins in the mutant viruses are topologically arranged as the wild-type. 
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FIG. 36. The topology of the L protein in cysteine mutants of HBV 
A. IP analysis to resolve the L protein topology. 1 ml supernatant of transfected HuH-7 cells with plasmid 
producing the indicated mutant viruses were subjected to IP by the polyclonal anti-preS1 antiserum (Rabbit anti-
Myrcludex B) in the presence or absence of 0.5% NP-40. As a control, the same amount of supernatants was PEG-
precipitated (input). Precipitates were analyzed by Western blot (using mAb Ma18/7) to detect the L protein.  
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B. Trypsin digestion analysis of L protein topology. The supermatant of transfected HuH-7 cell producing the 
indicated mutant virus was concentrated by PEG-precipitation. Following incubation with trypsin in the absence (2) 
or presence (3) of 0.5% NP40, Western blot analysis was perfomed (using mAb Ma18/7) to determine the 
remaining L protein. As a control for the amount of input, the untreated viruses (1) were also subjected to the 
Western blot analysis. 
 
2.4.5 The heparin-binding activity of the HBV particles with cysteine mutations 
As demonstrated above, the lost or reduced infectivity of cysteine mutant do not result from a 
changed preS-topology. Previous studies have demonstrated the importance of heparan sulfate 
glycosaminoglycans (HSPG) during HBV infection and it was suggested that HSPGs are 
responsible for primary attachment during HBV entry42,115. I therefore asked if the cysteine 
mutants interfere with virus infectivity at the primary attachment step, i.e., the interaction of 
virus particles to heparan sulfate. To answer this question, a heparin binding assay was set up in 
order to quantify the percentage of virus that can specifically bind to heparin, which has a similar 
structure to heparan sulfate (Fig. 37A). Supernatants of HuH-7 cells between day 3 and day 8 
post-transfection were applied to a heparin affinity column, and the bound viral particles were 
eluted with increasing concentrations of sodium chloride. Unbound particles in the flow-through 
and the eluted fraction were quantified by DNA-dot blot assay of the CsCl density gradients. 
Virions containing wild-type S and L protein bound to the heparin column with ~85% yield. The 
binding capacity of the heparin column was not saturated, since a 5-fold higher amount of input 
did not change the ratio of bound virus to unbound virus. This also suggests that a portion of 
virons are unable to bind heparin, as well as the majority of nonenveloped capsids (Fig. 37B). 
Furthermore, fine characterization of the eluate by three-step increasing concentration of sodium 
chloride showed that the majority of the bound virions could be eluted at 340 nM, while some 
bound virions could only be eluted at 540nM. The 2 M eluate mainly contained marginal free 
capsids (Fig. 37B). Using this binding assay, cysteine mutants were evaluated with respect to their 
binding capacity. The CYL-I mutant in the L protein with impaired infectivity did not show 
remarkable change of heparin binding. However, mutants containing cysteine mutations in the 
AGL of the S protein, which lead to a loss of infectivity, also lost their ability to bind heparin. In 
contrast, theAGL cysteine mutations in the L protein did not significantly reduce the capability 
of binding to heparin. This coincides with their remained infectivity. The bound virus can also be 
visualized in the overall elution (Fig. 37C) and the elution at 340 nM (data not shown).  
In conclusion, There is a correlation between virion infectivity and the heparin-binding activity 
when the mutations were introduced into the AGL of S and L, indicating that the AGL of S is 
the main determinant involved in the virus interaction with HSPG, which is proposed to mediate 
primary attachment during virus entry. The reduced infectivity of the cysteine mutants in the 
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CYL-I of L protein do not correlate with the heparin-binding activity leaving the underlying 
mechanism unsolved. 
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FIG. 37. Heparin-binding activity of viruses with cysteine mutations in the S or L protein 
A. Schematic illustration of heparin binding assay. Supernatants of HuH-7 cells containing cysteine mutants were 
applied to the heparin column. The flow-through (FT) was collected and the bound material was eluted in 12 
fractions by 3 steps of increasing concentration of sodium chloride (340nm, 540nm and 2M). The eluted fractions 
consist of three peaks as visualized by the blue (OD254) and the red lines (OD280). 
B. Characterization of the heparin-binding capacity and the elution profile of recombinant HBV virons. HBV-DNA 
specific Dot-blot of fractions of an analytical CsCl density gradients were obtained from the input, flow though and 
elution fractions of heparin column. 10 ml supernatant of HuH-7 cells, which was transfected with HBV L-M- and 
wt L, was diluted to final volume of 50 ml, applied to the column and eluted by three-step increasing concentration 
of sodium chloride as described in (A). 4% of input (Input), 4% of flow through (FT) and 16% of elution (Eluteall) 
were applied to the CsCl density gradient and DNA dot-blot analysis was performed (row 1-3). Dot-blot of row 4-6 
was obtained as same as row 1-3 except that 50 ml undiluted supernatant of HuH-7 cells was used. The three peak 
virus-containing fractions (Elute340mM, Elute540mM, Elute2M) were individually applied to the analytical CsCl density 
gradient and HBV-DNA Dot-blot analysis (row 7-9). Linearized pCHT-9/3091 with indicated copy numbers was 
used as the standard (the lowest row). The virus containing fraction was further quantified using software Quantity 
One, and the percentage of bound virus was calculated and shown in the box. 
C. The binding capability of cysteine mutants in the L and S protein. 10-50 ml of supernatant of HuH-7 cell post-
transfection was applied to the column. 4% of input and flow through were subjected to analytical CsCl gradient as 
well as 16 % of the overall elution (Eluteall). The percentage of bound virus are quantified, calculated and shown in 
the box. 
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3. Discussion 
3.1 Analysis of different parameters on their effect on HBV infection in HepaRG cells 
The HepaRG cell line was obtained from liver tumor tissue of a female patient suffering hepatitis 
C virus (HCV) associated hepatocellular carcinoma (HCC)171,173. This cell line was shown to be 
HCV-free and has the potential to differentiate into hepatocyte-like cells in the presence of 
DMSO and hydrocortisone. The differentiated HepaRG cells are susceptible to HBV, which was 
prepared from the culture supernatant of HepG2.2.15 cells171. HBV infection of HepaRG cells 
has rarely been reported so far with particles produced after transient transfection, e.g. HuH-7 
cells transected with replication-competent plasmid. In contrast, HDV particles produced by 
transient transfection have been used to infect HepaRG cells to investigate the infectivity 
determinant of viral envelope43,122,126. In the present study, we intended to set up an improved 
infection assay to systematically investigate infectivity determinants of HBV on HepRG cells 
with simple and visible read-outs. The specificity of infection was ensured by use of a competing 
peptide. Our effort consists of several critical steps. 
First, in order to produce sufficient amount of virus particles to support in vitro infection, we 
optimized virus preparation. The viruses were produced by co-transfection of HuH-7 cells with 
L-deficient over-length genomic construct and a helper construct. The complementation enables 
us to conveniently introduce mutations into envelope proteins without interfering with 
overlapping polymerase. The HuH-7 cells were co-transfected with these two plasmids using 
polyethylenimine (PEI). The PEI-mediated transfection on HuH-7 cells achieved transfection 
efficiency of ~30%, judged by the paralleled transfection with the GFP-expressing plasmid using 
the same expression vector (pcDNA3.1/Zeo) as the over-length HBV genomic construct. The 
efficiency of PEI-mediated transfection is ~5 fold higher than the transfection mediated by 
calcium phosphate (data not shown). Viruses produced in the supernatant could reach 5-10×107 
GE/ml, as determined by DNA-dot blot analysis of the virus-fractions of a CsCl-gradient (Fig. 
8). This method allows the separation of enveloped virions from free capsids, which are also 
produced for a still unknown reason. The virus concentration in the supernatant is an important 
factor for a successful infectivity assay on HepaRG cells. In previous studies, where viruses were 
harvested from the a stable cell line HepG2.2.15, virus concentrations in the supernatant could 
reach 1×107/ml in stationary culture199, 1.4×108/ml with optimized protocol200, and 8×107/ml 
for the infection of HepaRG cells171. Nevertheless, the viruses in the supernatants have to be 
concentrated by precipitation with 6% PEG and resuspension in 1/100th of the original volume. 
Generally, ~2×108 GE virus particles (suspended in <100µl) were used to infect ~106 HepaRG 
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cells (1 well of a 12-well plate). In contrast, the viruses in the supernatant of HepAD38 cells were 
apparently much more abundant (Fig. 8). When concentrated with PEG, virus concentration 
could reach 5×1011 GE/ml, infect 30% of HepaRG cells (Fig. 14B) and 90% of PHH (data not 
shown) of a multiplicity of 104 GE/cell.  
The second step was to optimize HepaRG cells. In the current study, we validated cell passages 
(from passage 27-38) for comparable susceptibilities and enhanced the infection by optimizating 
DMSO concentrations. The most significant difference compared to previous reports171,201 was 
the usage of 0.5% DMSO for cell differentiation. Cell death (apoptosis) of HepaRG cells 
differentiated in the presence of 0.5% DMSO was less pronounced when compared to 2% 
DMSO. Therefore, low-dose DMSO might increase the overall number of susceptible cells. 
Considering the fact that the concentration of DMSO has to be 2% during and post inoculation, 
it is surprising that HepaRG cells treated with increasing DMSO concentration from 0.5% to 
2%, or with decreasing DMSO concentration from 2% to 0.5% during this period, were less 
susceptible than those treated with constant 0.5% DMSO (Figure 10). This supports the notion 
that low concentration of DMSO (0.5%) is sufficient to differentiate HepaRG cell into a 
susceptible status for HBV infection. However, 2% DMSO resulted in the highest values of 
secreted viral marker in the following period (inoculation and post inoculation). Three 
possibilities can explain this observation. (1) High concentration of DMSO helps to accelerate 
post-entry process of the virus, e.g., endocytosis, intracellular transport of virus, or conversion of 
viral rcDNA to cccDNA. (2) High concentration of DMSO during infection enhances the viral 
replication rather than increases the number of infected cells, as previous observation showed 
that the presence of DMSO increased the replication of HBV and DHBV169,200,202. Comparing the 
number of infected cells under different DMSO concentration would help to clarify this 
possibility. (3) High concentration of DMSO could enable or increase the rate of virus spread, 
i.e., infection of naïve cells by progeny viruses. However, this explanation is contradicted by our 
observation that the progeny viruses produced by infected HepaRG cells were ~100-fold less 
abundant than the inoculated viruses (data not shown). Nevertheless, application of entry 
inhibitors to HepaRG cells after infection, such as inhibitory peptide and neutralizing antibody, 
might clarify this possibility.  
As last point, we intended to establish a sensitive single-cell-based read-out for quantifying HBV 
infection. In addition to determining the secreted viral marker (HBsAg/HBeAg), IF-analysis 
with a rabbit polyclonal anti-core antibody was developed to visualize the infected cells. The 
HBcAg-specific IF staining was quantified by counting infected cells. The number of infected 
cells is linearly correlated to the amount of virus input and the secreted HBsAg in a broad range 
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(Fig. 9). Moreover, even if the value of HBsAg assay (AxSYM, Abbott) goes below the cut-off 
due to low percentage of infection, the infection can still be quantified by the number of infected 
cells. Therefore, this new method can help us investigate infection events when the assembly or 
infectivity of virus is severely reduced. 
At the time point we performed IF (day 11-13 p.i.), core-proteins in the infected HepaRG cells 
were predominantly stained in the nucleus, along with some speckle-like structures in the 
cytoplasm. In contrast, the S-protein stained by a sheep anti-HBsAg antibody exhibited diffused 
staining pattern throughout the cytoplasm (data not shown). It is not clear if this anti-core 
antibody predominantly binds capsids or core proteins, and it is also not clear if the stained 
core/capsids are enveloped, because the Triton-100 was used to permeabilize the cell for the 
intracellular staining. This permeabilization could expose enveloped capsids to the antibody 
recognition as well. Studies have suggested that HBV virions, subviral particles, and unenveloped 
nucleocapsids might be released by distinct pathways99,101. Lambert et al. has proposed that HBV 
virion bud through late endosomal multivesicular bodies (MVB) based on the fact that Vps4 
(Vacuolar protein sorting 4) is colocalized with viral protein, and that dominant negative Vps4 
mutant blocks viral secretion101. Thus, the core-positive speckle in our study could be the late 
endosomal class E compartments as observed by Lambert. With our contribution to reaching 
high-levels of infection, the HepaRG cells might present a better model to investigate the viral 
assembly than non-susceptible cells, because it support the entire virus life cycle from entry to 
release.  
Another aspect related to endosomal trafficking is the entry process of HBV. Although DHBV 
infection has been suggested to be mediated by endocytosis65,66, it is still poorly understood 
whether endocytosis is required for HBV entry. However, endocytosis seems to be favored to 
play a role because inhibition of endocytosis by hypertonic medium also blocks HBV entry 
(Schulze A., personal communication; Glebe D., unpublished results). The involvement of 
endosomes in both pathways for virus entry and assembly raises interesting questions: do the 
incoming viruses and newly formed viruses actually “see” each other in a common compartment, 
and what is the influence on HBV life cycle? 
The inoculation of HepaRG cells with virus for 2 to 4 hours is not sufficient to reach the plateau 
of infection, but inoculation overnight significantly increases the infection (data not shown)112. 
Concentration rather than MOI dependent infection was observed in HBV infection (personal 
communication with Stephan Urban). Increasing ratios of virus-to-cell (from 10 to 10000 
GE/cell) during inoculation did not result in a saturation of infection with regarding to the 
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number of infected cells (Fig. 9). The infection can be further enhanced by spin-down-
inoculation (Fig. 11). For retroviral infection, the spin-down procedure increases the reversible 
binding of virus to the cells and counteracts forces of diffusion179. We also observed that the 
HBV particles bound to the surface of HepaRG cells were significantly increased after spin-
down inoculation (data not shown). All these data suggest that a low-affinity binding process is a 
prerequisite step to establish a productive entry. This phenomenon also suggests that HBV 
infection can only be established when substantial amounts of virus particles are bound on the 
cell surface, and that post-entry processes might be critical for the HBV infection, i.e., only a 
small potion of incoming/uptaken virus could successfully convert their rcDNA into cccDNA. 
In almost fully-infected PHHs (unpublished observation), the early kinetics of uptaken virus 
DNA and the cccDNA formation could be helpful to elucidate this process. 
An interesting observation is that infected HepaRG cells are mostly found with a canaliculus 
staining. This indicated the infected HepaRG cell is polarized similarly to primary human 
hepatocyte, where the membrane toward canaliculus forms an apical membrane. One 
explanation is that those cells forming canaliculus allow robust virus assembly and secretion. 
However, this explanation is contradicted to the well-known fact that HuH-7 and HepG2 cell 
well support HBV replication even the canaliculi are poorly formed in those cells. The second 
explanation is that the canaliculus membrane is the main entry site for HBV in cultivated 
HepaRG cells. The last explanation is that the formation of canaliculi represents a fully-
differentiated state of hepatocytes, which allows virus entry from the side of basal membrane. 
The visualization of virus entry would be helpful to distinguish these possibilities. 
3.2 The role of the N-terminus of the L protein in HBV infection 
It has been assumed for a long time that the N-terminus of the L protein plays an important role 
in receptor binding during HBV infection. The first study to pinpoint this site was published by 
Neurath et al., who highlighted aa 10-36 (referred to as Neurath’s site) from the preS1 domain as 
the specific binding site using a synthetic peptide in a HepG2 cell-binding assay45. Since more 
than 20 years, this conclusion has not been undermined. Instead, using Neurath’s site, many 
following studies identified several receptor candidates on hepatocytpe, e.g., the IL-6, SCCA-1, 
IgA receptor, or 31 kD protein on HepG2 cells (summarized in 1.1.5). However, there is almost 
no functional data connecting these proteins to infectivity studies.  
Other studies kept narrowing down the receptor binding site on the viral envelope protein using 
different methods. In 1992, Sominskaya et al. used a known neutralizing mAb, Ma18/7, to 
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underline the receptor binding site at aa 20-23118,203. Studies on other neutralizing antibodies also 
underlined aa 25-32 with mAb 5a19119,204 and aa 26-34 with mAb KR127119,120.  In 2001, Paran et 
al. identified aa 18-23 as the receptor-binding viral epitope using protein-coupled beads38. 
Collectively, all these studies showed that the central or C-terminal Neurath’s site is the receptor-
binding site.  
Grippon et al. and Bruss et al. identified the N-myristoylaton of L protein and Le Seyec et al. 
defined the N-terminal 78 aa of L protein as the essential infectivity determinant with 
experiments analyzing the virus infectivity instead of binding29,121,205. A great idea coming from 
these studies was to synthesize and characterize the peptide comprising aa 2-78 with a N-
myristoylation. Surprisingly, this peptide is highly active in inhibiting HBV infection and also 
exhibits binding activity to hepatocytes. Compared to the previous findings, studies on the 
peptide revealed that the N-terminal region (aa 9-15) of the Neurath’s site is essential for binding 
to differentiated hepatocytes104,112,117. The different results on mapping the receptor-binding site 
are apparently resulted from the fact that these peptide studies used N-myristoylated peptide and 
addressed to infectivity rather than binding. Thus, when the N-terminal myristoyl moiety is taken 
into account, the receptor-binding site of L protein is strongly dependent on aa 9-15, the N-
terminal region of Neurath’s site. 
A nearby sequence to the binding site, aa 2-8, was analyzed to details in this study. We show the 
peptide with serial deletion in this region drastically lost its activity. Furthermore, the substitution 
with alanines and the elongation with foreign sequence, such as myristoylation motif of VP4, 
severely deteriorate the function of inhibitory peptide. As a complementary approach, we show 
that the very N-terminus of L protein, aa 2-8 and aa -11-1, do not just confer the N-
myrsitoylation recognition site, but these sequences themselves are also strictly needed for virus 
infectivity. This seems to contradict the diverse N-terminal sequences of L proteins in different 
genotypes. However, it should be pointed out that aa 2-8 of L protein are relatively conserved 
among all genotypes, implying that it plays a critical function. One can speculate that, during the 
evolution of HBV, the N-terminus of L protein selectively chose some residues that enable 
myristoylation but also kept its critical function as an adapter. Considering that the aa -11-1 in 
some genotypes are dispensable for virus assembly and infectivity, one might ask why these 
residues are still present, and do they play a role in other aspects like viral pathogenesis. 
It should be pointed out that, beside as a myristoylation motif, the strict and extraordinary short 
sequence (aa 2-8) connects two critical elements for HBV infection, receptor-binding site and the 
N-myristoyl group.  Therefore, I propose that this motif additionally acts as a bridge to render 
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the two infectivity determinants in a proper position to further interact with the cellular binding 
partner. As long as the receptor of HBV is still unknown, the proposed cooperation between the 
N-myristoyl group and the receptor binding site cannot be illustrated in detail. However, this 
notion is consistent with our unpublished observation that myristoylation and the following 
aa11-15 need to be present in the same molecule of L protein (Supplemental, Fig. S4).  
To get insight into how this linker plays its role, we have to understand how the myristoyl group, 
in generally, interact with its partner. The most commonly described function of myristoyl group 
is the targeting of modified proteins to membranes by inserting the hydrophobic C14 carbon 
chain into the lipid bilayer from the cytoplasmic side189. It affects the protein’s localization and 
increases the affinity of soluble proteins for membranes, and thus enables the further 
interactions between the modified proteins and its interaction partner. HIV Nef is one of the 
well-known examples for this kind of interaction206. Until now, to my knowledge, there is no 
single reported case, in which the myristoyl group of one protein could interact with another 
protein. Thus it could be assumed that, in the case of HBV, virions also use the myristoyl group 
to interact with cellular membrane rather than directly with the receptor. This assumption is 
supported by the following observations of our laboratory. First, the myristoylated peptide, 
HBVpreS/2-48myr, have been visualized to interact with the cell surface of hepatocytes. When the 
peptide is present at µM concentration, this interaction becomes sequence-independent (Anja 
Meier, unpublished results). Second, in a liposome-leakage assay, the pore-formation activity was 
only observed when the peptide was N-myristoylated (Caroline Gähler, unpublished results). In 
the present study, this assumption is validated by successful replacing the myristoyl group of the 
inhibitory peptide with a type II trans-membrane protein (Us9-B48). Our results also 
demonstrate the topology of the peptide to execute inhibition. Moreover, Us9-B48 provides us 
an alternative to inhibit HBV entry: gene transfer of membrane anchored peptide. It is 
noteworthy to mention that, to inhibit the early event of HIV infection, a similar strategy to 
anchor inhibitory peptide on the cellular membrane has been adopted. Hildinger et al. firstly 
showed that membrane-associated C46 blocks HIV entry207. Following studies reveal that it 
interfere with the fusion event, as the soluble C46, by binding to the N-terminal domain of gp41 
and preventing formation of the six-helix bundle208,209. Moreover, the delivery of membrane-
associated C46 via foamy virus vector has proved to be successful to block HIV replication210. A 
liver-specific gene delivery thus is desirable for the possible application of Us9-B48 as an entry 
inhibitor of HBV infection. 
Since the myristoyl group itself is not sufficient to confer permanent anchoring211, stable binding 
to lipids is often mediated by other means, such as subsequent palmitoylation of nearby cysteine 
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residues, or the presence of clusters of basic amino acids near the myristoyl group to allow the 
interactions with negatively charged lipids. The L protein of HBV apparently does not have any 
of those properties. However, since the receptor-binding site is so close to the N-myristoyl 
group, it is rational to assume that interaction between the receptor and aa 9-15 of L protein 
stabilizes the anchoring of the myristoyl group. In return, the anchoring of the myristoyl group 
could also stabilize the sequence-specific receptor-binding.  
A more important inference from the vicinity of viral receptor-binding site and N-myristoyl 
group is that the interaction site on cellular receptor must be close to the membrane (or the 
receptor has a very small ectodomain). If this scenario holds true, it could be similar to the model 
of recoverin proposed by Valentine et al., who determine the structure of myristoylated recoverin 
bound to lipid bilayers by solid-state NMR. They demonstrated that membrane binding by 
recoverin is achieved primarily by insertion of the myristoyl group into the membrane bilayer 
with apparently little rearrangement of the protein structure. The N-terminal region of recoverin 
points toward the membrane surface allowing an exposed crevice, near the membrane surface, to 
serve as a potential binding site for rhodopsin kinase212. The close virus-binding site of HBV 
receptor near the membrane surface might also explain why the preS region are mostly 
unstructured187, since a flexible preS region could stretch to the membrane when the virion is 
bound to HSPG42,115. 
Nevertheless, several questions remain to be addressed with respect to the cooperative 
interaction between the myristoyl group and receptor-binding site. The first question is: Where is 
the myristoyl group initially located in virion? It is commonly thought that the myristoyl group is 
closed to the virus envelope. However, we could not exclude the possibility that preS or AGL, 
which is in the outside of viral particle, might form hydrophobic pocket to accommodate the 
myristoyl group.  
The second question is: What triggers the myristoyl switch to the cellular membrane? In some 
proteins, the myristoyl group is sequestered inside the molecule, but is exposed after an 
appropriate signal has been received. Several myristoyl switch triggers have been characterized, 
such as the binding of calcium213,214, the hydrolytic switch of the ARF1 GTPase215, and the 
autoinhibitory switch of c-Abl tyrosine kinase216. Myristoyl switch of HIV-1 matrix protein is 
regulated by entropic modulation of a pre-existing equilibrium217. In some cases, conversion 
between myristoyl group-exposed and -sequestered states is accompanied by conformational 
changes of protein structure. For example, in a soluble state, the myristoyl group of PKA is 
bound to a hydrophobic pocket in the C-terminal lobe. In the membrane-associated form, the 
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N-terminus extends its helical conformation, thus exposing the myristoyl group to the solvent 
and/or membrane218. Interestingly, the NMR study on the preS modified by N-myrisoylation 
suggested that the conformational transition induced by fatty acylation is important for efficient 
attachment of virus to cell receptors219. One might speculate that the receptor-binding or the 
downstream aa 49-78 of L protein could be involved in the myristoyl switch of HBV.  
The third question is: Whether the N-terminus plays a role in later fusion events? For enveloped 
viruses, fusion is mediated by viral fusion protein, which contains a small hydrophobic sequence 
termed fusion peptide. Upon appropriate triggering, the fusion peptide interacts with the target 
membrane and undergoes a conformational change that drives the membrane fusion. Actually, 
the putative fusion peptide of HBV has been described at the N-terminus of S domain220 and a 
synthetic peptide comprising this predicted fusion region was shown to interact with 
membranes, and destabilize liposomes in a pH-dependent manner221. Interestingly, this year, 
Nunez et al. from the same lab reported that preS domains are also able to insert themselves into 
the hydrophobic core of bilayer. Moreover, the insertion resulted in a conformational change of 
preS1 which increased the helical content222. Notably, the preS was not myristoylated in the study 
of Nunez. As a well-known fact, the myrisoylation at the N-terminus of peptide can significantly 
enhance its membrane binding activity. Therefore, it could be expected that the authentic preS, 
with myristoylation, is more potent for inducing the lipid mixing or leakage assay. Thus, a study 
of our laboratory was initiated to measure the activity of the peptide, HBVpre/2-48myr, in 
inducing membrane-leakage of liposomes. At a concentration around 70 µM, the genotype D-
derived peptide penetrates the liposome in a sequence- and myristoylation-dependent manner 
(unpublished result of Caroline Gähler). Furthermore, the myristoylated peptide comprising the 
N-terminus of different genotypes or chimeric genotypes were synthesized and their membrane-
leakage activity were determined (Supplemental, Fig. S5). Although the membrane activity of 
peptide was not well correlated with the infectivity of virus, it appeared to be highly dependent 
on the N-terminal residues of L protein. For example, the peptides of genotype E and the 
chimera E10-D, drastically increased the membrane-leakage activity, while the genotype B 
exhibited slow kinetics. If the N-terminus of L protein can be further confirmed to act as a 
fusion peptide, it might represent a different model compared to the commonly accepted class-I 
and class-II fusion protein223. It must be pointed out that the hydrophobic fusion peptide of HIV 
can be substituted by fatty acid in lipid merging and fusion224, indicating the intrinsic fusion 
activity of myristoyl chain. A similar case might come from the reovirus fusion-associated small 
transmembrane (FAST) proteins, which has been shown to be myristoylated in the ectodomain, 
capable of inducing efficient membrane fusion under physiological conditions. The reovirus 
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FAST proteins are small proteins, containing a moderately apolar N-proximal region, termed the 
hydrophobic patch. Corcoran et al. synthesized a myristoylated peptide comprising the 
hydrophobic patch of p14 of reptilian reovirus (Fig. 38), and demonstrated that it is mostly 
disordered in solution but mediated extensive lipid mixing in a liposome fusion assay in a 
myristoylation- and sequence-dependent manner. Thus they proposed that p14 ectodomain is 
composed of a fusion peptide motif which depends on myristoylation for the membrane fusion 
activity225. 
 
FIG. 38. p14 contains a hydrophobic patch in its 
ectodomain (modified from Jennifer A. Corcoran225). 
The locations of the myristoylation consensus sequence, 
hydrophobic patch, transmembrane anchor, polybasic 
region, and polyproline region are indicated in structural 
models of p14. The p14 hydrophobic patch (residues 2–21, 
boldface) is located within the small 38-residue ectodomain 
of p14. The p14 hydrophobic patch peptide (myr-30HP) 
included residues 2–31 with the N-terminal myristic acid 
modification on Gly2. 
 
 
 
 
Our preliminary investigation on aa 49-78 elicit great interest about its function.  Since it is 
apparently not involved in binding to cellular receptor, it might be worth looking into if it 
behaves as a switch (as mentioned above) to help the conformational changes when the N-
terminal region binds to a cellular receptor. It must be pointed out that the conserved sequence 
PHGGLLGWSPQ is close to a motif (PHGGGWGQ) in the prion protein, which constitute a 
pH-dependent folding site226. In the present study, we showed that two proline residues in this 
domain, compared to the proline outside this domain, are highly important for virus infectivity. 
Proline residue has an exceptional conformational rigidity compared to other amino acids. It is 
often found in a hinge or a kink and acts as a disruptor of alpha helices and beta sheets. 
Interestingly, HBV preS is a proline-rich sequence (18 prolines out of 108 residues), and this 
structure might provide the flexibility of preS domain to interact with receptor. 
3.3 The role of preS2 in HBV assembly and infectivity 
In this work, the whole preS2 region except 5 aa in the N-terminus was mutated in a 
comprehensive manner, and the effect of mutations were further characterized with respect to 
virus assembly and infectivity. Le Seyec et. al. have shown that consecutive 10 amino acids in this 
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region can be deleted without interference with virus assembly and infectivity123. In 
complementary to their work, we show that larger deletions, exceeding 30 amino acids (Δ114-
143), lead to an abolished virus assembly. However, substitution of these 30 amino acids (S114-
143) rescued the viral assembly and partially infectivity. This indicates that aa 114-143 is required 
for virus assembly in a length-dependent but not sequence-dependent manner.  
We also showed that 20 aa in the C-terminal part of preS2 can be deleted (Δ144-163) with 
marginal effect on assembly and no effect on infectivity. Therefore, it is rational that whole 50 aa 
actually serve as a spacer. The entire 50 amino acids of preS2 were thus substituted with 
overlapping pol-ORF. Due to inefficient expression of the L-protein, the virion secretion can 
not be detected. The substitution of the entire 50 amino acids with a scrambled sequence finally 
clarify that the preS2 domain is only required as a spacer for virus assembly. There is also an 
interesting question: if the spacer function of preS2 are also required during virus entry. 
In consistent to the result from Le Seyec et. al., we also observed an increased secretion when the 
amino acids 114-123 were deleted from the preS2 of the L-protein (data not shown). Moreover, 
we showed that the 20 amino acids deletion was still tolerated. Indeed, HBV isolates from 
patients reveal that the naturally occurred deletion in the preS2 region is mostly located within aa 
114-133227-229. So far, to my knowledge, no HBV isolate has been reported with a larger preS2 
deletion than 20 amino acids. This fact fits to the observation that 30 amino acids deletions 
abrogate viral assembly. It is noteworthy to point out that there is a conserved sequence 
“AGGSSSG” within aa 134-143, which might providing a flexible connection between capsid 
binding region and transmembrane domain of L protein.  
Consistent with several independent works122,124,194, we show that the deletion of so-called TLM 
motif (aa 149-160) does not interfere with virus infectivity. Collectively, these data rule out the 
possibility for TLM to play a role during virus entry, such as translocation of the virion into 
cytosol or fusogenic activity 143. On the other hand, a deletion of a nearby region (Δ164-183) 
constitutive of TM-I abolishes virus infectivity. This is consistent with recently published data, 
which showed that deletion of a small hydrophobic cluster (aa 175-178) at TM-I is enough to 
abolish HBV infectivity201. It has been supposed that TM-I might act as fusion peptide141,220. 
However, two elements related to fusion event, PEST sequence (aa 157-169) and heptad repeat 
motif, are both dispensable for virus infectivity. The role of TM-I during virus infection is still 
unclear. 
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3.4 The role of S-domain in HBV entry 
Heparan sulfate proteoglycans (HSPGs) have been described as primary attachment site or 
receptor for many viruses. In the present study, we showed that, for the first time, the AGL in 
the S protein determine HBV infectivity and further correlate the role of AGL to HSPG-binding 
activity. 
A previous study from our lab shows that HBV entry in hepatocytes depends on the interaction 
with cellular HSPG and further suggests that the preS domain in the L protein is involved in 
HSPG-binding42 based on the following observation. (1) Heparin-binding activity was lost when 
the viral particle was digested with trypsin to remove preS. (2) HBsAg bound much weaker to 
heparin than virion. In view of this data, we initially expected that a reduced heparin-binding 
activity might be observed in the virions with CYL-I-mutated L protein, since these mutants 
exhibited a reduced infectivity and the mutation in CYL-I might change the topology of preS in 
the L protein. Unexpectedly, it turned out that these mutants did not change their preS topology 
and did not loose their heparin-binding activity. However, the AGL mutants lost their heparin-
binding activity without changing the preS topology. 
The discrepancy between the present study and the previous work can be explained by two 
possibilities: (1) The preS domain and the antigenic loop, of which both are exposed on the 
surface of virion, cooperatively bind to the heparin column. (2) The antigenic loop exclusively 
binds to heparin, but that fact that virus digested by trypsin fail to bind heparin is due to an 
interrupted antigenic loop caused by trypsin digestion. 
In most cases, the interaction between cell surface HSPG and its ligands is thought to be 
nonspecific and probably based on electrostatic attractions between the highly charged sulfated 
proteoglycans and basic residues. The linear sequences XBBXBX,  XBBBXXBX, 
TXXBXXTBXXXTBB (B is Arg or Lys and T define a turn) are common HSPG binding motifs 
found in proteins, such as interleukin-8, and fibroblast growth factors230. Some viruses also use 
clustered basic residues for their interactions with HSPG. These interactions provide initial 
attachment sites and concentrate viruses in the proximity of the cell surface to facilitate 
interactions with specific receptors231-235. Two HSPG binding motifs of pseudorabies virus (PRV) 
glycoprotein gC, SRRKPPRN and AHGRKRI, were found in the N-terminus of the protein236. 
The HSPG binding domain of HIV-1 gp120 was mapped to three sequences, RGKVQK, 
RPNNNTRKRIR and KAKRR237. A basic motif of KKTK was found in the fiber shaft of 
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human adenovirus type 5 to interact with HSPGs238. A Loop in DENV-2 envelope protein, 
which contains three Lys residues (KFKIVK), constitutes the HSPG binding site.  
Unlike the known HSPG-binding motifs in the viruses mentioned above, most basic residues in 
the envelope proteins of HBV are not clustered. In the genotype-D virus, there are 17 arginine 
or lysine residues in the L protein consisting of 389 amino acids. They are R24, K38, K46, R88, 
R92, R102, R124, R126, R156, R187, R236, R241, R242, R285, K304, K323 and R332. Among 
them, only 6 residues are located in the infectivity-determining region. Since the other residues 
can be either deleted or substituted without interfering with virus infectivity, they should not be 
the critical residues responsible for HSPG-binding. Among these 6 residues, 3 of them are 
located in aa 2-78 (R24, K38 and K46). When compared with amino acid sequences from 
different genotypes, only K38 is conserved among these three residues. R24 and K46 were often 
replaced with glycine and glutamine. In contrast, the other 3 residues located in the AGL (R285, 
K304 and K323) are highly conserved. Since these residues are also present in the S-protein, they 
are often numbered as S-R122, S-K141, and S-K160 according to their positions in the S-protein. 
These highly conserved basic residues in the S-domain indicate that they are likely more 
important for virus-HSPG interaction than those in the preS domain. 
It is noteworthy to mention that two of the three basic residues in AGL (S-R122 and S-K160) 
could be exclusively replaced with lysine and arginine in different virus serotypes. These changes 
constitute two pairs of epitopes defined by antibody recognition, named “d” or “y” and “w” or 
“r”. Determinant “d” has a lysine at the position 122, while “y” has an arginine at the same 
position; “w” has a lysine at position 160 while “r” has an arginine at that position (see 1.1.2). 
The accessibility of these residues to antibody recognition shows that they are exposed in the out 
surface of viral particle and, thus, should be also accessible to HSPG-binding.  
The notion that AGL is responsible for HSPG-binding is supported by an observation: A point 
mutation at S-R122 leads to decreased heparin-binding activity and loss of HDV infectivity 
(Sureau C., personal communication). The decreased heparin-binding activity by single-point 
mutation suggests that the affinity between AGL and HSPG is quite weak. However, since the 
protein content of HBV envelope is rather high and the AGL is present in all envelope proteins, 
the avidity between virus particle and heparin could still be high enough to support a stable 
interaction.  
It should also be kept in mind that the majority of HBsAg do not bind to heparin column in 
contrast to virions. This fact seems contradict to our conclusion that AGL is responsible for 
binding with HSPG. This contradiction could be explained by two possibilities. The first is that 
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some basic residues in the preS region also contribute to the binding with HSPG. However, 
since the 20 nm sphere particles are the main component of HBsAg and the 42 nm virions 
apparently contain more envelope proteins per particle, the second explanation is that the avidity 
but not affinity of virion to HSPG are higher than that of sphere particle solely due to the 
abundance of envelope proteins. One could deduce that filament, apparently with more 
abundant envelope protein, could bound to HSPG more tightly than virion and sphere particle. 
Indeed, it is the case according to an unpublished observation (Caroline Gähler, unpublished 
data). 
It is demonstrated that the lost infectivity of C121 or C124 mutants is not related to a typical 
PDI activity43. However, treatment of hepatitis delta virion with reducing agents leads to the loss 
of virus infectivity. This argues that proper-formed disulfide bridges in the envelope are critical 
for virus infectivity. Although it can not be excluded that atypical recognition sites rather than 
CXXC motif are utilized by PDI or other enzyme, there is a simple explanation for the loss of 
infectivity when the virus bears mutation at cysteine residue of AGL or is treated with reducing 
agents. The mutations or treatments change the conformation of AGL, which might disable the 
interaction between the basic residues and the heparan sulfate.  
In view of the role of AGL we proposed, the following questions are interesting and should be 
further investigated. (1) Do the neutralizing antibodies induced by commonly used vaccine, 
which only contain S protein, play their role by preventing the S-domain from binding to HSPG? 
(2) Do the two well-known escape mutants, S-G145R (introduction of a positively charged 
residue) and S-D144A (removal of a negatively charged residue), not only disable antibody 
recognition but also result in a higher affinity between the virion and HSPG? (3) Can the 
abolished infectivity of AGL mutant described in the present work be rescued by introduction of 
positively charged residues or the HSPG-binding motifs with high affinity? 
3.5 Model for HBV attachment and receptor binding  
According to the information obtained from this works and the published dataa, I propose here 
a model for a multi-step interaction between virion and hepatocyte during the attachment and 
receptor-mediated binding (Fig. 39).  
To enable the initial attachment, both the S-protein and the S-domain of L-protein interact with 
the HSPG via (one of) the three basic residues in the AGL (Sureau C., unpublished results). 
Since the S-protein is much more abundant than L-protein on the surface of virus particle, the 
main contribution to viral attachment is from the AGL of S-protein and the role of L protein in 
this process would be marginal (concluded from Chapter 2.4). At this time point, the N-terminal 
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myristoyl group of L protein is still associated with the virus membrane for the free virus and the 
HSPG-associated virus. Meanwhile, the interaction site of virus receptor with preS1 is in a close 
proximity to the membrane, or simply that virus receptor is a molecule with small ectodomain, 
(concluded from Chapter 2.2, the inhibitory activity of shorter peptide preS/2-48myr is higher 
than preS/-11-48myr). During the specific interaction, aa 2-48 of preS1 domain of L protein are 
involved. The aa 49-78 act as a switch to project the viral membrane associated N-terminus 
(speculation from Chapter 2.4). Afterwards, the interaction between the essential binding site and 
the virus receptor occurs. The affinity of this interaction is greatly enhanced by the insertion of 
myristoyl group into cellular membrane. The adapter sequence, aa 2-8, is critical to enable this 
close cooperation between the myristoyl group and essential binding site (concluded from 
Chapter 2.2, aberrant aa 1-8 impairs the activity of peptide and abolishes the infectivity of virus). 
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FIG. 39. Model of HBV entry. 
(1) During virus attachment, both L and S protein on the virus membrane attach to HSPG via the AGL, but the S 
protein is the main contributer to the attachment due to its high abundance on the viral envelope.  
(2) Prior to the preS-mediated receptor binding, the myristoyl chain is hidden while the essential binding site (aa9-
15) and aa 49-78 are exposed.  
(3) Conformational change of preS (via aa 49-78?) switchs the N-terminus to the cellular membrane.  
(4) The viral receptor-binding site interacts with a specific receptor in proximity of the membrane.  
(5) The myristoyl group inserts into the membrane, consolidating the interaction between the preS1 and its receptor.  
(6) The atypical linker (aa 2-8) enables the cooperation of myristoyl group and receptor binding site. 
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4. Materials and Methods 
4.1 Materials 
4.1.1 Instruments, consumables, software and reagents 
Instruments and consumables Supplier 
ABI PRISM 7000 Gene Analyzer Applied Biosystems 
Autoclaver, 5050 ELV Tuttnauer Systec 
Incubator (37ºC) Heraeus 
Ice machine Scotsman 
Electrophoresis plates Amersham Pharmacia (Hoefer) 
Electrophoresis chambers 
EMBL86 (V150), Amersham 
Pharmacia (Hoefer): „Mighty Small“ 
Filter paper Whatman 
Fraction collector Beckman 
Cell culture flask (75 bzw. 25 cm2) Greiner 
Cell culture dish (60mm x 1,5cm ;145mm x 2cm) Greiner 
Centrifuge J2-21M/E (JA-14/JA-20) Beckman 
Cryo-tube Greiner 
Refrigerators (4ºC/-20ºC) Liebherr 
Microscope, Axiovert25 Zeiss 
Microscope, DM IRB Leica 
Cell culture plate (6, 12, 24-well) Greiner 
Mixer Thermomixer compact, Eppendorf 
Parafilm Pechiney Plastic Packaging 
Pasteur Pipet WU Mainz 
Thermocycler Thermo Hybaid 
pH-Meter Metrohm 
Photometer (DNA/Proteine) Eppendorf, Amersham Pharmacia 
Photometer OD600nm (DU 7400) Beckman 
Pipeter Gilson 
Pipet helper Hirschmann, Integra Biosciences 
Polystyrene reaction tube (15 or 50ml) Falcon 
Power Supply 
Monacor, LKB Brumma, Amersham 
Pharmacia 
Reaction tube 0,5 ml, 1,5 ml, 2 ml Eppendorf, Sarstedt 
Film Kodak 
Sample mixer (rotation)  NeoLab 
Shaker (30ºC), Certomat BS-1 B.Braun Biotech International 
Shaker (RT/ 4ºC) GFL, Heidolph 
Shaker for Bacterial culture (37ºC) GFL, Infors 
Biosafety Cabinet, NapFlow, NapCo 
0.2μm and 0.45μm sterile filters Fisherbrand 
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Sterile filter bottles (500ml/Nalgene) Nalge Nunc 
Sterile plastic pipettes  Sarstedt 
Nitrogen tank, Cry300 Thermo Forma 
TC-Plate 6-well Greiner 
Freezer –80ºC Nap Coil 
Trans-Blot SD, Semi-Dry Transfer Cell Bio-Rad 
Vacum Hand Control Vacuubrand 
Vortexer Bender + Hobein AG, Neolab 
Water bath Medingen, Braun 
Cell Counter IVO 
Centrifuge, Biofuge Heraeus 
Centrifuge, Multifuge3 S-R Heraeus 
Nitrozellulose-Membran (0,2μm, 0,4μm) Schell und Schleicher 
Parafilm Serva 
PVDF-Membrane Schleicher & Schüll 
Sterile filter Schleicher & Schüll 
    
Softwares Supplier 
Vector NTI InforMax, Invitrogen 
Quantity One Biolab 
    
Chemical reagent Supplier 
Acrylamid/Bisacrylamid mixture, 29:1 Roth 
3-Amimophtalhydrazid Sigma 
Agarose Gibco 
Ammonium acetate AppliChem 
Ammonium peroxodisulfate (APS) Roth 
Ammonium sulfate Gerbu 
Ampicillin Sigma 
Aqua ad iniectabilia Braun 
Bacto-Agar Difco 
Bacto-Trypton Difco 
Bacto-Yeast Extract Difco 
Big Dye Applied Bioscience 
β-Mercaptoethanol Merck 
BSA (Bovine serum albumin) Roth 
Cesium chloride Sigma 
Coomassie brilliant blue G250 Sigma 
Coomassie brilliant blue R250 Sigma 
p- Coumaric acid Sigma 
Cyanbromid Sigma 
deoxyribonucleoside triphosphate Sigma 
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Di-Kaliumhydrogenphosphat Merck 
Di-Natriumhydrogenphosphat (Na2HPO4) J.T.Baker 
DMSO (Dimethylsulfoxid) Merck 
dNTP Mix Roche 
DMEM (Dulbecco`s modified Eagles medium) Invitrogen 
DTT Biovectra 
ECL Reagent 
Amersham Pharmacia, or home-made 
solution 
EDTA-Dihydrate Roth 
Acetic acid Roth 
Ethanol absolute Riedel de Haen 
Ethanol 99% Chemikalienlager 
Ethidium bromide Sigma 
FCS (fetal calf serum) Invitrogen 
FCS (fetal calf serum) Biochrom 
Formaldehyd, 37% J.T. Baker 
Glutamin-solution (200mM)/Cell culture Gibco 
Glutamin Invitrogen 
Glycerin 99,5% J.T.Baker 
Glycin p.a. min. 99% Glykokoll AppliChem 
Hydrocortison Sigma 
pH indicator paper Merck 
Insulin Sigma 
Isopropanol AppliChem 
Calcium acetate Roth 
Calcium chloride Sigma 
Calciumdi hydrogen phosphate Gerbu 
Milk powder Roth 
Methanol 100% Chemikalienlager 
Sodium acetate J.T. Baker 
Sodium bicarbonate-solution (NaHCO3/ 7.5%) Gibco 
Sodium carbonate, water free AppliChem 
Sodium deoxycholate Sigma 
Sodium chloride Grüssing 
Sodium dihydrogenphosphate (NaH2PO4) Merck 
Sodium hydroxide J.T. Baker 
NP40 Sigma 
Orange G Sigma 
PEG 8000 Sigma 
Protease inhibitor Cocktail Roche 
Rainbow colored protein molecular weight markers Amersham Pharmacia 
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SDS (sodium dodecyl sulfate) Serva 
Silver Nitrate AppliChem 
Sucrose, D(+) Roth 
TEMED (N,N,N´,N´-Tetramethylethylendiamin) Roth 
Tris Roth 
Triton X100 Serva 
Tween 20 Roth 
William’s E Medium Invitrogen 
Dulbecco’s Modified Eagle Medium Invitrogen 
William’s E Medium Invitrogen 
    
Enzymes Supplier 
Deep Vent Polymerase (exo+) New England Biolabs (NEB) 
Calf Intestine Phosphatase New England Biolabs (NEB) 
T4 DNA Ligase New England Biolabs (NEB) 
Klenow Fragment Roche 
DNase I Roche 
Shrimp Alkaline Phosphatse (SAP) New England Biolabs (NEB) 
RNase A Boehringer 
Trypsin Gibco 
    
Antibiotics Supplier 
Ampicillin Sigma 
Chloramphenicol Sigma 
Kanamycin Serva 
Penicillin Sigma 
Streptomycin Sigma 
    
Primary antibodies Supplier 
Ma18/7 
hybridoma kindly provided by W.H. 
Gerlich, Giessen 
Rabbit anti MRP2 
gift from Keppler O, University of 
Heidelberg 
Rabbit anti core H363 
gift from Schaller H, ZMBH, 
Heidelberg 
Mouse anti core #312 
gift from Schaller H, ZMBH, 
Heidelberg 
Mouse anti core #158 
gift from Schaller H, ZMBH, 
Heidelberg 
    
Secondary antibodies Supplier 
Goat-anti-Rabbit peroxidase Dianova 
Goat-anti-Mouse peroxidase Dianova 
Mouse-anti-Goat peroxidase ImmunoResearch Laboratries 
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Goat anti-Mouse IgG Alexa 488  Invitrogen 
Goat anti-Mouse IgG Alexa 546 Invitrogen 
Goat anti-Rabbit IgG Alexa 488  Invitrogen 
Goat anti-Rabbit IgG Alexa 546 Invitrogen 
Goat anti-Mouse Alexa 680 Invitrogen 
Goat anti-Mouse Alexa 800 Invitrogen 
Goat anti-Rabbit Alexa 680 Invitrogen 
Goat anti-Rabbit Alexa 800 Invitrogen 
    
Kits Supplier 
Plasmid Maxi and Midi kit Qiagen 
Terminator-cycle Sequencing kit  ABI 
Gel exaction kit Qiagen 
Fastplasmid Mini kit Eppendorf 
 
4.1.2 Oligonucleotides 
No. Name of primer Seqence(5'-3') bp 
55 MfeI-Pres-down GCAATTGATTATGCCTGCCA 20 
56 XhoI-PreS-up GGTCCCCAATCCTCGAGAAG 20 
57 1279stop-down GCCATGCAGTAGAATTCCACA 21 
58 1279stop-up TGTGGAATTCTACTGCATGGC 21 
59 1279stop-down-2 TGCAGTAGAATTCCACAACCT 21 
60 XhoI-PreS-up-2 GCAACATACCTTGATAGTCCA 21 
61 L muta S GTAGGCGTGTACGGTGGGAGGT 22 
62 L 114/123 AS GCCTCTCACTCTGGAATTCCACTGCATGGCCTGA 34 
63 L 114/123 S CAGTGGAATTCCAGAGTGAGAGGCCTGTATTTCC 34 
64 L 114/133 AS TGAACTGGAGCCGGAATTCCACTGCATGGCCTGA 34 
65 L 114/133 S CAGTGGAATTCCGGCTCCAGTTCAGGAACAGTAA 34 
66 L 114/143 AS GGCAGTAGTCAGGGAATTCCACTGCATGGCCTGA 34 
67 L 114/143 S CAGTGGAATTCCCTGACTACTGCCTCTCCCTTAT 34 
68 L 114/153 AS AATCCTCGAGAAGGAATTCCACTGCATGGCCTGA 34 
69 L 114/153 S CAGTGGAATTCCTTCTCGAGGATTGGGGACCCTG 34 
70 L 114/163 AS GATGTTCTCCATGGAATTCCACTGCATGGCCTGA 34 
71 L 114/163 S CAGTGGAATTCCATGGAGAACATCACATCAGGAT 34 
72 L 114/173 AS CACGAGAAGGGGGGAATTCCACTGCATGGCCTGA 34 
73 L 114/173 S CAGTGGAATTCCCCCCTTCTCGTGTTACAGGCGG 34 
74 L 114/183 AS TCTTGTCAACAAGGAATTCCACTGCATGGCCTGA 34 
75 L 114/183 S CAGTGGAATTCCTTGTTGACAAGAATCCTCACAA 34 
76 L 114/193 AS CGAGTCTAGACTGGAATTCCACTGCATGGCCTGA 34 
77 L 114/193 S CAGTGGAATTCCAGTCTAGACTCGTGGTGGACTT 34 
78 L 114/203 AS TCCCCCTAGAAAGGAATTCCACTGCATGGCCTGA 34 
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79 L 114/203 S CAGTGGAATTCCTTTCTAGGGGGAACTACCGTGT 34 
80 L 114/213 AS CTGCGAATTTTGGGAATTCCACTGCATGGCCTGA 34 
81 L 114/213 S CAGTGGAATTCCCAAAATTCGCAGTCCCCAACCT 34 
82 L 114/223 AS AGAGGTTGGTGAGGAATTCCACTGCATGGCCTGA 34 
83 L 114/223 S CAGTGGAATTCCTCACCAACCTCTTGTCCTCCAA 34 
84 L 114/233 AS CCAGCGATAACCGGAATTCCACTGCATGGCCTGA 34 
85 L 114/233 S CAGTGGAATTCCGGTTATCGCTGGATGTGTCTGC 34 
86 L 114/243 AS GAGGAAGATGATGGAATTCCACTGCATGGCCTGA 34 
87 L 114/243 S CAGTGGAATTCCATCATCTTCCTCTTCATCCTGC 34 
88 L 114/253 AS CAAGAAGATGAGGGAATTCCACTGCATGGCCTGA 34 
89 L 114/253 S CAGTGGAATTCCCTCATCTTCTTGTTGGTTCTTC 34 
90 L muta AS TGGCTGGCAACTAGAAGGCACA 22 
91 MS muta S AAGGTAGGAGCTGGAGCATTCG 22 
92 M(-) T1273C AS AATTCCACTGCGTGGCCTGAGGATGAG 27 
93 M(-) T1273C S TCATCCTCAGGCCACGCAGTGGAATTC 27 
94 S(-) T1438C AS TGTGATGTTCTCCGTGTTCAGCGCAGG 27 
95 S(-) T1438C S CGCTGAACACGGAGAACATCACATCAG 27 
96 MS muta AS GAGGTTGGTGAGTGATTGGAGG 22 
114 pcDNASEQ-F CCCACTGCTTACTGGCTTATCG 22 
115 pcDNASEQ-R GATGGCTGGCAACTAGAAGGCACAG 25 
116 HuL1240 InsA S ATGCAGTGGAATTCCAACAACCTTCCACCAA 31 
117 
HuL1389 DelC 
AS ATGTGATGTTCTCCATTTCAGCGCAGGGTCC 31 
118 HuL1389 DelC S GGACCCTGCGCTGAAATGGAGAACATCACAT 31 
119 
HuL1329 DelT 
AS AGAGGCAGTAGTCAGACAGGGTTTACTGTTC 31 
120 HuL1329 DelT S AACAGTAAACCCTGTCTGACTACTGCCTCTC 31 
121 
HuL1449 DelC 
AS TTGTCAACAAAAAAACCCCGCCTGTAACACG 31 
122 HuL1449 DelC S GGCGGGGTTTTTTTGTTGACAAGAATCCTCA 31 
123 L 144/163 AS GATGTTCTCCATAACAGGGTTTACTGTTCCTGAA 34 
124 L 144/163 S GTAAACCCTGTTATGGAGAACATCACATCAGGAT 34 
125 L 164/183 AS TCTTGTCAACAAGTTCAGCGCAGGGTCCCCAATC 34 
126 L 164/183 S CCTGCGCTGAACTTGTTGACAAGAATCCTCACAA 34 
127 L 149/160 AS CATGTTCAGCGCAGAGGCAGTAGTCAGAACAGGG 34 
128 L 149/160 S ACTACTGCCTCTGCGCTGAACATGGAGAACATCA 34 
129 HPreS2 WoS AS TGATGGTGACATGTTCAGCGCAGGGTCCCCAATC 34 
130 HPreS2 WoS S CCTGCGCTGAACATGTCACCATCAAGTCTCCTAG 34 
131 WoS HBV AS TTTTGTTAGGGTTTAAATGTATACCCAAATCAAG 34 
132 WoS HBV S GTATACATTTAAACCCTAACAAAACAAAGAGATG 34 
133 HBV WoPreS AS GTTGTTGCCCATGCTGTAGATCTTGTTCCCAAGA 34 
134 HBV WoPreS S AAGATCTACAGCATGGGCAACAACATAAAAGTCA 34 
135 WPreS2 HuS AS GATGTTCTCCATCTCCGGTGACAGTGCAGGGTCC 34 
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136 WPreS2 HuS S CTGTCACCGGAGATGGAGAACATCACATCAGGAT 34 
137 SphI AS GCAAAACAAGCGGCTAGGAGTT 22 
138 W21H2L AS AAGATTCTGCCCCACTGCAGGCCACCATGCTGCT 34 
139 W21H2L S TGGCCTGCAGTGGGGCAGAATCTTTCCACCAGCA 34 
165 NheI HuL B S GTGCGCTAGCATGGGAGGTTGGTCTTCCAAAC 32 
166 NheI HuL C2 S GTGCGCTAGCATGCAGTTAATCATTACTTCAA 32 
167 
NheI HuL E/G 
S GTGCGCTAGCATGGGGCTTTCTTGGACGGTCC 32 
182 Bst XI S CTCTATGGAAGGCGGGTAT 19 
183 C124S AS GTAGTCATGGAGGTCCGGCATGGTCCC 27 
184 C124S S GCCGGACCTCCATGACTACTGCTCAAG 27 
185 C139S AS GGTTTGGTAGAGCAACAGGAGGGATAC 27 
186 C139S S CCTGTTGCTCTACCAAACCTTCGGACG 27 
187 C149S AS ATGGGAATAGAGGTGCAATTTCCGTCC 27 
188 C149S S ATTGCACCTCTATTCCCATCCCATCAT 27 
189 Bst XI AS CCACTGAACAAATGGCACTA 20 
192 Nhe HuL G2A S GTGCGCTAGCATGGCCCAGAATCTTTCCACC 31 
193 Nhe HuS E2G S GTGCGCTAGCATGGGGAACATCACATCAGGAT 32 
194 C211A AS  TGGCCAAGAGCCACGGTAGTTCCCCCTA 28 
195 C211A S  ACTACCGTGGCTCTTGGCCAAAATTCGC 28 
196 C228A AS  GTTGGAGGAGCAGAGGTTGGTGAGTGAT 28 
197 C228A S   CCAACCTCTGCTCCTCCAACTTGTCCTG 28 
198 C232A AS  TAACCAGGAGCAGTTGGAGGACAAGAGG 28 
199 C232A S  CCTCCAACTGCTCCTGGTTATCGCTGGA 28 
200 P36A AS  CCTTGTTGGCATTGAAGTCCCAATCTG 27 
201 P36A S  GACTTCAATGCCAACAAGGACACCTGG 27 
202 P42A AS  TGGCGTCTGCCCAGGTGTCCTTGTTGG 27 
203 P42A S  GACACCTGGGCAGACGCCAACAAGGTA 27 
204 PP58/59AA AS CTCCGTGCGCTGCGGTGAAACCCAGCCCGA 30 
205 PP58/59AA S  GGTTTCACCGCAGCGCACGGAGGCCTTTTG 30 
206 LG11/12MN AS  GGGAAAGAAATTCATAGGATTGCTGGTGGAAA 32 
207 LG11/12MN S  AGCAATCCTATGAATTTCTTTCCCGACCACCA 32 
208 LG11/12RE AS  GGAAAGAATTCCCGAGGATTGCTGGTGGAA 30 
209 LG11/12RE S   GCAATCCTCGGGAATTCTTTCCCGACCACC 30 
210 L 16/48 AS ATGCTCCAGCGGGAAAGAATCCCAGAG 27 
211 L 16/48 S  ATTCTTTCCCGCTGGAGCATTCGGGCT 27 
212 L 49/75 AS  CTGGCAAAGTTCCTACCTTGTTGGCGT 27 
213 L 49/75 S  CAAGGTAGGAACTTTGCCAGCAAATCC 27 
214 L 16/75 AS  CTGGCAAAGTGGGAAAGAATCCCAGAG 27 
215 L 16/75 S      ATTCTTTCCCACTTTGCCAGCAAATCC 27 
216 L 11/15 AS  ACTGGTGGTCAGGATTGCTGGTGGAAA 27 
217 L 11/15 S   CAGCAATCCTGACCACCAGTTGGATCC 27 
218 L 41/45 AS  CTCCTACCTTGGTGTCCTTGTTGGGAT 27 
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219 L 41/45 S   CAAGGACACCAAGGTAGGAGCTGGAGC 27 
220 L 71/75 AS  CTGGCAAAGTAGCCTGAGGGCTCCACC 27 
221 L 71/75 S  CCCTCAGGCTACTTTGCCAGCAAATCC 27 
222 pVL seq-F  AAATGATAACCATCTCGC 18 
223 pVL seq-R GTCCAAGTTTCCCTG 15 
224 Flu FP2 S1 
GAAGGAATGATAGATGGTTGGTATGGTTTCGGG 
CAGAATCTTTCCACC 48 
225 Flu FP2 S2 
CAATAGCAGGGTTCATAGAAAACGGATGGGAAG 
GAATGATAGATGGTTG 49 
226 Flu FP2 AS 
TCTATGAACCCTGCTATTGCACCGAACAGACCC 
ATGCTAGCCAGCTTGG 49 
227 HIV FP2 S1 
GCAGCAGGAAGCACTATGGGCGCAGCCTCAGGG 
CAGAATCTTTCCACC 48 
228 HIV FP2 S2 
ATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCA 
GCAGGAAGCACTATG 48 
229 HIV FP2 AS 
CCAAGGAACAAAGCTCCTATTCCCACTGCCATG 
CTAGCCAGCTTGGGT 48 
230 Ras-HuL9 S 
CAGGTTTCATCACAGAAAGTGAATCCTCTGGGA 
TTCTTTCCCG 43 
231 Ras-HuL10 S 
CAGGTTTCATCACAGAAAGTGCCTCTGGGATTC 
TTTCCCGACC 43 
232 Ras-HuL11 S 
CAGGTTTCATCACAGAAAGTGCTGGGATTCTTT 
CCCGACCACC 43 
233 Ras-HuL AS 
CACTTTCTGTGATGAAACCTGAGCACCCATGCT 
AGCCAGCTTGGGTC 47 
234 Tri 57 S1 
CTCCACATGGTGGGCTGCTTGGCTGGAGTCCTC 
AGGCTCAGGGCATAC 48 
235 Tri 57 S2 
TCATGGGGGACTGCTCGGATGGTCCACACCTCC 
ACATGGTGGGCTGCT 48 
236 Tri 57 AS 
ATCCGAGCAGTCCCCCATGAGGTGGAGTGCTCC 
ACCCCAAAAGGCCTC 48 
237 Vp4 2 S 
CAGGTTTCATCACAGAAAGTGGGGCAGAATCTT 
TCCACCAGCA 43 
238 Vp4 5 S 
CAGGTTTCATCACAGAAAGTGCTTTCCACCAGC 
AATCCTCTGG 43 
239 Vp4 8 S 
CAGGTTTCATCACAGAAAGTGAGCAATCCTCTG 
GGATTCTTTC 43 
240 LCMV S1 
CTGCCTCACATCATCGATGAGGTGGGGCAGAAT 
CTTTCCACCAGC 45 
241 LCMV S2 
CAGATTGTGACAATGTTTGAGGCTCTGCCTCAC 
ATCATCGATGAG 45 
242 LCMV AS 
CTCAAACATTGTCACAATCTGACCCATGCTAGC 
CAGCTTGGGTCT 45 
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243 adw S 
TGGTCTTCCAAACCTCGAAAAGGCGGGCAGAAT 
CTTTCCACCAGC 45 
244 adw AS 
TTTTCGAGGTTTGGAAGACCAACCTCCCATGCT 
AGCCAGCTTGGGTCT 48 
245 vac8 S 
TCATGTTGTAGTTGCTTGAAAGATGGGCAGAAT 
CTTTCCACCAGC 45 
246 vac8 AS 
TTTCAAGCAACTACAACATGAACCCATGCTAGC 
CAGCTTGGGTCT 45 
247 fyn14 S 
CAATGTAAGGATAAAGAAGCAGCGAAACTGGGG 
CAGAATCTTTCCACCA 49 
248 fyn14 AS 
TGCTTCTTTATCCTTACATTGCACACAGCCCAT 
GCTAGCCAGCTTGGGT 49 
249 yes S 
AAGTAAAGAAAACAAAAGTCCAGCCATAAAAGG 
GCAGAATCTTTCCACC 49 
250 yes AS 
GACTTTTGTTTTCTTTACTTTTAATGCAGCCCA 
TGCTAGCCAGCTTGGG 49 
251 psd95 S 
CTCTGTATAGTGACAACCAAGAAATACGGGCAG 
AATCTTTCCACCAGC 48 
252 psd95 AS 
CTTGGTTGTCACTATACAGAGACAGTCCATGCT 
AGCCAGCTTGGGTCT 48 
253 Gap43 S 
ATGAGAAGAACCAAACAGGTTGAAAAGAATGGG 
CAGAATCTTTCCACCA 49 
254 Gap43 AS 
AACCTGTTTGGTTCTTCTCATACAGCACAGCAT 
GCTAGCCAGCTTGGGT 49 
255 B-D S 
TGGTCTTCCAAACCTCGAAAAGGCATGGGGCAG 
AATCTTTCCACCAGC 48 
257 E-D S 
TCTTGGACGGTCCCTCTCGAATGGGGGCAGAAT 
CTTTCCACCAGC 45 
258 E-D AS 
TTCGAGAGGGACCGTCCAAGAAAGCCCCATGCT 
AGCCAGCTTGGGTCT 48 
259 F-D S 
CCTCTCTCAACGACAAGAAGGGGCATGGGGCAG 
AATCTTTCCACC 45 
260 F-D AS 
CCTTCTTGTCGTTGAGAGAGGTGCTCCCATGCT 
AGCCAGCTTGGGTCT 48 
261 Nhe Short B S GCTGGCTAGCATGGGGACAAATCTTTCTGTCCCC 34 
263 B-D withW S 
TGGTCTTCCAAACCTCGAAAAGGCTGGGGGCAG 
AATCTTTCCACCAGC 48 
266 B-D G2A AS 
TTTTCGAGGTTTGGAAGACCAACCGGCCATGCT 
AGCCAGCTTGGGTCT 48 
267 B-D G12A S 
TGGTCTTCCAAACCTCGAAAAGGCatgGCCCAG 
AATCTTTCCACCAGCA 49 
269 E short B S 
TCTTGGACGGTCCCTCTCGAATGGGGGACAAAT 
CTTTCTGTCCCC 45 
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271 VP4 Short B S 
GCTCAGGTTTCATCACAGAAAGTGGGGACAAAT 
CTTTCTGTCCCC 45 
272 VP4 Short B AS 
TTTCTGTGATGAAACCTGAGCACCCATGCTAGC 
CAGCTTGGGTCT 45 
273 I S 
ATCCTCAGGCCATGCAGTGGAATTCCTATATCA 
ACATTACTGGCCCCACTCCTAGTCTGTTCGCTA 
CTTCTTTCGCCCCCGATGTGGGCTCCAACGTAC 
ACAGGTTCCAATCGTC 110
274 II AS 
CCTAGGAATCCTGATGTGATGTTCTCCATCTGC 
AGCCCTGTAGGACCTAACAGTCTTCTGGTCGAT 
CCTGAAACGTCAGGTGTCGCCAGTGACGATTGG 
AACCTGTGTACGTTGG 110
275 III S 
AGAACATCACATCAGGATTCCTAGGACCCCTTC 
TCGTGTTACAGGCGGGGTTTTTCTTGTTGACAA 
GAATCCTCACAATACCGCAGAGTCTAGACTCGT 
GGTGGACTTCTCTCAA 110
276 YINI Sense ATCCTCAGGCCATGCAGTGG 20 
277 YINI Asense TTGAGAGAAGTCCACCACGA 20 
278 8H6 AS 
TGTATGGTGATGGTGATGGTGTTTGGAAGACCA 
ACCTCCCATGCT 45 
279 11H6 AS 
AGAATGGTGATGGTGATGGTGTTTTCGAGGTTT 
GGAAGACCAACC 45 
280 14H6 AS 
ATTATGGTGATGGTGATGGTGCCCCATGCCTTT 
TCGAGGTTTGGA 45 
281 8H6 S 
AAACACCATCACCATCACCATACAAATCTTTCT 
GTCCCCAATCCA 45 
282 11H6 S 
AAACACCATCACCATCACCATTCTGTCCCCAAT 
CCACTGGGATTC 45 
283 14H6 S 
GGGCACCATCACCATCACCATAATCCACTGGGA 
TTCTTCCCCGAT 45 
284 EcoRI AS GGTCGAATTCCACTGCATGGCCTGAGGAT 29 
285 XhoI AS AGTCCTCGAGAAGGTTGACGATATGGC 27 
286 XbaI AS CGACTCTAGACTCTGTGGTATTGT 24 
287 XhoI S CCTTCTCGAGGACTGGGGACCCTGTACCGAACAT 34 
288 BstXI AS AAGCCCAAGATGATGGGATGGGAAT 25 
289 B(-11-10)D AS AAAGAATCCCAGTGGATTGGGGACAGAAAGATTT 34 
290 B(-11-10)D S GTCCCCAATCCACTGGGATTCTTTCCCGACCACC 34 
291 B(-11-48)D AS GAATGCTCCAGCTCCCACCTTGTTGGCATCCGGC 34 
292 B(-11-48)D S AACAAGGTGGGAGCTGGAGCATTCGGGCTGGGTT 34 
293 B(-11-75)D AS TGCTGGCAAAGTAGTTGTGAGTATGCCCTGAGCC 34 
294 B(-11-75)D S ATACTCACAACTACTTTGCCAGCAAATCCGCCTC 34 
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4.1.3 Plasmids 
For each construct, the cloning strategy was summarized below (refer to the description in 4.2.1).  
No. Name of the constructs Note Abbrievation
        
 HBV genome expression: 
Wild-type 
pcDNA3.1/Zeo(-) HBV1.1 
containing 1.1-mer over-
length HBV genome HBV 1.1      
 
26 
  constructed by Kerry Mill  
Envelope-deficient 
pCHT HBV1.1-L(-)-949 
silence of start codon at 
949 by ATG→ACG / 
 
2 
  constructed by Kerry Mill  
pcDNA3.1/Zeo(-) HBV1.1-L(-)-949 
silence of start codon at 
949 by ATG→ACG HBV L- 
 
27 
constructed by Kerry Mill  
pCHT HBV1.1 LM(-)-949/Stop1279 
silence of start codon at 
949 and introducing of 
stop codon at 1279 / 6 
  55/60-(55/58-P2+59/60)#MfeI/XhoI→P2 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 
silence of start codon at 
949 and introducing of 
stop codon at 1279 HBV L-M- 
33 
 
  6-BstXI→P33 
pcDNA3.1/Zeo(-) HBV1.1 LMS(-)-
949/Stop1279/1453 
silence of start codon at 
949 and introducing of 
stop codon at 1279/1453 HBV L-M-S- 
35 
 
  constructed by Christina Damra 
With cysteine mutation 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C124S 
cysteine 124 of S was 
substituted by serine S C124S 
201 
 
  182/189-(182/183-P33+184/189-P33)#BxtXI→P33 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C139S 
cysteine 139 of S was 
substituted by serine S C139S 202 
  182/189-(182/185-P33+186/189-P33)#BxtXI→P33 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C149S 
cysteine 149 of S was 
substituted by serine S C149S 203 
  182/189-(182/187-P33+188/189-P33)#BxtXI→P33 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C211A 
cysteine 48 of S was 
substituted by alanine S C48A 204 
  182/189-(182/194-P33+195/189-P33)#BxtXI→P33 
pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C228A 
cysteine 65 of S was 
substituted by alanine S C65A 205 
  182/189-(182/196-P33+197/189-P33)#BxtXI→P33 
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pcDNA3.1/Zeo(-) HBV1.1 LM(-)-
949/Stop1279 C232A 
cysteine 69 of S was 
substituted by alanine S C69A 206 
  182/189-(182/198-P33+199/189-P33)#BxtXI→P33  
        
L protein expression: 
Wild-type 
pcDNA3.1/Zeo(-) HuL 
wild-type L protein of 
genotype D wt L or D 21 
  constructed by Kerry Mill  
pcDNA3.1/Zeo(-)-HuL(GT-B) L protein of genotype B B 138 
  165/109-P131#NheI/HindIII→P23 
pcDNA3.1/Zeo(-)-HuL(GT-C2) L protein of genotype C C 139 
  166/109-P132#NheI/HindIII→P23 
pcDNA3.1/Zeo(-)-HuL(GT-E) L protein of genotype E E 140 
  167/109-P133#NheI/HindIII→P23 
pcDNA3.1/Zeo(-)-HuL(GT-G) L protein of genotype G G 141 
  167/109-P134#NheI/HindIII→P23 
With preS2 mutation 
pcDNA3.1/Zeo(-) HuL-M(-)-1226 
silence of internal M-ORF 
by ATG→ACG LM109T 37 
  61/96-(61/92-P21+93/96-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) mHuL 114/123 deletion of aa 114-123 Δ114-123 40 
  61/96-(61/62-P21+63/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) mHuL 114/133 deletion of aa 114-133 Δ114-133 41 
  61/96-(61/64-P21+65/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) mHuL 114/143 deletion of aa 114-143 Δ114-143 42 
  61/96-(61/66-P21+67/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) mHuL 114/153 deletion of aa 114-153 Δ114-153 43 
  61/96-(61/68-P21+69/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) mHuL 114/163 deletion of aa 114-163 Δ114-163 44 
  61/96-(61/70-P21+71/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-S114/163 
aa 114-163 were shifted to 
corresponding residues of 
pol S114-163 85 
  116/96-(116/117-P21+118/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-S114/143 
aa 114-143 were shifted to 
corresponding residues of 
pol S114-143 86 
  116/96-(116/119-P21+120/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-S114/183 
aa 114-183 were shifted to 
corresponding residues of 
pol S114-183 87 
  116/96-(116/121-P21+122/96-P21)#EcoRI/XbaI→P21 
88 pcDNA3.1/Zeo(-) HuL-Del144-163 deletion of aa 144-163 Δ144-163 
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  61/96-(61/123-P21+124/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-Del164-183 deletion of aa 164-183 Δ164-183 89 
  61/96-(61/125-P21+126/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-Del149-160 
deletion of aa 149-160 
(TLM) Δ149-160 90 
  61/96-(61/127-P21+128/96-P21)#EcoRI/XbaI→P21 
pcDNA3.1/Zeo(-) HuL-Scramble 
114/163 
aa 114-163 were 
scrambled 114-163Scramble 
266 
  
276/277-(273/274-Ø+275/277-Ø)#EcoRI/XbaI→P21 
Ø: no template is needed for the amplification 
With cysteine mutation 
pcDNA3.1/Zeo(-) HuL C124S 
cysteine 124 of S-domain 
was substituted by serine  L C124S 211 
  110/109-(110/183-P21+184/109-P21)#EcoRI/HindIII→P21 
pcDNA3.1/Zeo(-) HuL C139S 
cysteine 139 of S-domain 
was substituted by serine L C139S 212 
  110/109-(110/185-P21+186/109-P21)#EcoRI/HindIII→P21 
pcDNA3.1/Zeo(-) HuL C149S 
cysteine 149 of S-domain 
was substituted by serine L C149S 213 
  110/109-(110/187-P21+188/109-P21)#EcoRI/HindIII→P21 
pcDNA3.1/Zeo(-) HuL C211A 
cysteine 48 of S-domain 
was substituted by alanine L C49A 214 
  110/109-(110/194-P21+195/109-P21)#EcoRI/HindIII→P21 
pcDNA3.1/Zeo(-) HuL C228A 
cysteine 65 of S-domain 
was substituted by alanine L C65A 215 
  110/109-(110/196-P21+197/109-P21)#EcoRI/HindIII→P21 
pcDNA3.1/Zeo(-) HuL C232A 
cysteine 69 of S-domain 
was substituted by alanine L C69A 216 
  110/109-(110/198-P21+199/109-P21)#EcoRI/HindIII→P21 
With N-terminal variation 
pcDNA3.1/Zeo(-)-W(1-21)H(2-389)-L 
N-terminal 21 amino acids 
of WHV L protein was 
fused to aa 2 of wt L WHV 21 92 
  97/96-(97/138-P55+139/96-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL G2A 
G2A mutation to abolish 
the myristoylation G2A 217 
  192/56-P21#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL G2A/L11R 
combination of G2A and 
L11R mutation G2A/L11R 218 
  192/56-P186#NheI/EcoRI→P21  
pcDNA3.1/Zeo(-) HuL G2A/L11R 
Del164/183 
combination of G2A, 
L11R mutation and 
deletion of TM1 
G2A/L11R 
ΔTM1 219 
  192/56-P21#NheI/EcoRI→P89  
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pcDNA3.1/Zeo(-) HuL P36A 
proline 36 was substituted 
by alanine P36A 220 
  61/56-(61/200-P21+201/56-P21)#NheI/EcoRI→P21  
pcDNA3.1/Zeo(-) HuL PP58/59AA 
prolines 58/59 were 
substituted by alanines PP58/59AA 222 
  61/56-(61/204-P21+205/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL LG11/12MN 
LG at aa 11-12 was 
substituted by MN LG11/12MN223 
  61/56-(61/206-P21+207/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL LG11/12RE 
LG at aa 11-12 was 
substituted by RE LG11/12 RE224 
  61/56-(61/208-P21+209/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del16-48aa deletion of aa 16-48 Δ16-48 225 
  61/56-(61/210-P21+211/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del49-75aa deletion of aa 49-75 Δ49-75 226 
  61/56-(61/212-P21+213/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del16-75aa deletion of aa 16-75 Δ16-75 227 
  61/56-(61/214-P21+215/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del11-15aa deletion of aa 11-15 Δ11-15 228 
  61/56-(61/216-P21+217/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del41-45aa deletion of aa 41-45 Δ41-45 229 
  61/56-(61/218-P21+219/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Del71-75aa deletion of aa 71-75 Δ71-75  
230 
  61/56-(61/220-P21+221/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Flu24 to2 
fusion peptide of fluenza 
virus was fused to aa 2 of 
wt-L Flu24-L 241 
  61/56-[61/226-P21+225/56-(224/56-P21)]#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL HIV23 to2 
fusion peptide of HIV gag 
was fused to aa 2 of wt L HIV23-L 242 
  61/56-[61/229-P21+228/56-(227/56-P21)]#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL Tri57-67 Triplication of aa 57-67 Tri57-67 243 
  61/56-[61/236-P21+235/56-(234/56-P21)]#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL aa9 to9 
VP4 myristoylation 
cassette was fused to aa 9 
of wt L VP4-9 244 
  61/56-(61/233-P21+230/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL aa9 to10 
VP4 myristoylation 
cassette was fused to aa 10 
of wt L VP4-10 245 
  61/56-(61/233-P21+231/56-P21)#NheI/EcoRI→P21 
246 
  pcDNA3.1/Zeo(-) HuL aa9 to11 
VP4 myristoylation 
cassette was fused to aa 11 
of wt L VP4-11 
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61/56-(61/233-P21+232/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL aa9 to2 
VP4 myristoylation 
cassette was fused to aa 2 
of wt L VP4-L 247 
  61/56-(61/233-P21+237/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL aa9 to5 
VP4 myristoylation 
cassette was fused to aa 5 
of wt L VP4-5 248 
  61/56-(61/233-P21+238/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) HuL aa9 to8 
VP4 myristoylation 
cassette was fused to aa 8 
of wt L VP4-8 249 
  61/56-(61/233-P21+239/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) lcmv-HuL 
myristoylation cassette of 
LCMV was fused to aa 2 
of wt L LCMV-L 250 
  61/56-[61/242-P21+241/56-(240/56-P21)]#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) adw(B-D without M)-
HuL 
N-terminal 11 aa of L 
protein of genotype B was 
fused to aa 2 of wt L B11-D  M1(-)251 
  61/56-(61/244-P21+243/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) vac-HuL 
N-terminal myristoylation 
motif of Vac8 protein was 
fused to aa 2 of wt L Vac8-L 252 
  61/56-(61/246-P21+245/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) fyn14-HuL 
N-terminal myristoylation 
motif of Fyn protein was 
fused to aa 2 of wt L Fyn-L 
 
253 
  61/56-(61/248-P21+247/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) yes-HuL 
N-terminal myristoylation 
motif of Yes protein was 
fused to aa 2 of wt L Yes-L 254 
  61/56-(61/250-P21+249/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) psd95-HuL 
N-terminal myristoylation 
motif of psd95 protein 
was fused to aa 2 of wt L psd95-L 255 
  61/56-(61/252-P21+251/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) gap43-HuL 
N-terminal myristoylation 
motif of Gap43 protein 
was fused to aa 2 of wt L Gap43-L 256 
  61/56-(61/254-P21+253/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B11-D 
N-terminal 11 aa of L 
protein of genotype B was 
fused to aa 1 of wt L B11-D 257 
  61/56-(61/244-P21+255/56-P21)#NheI/EcoRI→P21 
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pcDNA3.1/Zeo(-) E10-D 
N-terminal 10 aa of L 
protein of genotype E was 
fused to aa 1 of wt L E10-D 258 
  61/56-(61/258-P21+257/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) F-D 
N-terminal 11 aa of L 
protein of genotype F was 
fused to aa 1 of wt L F11-D 259 
  61/56-(61/260-P21+259/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-D with W 
N-terminal 11 aa of L 
protein of genotype B was 
fused to aa 1 of wt L with 
M1W mutation B11-D  M1W260 
  61/56-(61/264-P21+263/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-D-G2A  
N-terminal 11 aa of L 
protein of genotype B was 
fused to aa 1 of wt L with 
G(-10)A mutation B-D  G-10A 261 
  61/56-(61/266-P21+265/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-D-G12A  
N-terminal 11 aa of L 
protein of genotype B was 
fused to aa 1 of wt L with 
G2A mutation B-D G2A 262 
  61/56-(61/244-P21+267/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) Short B 
N-terminal 11 aa of L 
protein of genotype B was 
deleted Bt 263 
  261/109-P138#NheI/HindIII→P21 
pcDNA3.1/Zeo(-) E-B 
N-terminal 10 aa of L 
protein of genotype E was 
fused to aa 1 of Bt E10-Bt 264 
  61/109-(61/258-P138+269/109-P138)#NheI/HindIII→P21 
pcDNA3.1/Zeo(-) N-VP4-short B 
VP4 myristoylation 
cassette was fused to Bt VP4-Bt 265 
  61/109-(61/272-P138+271/109-P138)#NheI/HindIII→P21 
pcDNA3.1/Zeo(-) gtB-8H6 
aa 8-13 of L protein of 
genotype B were replaced 
by His-6 tag 8H6 267 
  61/286-(61/278-P138+281/286-P138)#NheI/XbaI→P21 
pcDNA3.1/Zeo(-) gtB-11H6 
aa 11-16 of L protein of 
genotype B were replaced 
by His-6 tag 11H6 268 
  61/286-(61/279-P138+282/286-P138)#NheI/XbaI→P21 
269 
  pcDNA3.1/Zeo(-) gtB-14H6 
aa 14-19 of L protein of 
genotype B were replaced 
by His-6 tag 14H6 
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61/286-(61/280-P138+283/286-P138)#NheI/XbaI→P21 
pcDNA3.1/Zeo(-) B-PreS1-D 
N-terminal 124 residues 
of L protein of genotype 
B was fused to 
corresponding site of 
genotype D B124-D 270 
  165/284-P138#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-PreS2-D 
N-terminal 167 residues 
of L protein of genotype 
B was fused to 
corresponding site of 
genotype D B167-D 271 
  165/285-P138#NheI/XhoI→P21 
pcDNA3.1/Zeo(-) B-AGL-D 
N-terminal 207 residues 
of L protein of genotype 
B was fused to 
corresponding site of 
genotype D B207-D 272 
  165/286-P138#NheI/XbaI→P21 
pcDNA3.1/Zeo(-) B-21-D 
N-terminal 19 residues of 
L protein of genotype B 
was fused to 
corresponding site of 
genotype D B19-D 274 
  61/56-(61/289-P21+290/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-59-D 
N-terminal 59 residues of 
L protein of genotype B 
was fused to 
corresponding site of 
genotype D B59-D 275 
  61/56-(61/291-P21+292/56-P21)#NheI/EcoRI→P21 
pcDNA3.1/Zeo(-) B-86-D 
N-terminal 86 residues of 
L protein of genotype B 
was fused to 
corresponding site of 
genotype D B86-D 276 
  61/56-(61/293-P21+294/56-P21)#NheI/EcoRI→P21 
 
4.1.4 Peptides 
Name Sequence Modification 
D preS/2-48myr 
Myr-GQNLSTSNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-myristoylation 
C preS/-10-48myr 
Myr-GGWSSKPRQGMGTNLSVPN 
PLGFFPDHQLDPAFGANSNNP 
DWDFNPNKDHWPEAKQVG-OH N-myristoylation 
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C preS/2-48myr 
Myr-GTNLSVPNPLGFFPDHQL 
DPAFGANSNNPDWDFNPNKD 
HWPEAKQVG-OH N-myristoylation 
C preS/-10-48Stear 
Stear-GGWSSKPRQGMGTNLSVPN 
PLGFFPDHQLDPAFGANSNNP 
DWDFNPNKD HWPEAKQVG-OH N-Stearoylation 
C preS/2-48Stear 
Stear-GTNLSVPNPLGFFPDHQL 
DPAFGANSNNPDWDFNPNKD 
HWPEAKQVG-OH N-Stearoylation 
preS/2-48Stear 
Stear-GQNLSTSNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/5-48Stear 
Stear-LSTSNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/6-48Stear 
Stear-STSNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/7-48stear 
Stear-TSNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-myristoylation 
preS/8-48stear 
Stear-SNPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/9-48stear 
Stear-NPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/A2-8/9-48stear 
Stear-AAAAAAANPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
preS/A2-9/10-48stear 
Stear-AAAAAAAAPLGFFPDHQL 
DPAFRANTANPDWDFNPNKD 
TWPDANKVG-OH N-Stearoylation 
B-Dmyr 
Myr-GGWSSKPRKGMGQNLSTSN 
PLGFFPDHQLDPAFRANTANP 
DWDFNPNKDTWPDANKVG-OH N-myristoylation 
VP4-Dmyr 
Myr-GAQVSSQKVGQNLSTSN 
PLGFFPDHQLDPAFRANTANP 
DWDFNPNKDTWPDANKVG-OH N-myristoylation 
Myrcludex B 
Myr-GTNLSVPNPLGFFPDHQL 
DPAFGANSNNPDWDFNPNKD 
HWPEANKVG-OH N-myristoylation 
 
4.1.5 Cells 
Cells Description Suppliers 
HuH-7  Human hepatoblastoma cell line239 Lab 
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HepaRG  HBV susceptible hepatoma cell line171 Grippon 
HepAD38 
Inducible human hepatoblastoma cell line harbors a integrated 
tetracycline responsive 1.2 fold HBV genome (serotype ayw, 
genotype D)150  T. Block 
DH5α  
E. Coli adjusted for molecular cloning purposes. E. coli 
(Escherichia coli) DH5α240: 
SupE44, Δ(lacZYA-argF)U169, Φ80dlacZΔM15, recA1, endA1, 
gyrA96, thi-1, relA1, hsdR17(rk-, mk+), deoR BRL 
 
4.2. Methods 
4.2.1 General Cloning strategy 
The cloning strategy for most of the mutants is based on PCR-amplification of two or several 
overlapping fragments located upstream and downstream of the mutation site. Taken the 
plasmid Δ114-123 as an example, for the first fragment primers 61 and 62 were used to amplify 
the target sequence from plasmid P21, and this step was noted as 61/62-P21. The second 
fragment was generated from plasmid P21 using the primers 63 and 96, and this step was noted 
as 63/96-P21. After purification by extraction of the fragments from agarose gels, these two 
PCR-products were mixed and subjected to a second round of amplification using the primers 
61 and 96, and this step was noted as 61/96-(61/62-P21+63/96-P21). The final PCR product 
with expected size were purified, hydrolyzed with EcoRI and HindIII and inserted into the 
EcoRI-HindIII-digested P21 vector. Therefore, the whole cloning strategy was noted as 61/96-
(61/62-P21+63/96-P21)#EcoRI/HindIII→P21. The correctness of sequences generated by 
PCR was verified by DNA sequencing. 
4.2.2 Agarose electrophoresis 
DNA was analyzed by agarose gel electrophoresis. Agarose was dissolved in TAE buffer by 
heating. 0.1 µg/ml ethidium bromide was added to the liquid agarose before it was casted into an 
electrophoresis tray. The density of the gel used was dependent on the expected DNA size. The 
samples were loaded with 1x agarose gel sample buffer and separated by electrophoresis at 50-
120 V. The fragment sizes were compared to molecular weight markers. 
4.2.3 Gel exaction of DNA fragments 
When it is necessary to separate the DNA from the raw PCR products or digestion product, the 
sample were loaded on agarose gels of the suitable percentage procedure. After proper 
separation of the fragments, DNA was visualized under a low energy UV source and cut out of 
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the gel using a clean blade. DNA fragments were then purified from the gel with the Gel 
exaction kit (Qiagen) according to the manufactures protocol. Purity and yield of the DNA was 
determined by agarose gel electrophoresis and UV spectroscopy. 
4.2.4 Polymerase Chain Reaction (PCR) 
A gerenal PCR recipe is the following (for a 50µl reaction volume): 
RNase free Water       38µl 
Deep vent Polymerase buffer with magnese (10×)   5µl 
dNTP mixture (25mM each)     0.5µl 
Deep vent Polymerase (5U/µl)     0.5µl 
Sense primer (100pMl)        0.5µl 
Antisense primer (100pM)      0.5µl 
Template        5µl 
The templates are either 10ng/µl plasmid or purifed DNA fragment from Gel exaction kit eluted 
in 50µl water (2.5µl each for the overlapping PCR). 
The parameter of thermocycling is the following: 
Step1,   95ºC,   5 minutes 
Step2,   95ºC,   20 seconds 
Step3,   54ºC,   20 seconds 
Step4,   72ºC,   varied time, 1min/800bp product 
Go to Step2 for 35 cycles 
Step5,   72ºC,   7 minutes 
Step6,   4ºC,   hold 
4.2.5 Competent cells preparation and transformations 
A single colony from a E .coli DH5α strain was grown over-night in 2 ml LB medium with 0.02 
M MgSO4/ 0.01 M KCl with vigorous shaking (~300 rpm). It was diluted 1:10 into fresh 
medium with the same constituents and grown for 90 min, at 37ºC to an OD600 of 0.45. 
Cultures were incubated on ice for 10 min after which the cells were pelleted by centrifugation at 
6000 rpm at 4ºC for 5 min. Cells were resuspended in TFB I (30 ml/ 100 ml culture), incubated 
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5 min on ice, pelleted again by centrifugation at 6000 rpm at 4ºC for 5 min and finally 
resuspended in TFB II (4 ml per 100 ml culture). 100 µl aliquots of the competent bacteria were 
frozen at –80ºC. 
TFB I:  
30 mM KOAc, 50 mM MnCl2, 100 mM RbCl2, 10 mM CaCl2, 15% w/v glycerin, pH 5.8 
TFBII  
10 mM MOPS, pH 7.5, 75 mM CaCl2, 100 mM RbCl2, 15% w/v glycerin 
Both the solutions were sterilized and stored at 4ºC. 
4.2.6 DNA sequencing 
All constructs generated were verified by sequencing. The sequencing is performed either by a 
commercial vendor (GATC, Constanze) or using the ABI Prism® BigDyeTM Terminator Cycle 
Sequencing Ready Reaction Kit (PE Applied Biosystems) and performed as described in the 
product manual. Shortly, template DNA (0.5 µg), the respective primer (10 pmol) and 2 µl Big 
DyeTM terminator ready reaction mix were combined in a total volume of 10 µl and the 
sequencing reaction was carried out as follows: 25x (96ºC, 30 sec; 50ºC, 15 sec; 60ºC, 4 min). 
Sequencing was done on an automated sequencer. 
4.2.7. Plasmid preparations 
For a middle or large scale prasmid preparation for transfection, Plasmid midi or max kit 
(Qiagen) were used and performed according to the product manuals. 
For a fast and small scale plasmid preparation for cloning, the Fastprep mini kit (Eppendorf) was 
used and performed according to the product manual. 
4.2.8 SDS-PAGE 
This method separates a protein mixture dependent on its molecular weight (MW) composition. 
It was performed as described in standard protocols [Ausubel, et al., 2004]. The polymer density 
of the separation gel depends on the expected MW of the target protein (MW<30 kDa = 15 % 
(w/v) PAGE gel, MW >30 kDa = 12 % (w/v) PAGE gel). Proteins are denaturated in SDS-
PAGE sample buffer by 5 min heat denaturation at 95 ºC prior to electrophoresis in SDS-PAGE 
buffer at 80-120 V. 
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4.2.9 Western blot 
After SDS-PAGE, proteins were transferred to PROTRAN nitrocellulose membrane using a 
semi-dry blotting chamber. The gel was placed in contact to a nitrocellulose membrane, and was 
sandwiched with two sheets of Whatmann paper in both side. The proteins migrate from the gel 
onto the membrane in an electric field of 1.3 mA/cm² for 20 minutes. Membranes were blocked 
with PBS/5% milk powder/ 0.05% Tween 20 at room temperature for 1 h. Antisera/antibodies 
was diluted in blocking buffer. Bands were visualized with enhanced chemiluminescence (ECL) 
substrate or with an Odyssey Infrared Imaging System (LI-COR). 
Home-made ECL Solution I: 
0.5 ml luminol stock (A), 0.22 ml coumaric acid stock (B), 5 ml 1 M Tris HCl pH 8.5, 45 ml 
distilled water. 
Home-made ECL Solution II: 
32 microlitres 30% hydrogen peroxide, 5 ml 1 M Tris HCl pH 8.5, 45 ml distilled water. 
Stock A (250 mM Luminol in DMSO): 
dissolve 0.8858g Luminol (Sigma #09253, MW, 177.16) in 20 ml DMSO, aliquot to 0.5ml/tube, 
labeled as A. 
Stock B (90 mM coumaric acid in DMSO): 
dissolved 0.2955g coumaric acid (Sigma #9008, MW, 164.16)in 20ml DMSO, aliquot to 
0.22ml/tube, labled as B. 
4.2.10 Immunoprecipitation 
To analyse the preS topology of HBV particle, 1ml supernatant of transfected HuH-7 cells were 
mixed with 5µl polyclonal anti-preS1 antiserum (Rabbit anti-Myrcludex B) in the absence or 
presence of NP40 (0.5 % v/v). The incubations were performed overnight for about 18-24 
hours at 4ºC under rotation. 20µl of protein G-Sepharose (1:1 in suspension buffer) was washed 
by PBS and subsequently added to bind the immunoprecipitates, and the samples were incubated 
for a further hour at 4ºC while shaking. The beads were then collected by centrifugation at 500g 
for 3 minutes. Beads were washed three times with the extraction buffer and analyzed together 
with their corresponding supernatants on the SDS-PAGE followed by Western blot.  
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4.2.11 Cultivation of HuH-7 cells 
HuH-7 cells were passaged every 3-4 days by trypsinization and split at the ratio 1:5. The cells 
were grown in DMEM medium supplentmented with 10% fetal calf serum (FCS), 2 mM L-
Glutamin, 100 U/ml penicillin and 100 µg/ml streptomycin. 
4.2.12 Cultivation and infection of primary human hepatocytes and HepaRG cells 
HepaRG cells were passaged weekly by trypsinization. 2×106 HepaRG cell were left in one T-75 
flask and supplemented with 10-15 ml Growing medium. For infection assay, 2×105 HepaRG 
cells are seeded in one well of 12-well-plate for 2 week and differentiated in Low differentiation 
or High differentiation medium for another 2 weeks. Then HepaRG cells are ready for the 
infection.  
For the preparation of PHH, tissue samples were obtained and experimental procedures were 
performed according to the guidelines of the charitable state controlled foundation HTCR, with 
the informed patient's consent241. PHH were seeded at 1.6×105 cells per cm2 with PHH-1 
medium. 4 hours and 1 day post-plating, the PHH was refreshed with PHH-2 medium. Then the 
PHH was further cultivated less than 3 days before the starting of infection. 
For infection, cells of a 12-well plate were inoculated with 500 µl of medium containing 4% 
PEG 8000 and concentrated virus. To ensure that HBV-entry proceeds via the authentic preS1-
mediated pathway, or to test the inhibitory activity of peptides, the peptide stock was added to 
the inoculum to desired concentration. Virus incubation took place overnight at 37ºC. 
Afterwards cells were washed three times with PBS and subjected to further cultivation for 11 
days. Hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) secreted into the culture 
supernatant was determined by Abbott AxSYM® HBsAg or HBeAg assay (Abbott 
Laboratories).  
Growing medium: 
Williams E medium 500ml 
+ 50ml FCS (Biochrom) 
+ 5ml Pen/Strep Stock (penicillin, 10000 U/ml; streptomycin 10 mg/ml) 
+ 250µl Hydrocortison [50µM] 
+ 250µl Insulin [5µg/ml] 
Low differentiation medium: 
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 Williams E medium 500ml 
+ 50ml FCS (Biochrom) 
+ 5ml Pen/Strep Stock (penicillin, 10000 U/ml; streptomycin 10 mg/ml) 
+ 250µl Hydrocortison [50µM] 
+ 250µl Insulin [5µg/ml] 
+ 2.75ml DMSO 
High differentiation medium: 
 Williams E medium 500ml 
+ 50ml FCS (Biochrom) 
+ 5ml Pen/Strep Stock (penicillin, 10000 U/ml; streptomycin 10 mg/ml) 
+ 250µl Hydrocortison [50µM] 
+ 250µl Insulin [5µg/ml] 
+ 11ml DMSO 
PHH-1 medium: 
Williams E medium 500ml 
+ 50ml FCS (Biochrom) 
+ 5ml Pen/Strep Stock (penicillin, 10000 U/ml; streptomycin 10 mg/ml) 
+ 250µl Hydrocortison [50µM] 
+ 250µl Insulin [5µg/ml] 
+ 200mM L-glutamine  
PHH-2 medium: 
Williams E medium 500ml 
+ 50ml FCS (Biochrom) 
+ 5ml Pen/Strep Stock (penicillin, 10000 U/ml; streptomycin 10 mg/ml) 
+ 250µl Hydrocortison [50µM] 
+ 250µl Insulin [5µg/ml] 
+ 200mM L-glutamine  
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+ 2.75ml DMSO 
Insulin Stock [5µg/ml] 
100mg Insulin I1882 (Sigma) were dissolved wtih 10ml Braun H2O and 100µl Essigsäure 
versetzen, sterile filtered, aliquot to 250µl and stored at -20ºC. 
Hydrocortison Stock [100mM] 
1g Hydrocortison H4881 (Sigma) were dissolved with 20ml Braun H2O, sterile filtered, aliquot to 
250µl and stored at -20ºC 
4.2.13 Transfection of HuH-7 cells using polyethylenimine  
The human hepatoblastoma cell line HuH-7239 was transfected with appropriate mixtures of 
expression plasmids using the polyethylenimine-procedure241. Shortly, 4×106 cells (in a 10-cm-
dish) were incubated for 6 hours with the mixture of 75 µg polyethylenimine and 10 or 12 µg 
plasmid DNA. The cells were refreshed and further cultivated in Dulbecco's Modified Eagle 
Medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. 
PEI stock solution (100mg/ml): 
In 50ml Falcon tube, 5g PEI (Polyethylenimine, MW-22,000; Cat. No.408727, Aldrich) was 
dissolved with Braun-water to final volume of 50ml then was sterilized with 45µm filter. Aliquots 
of 500ul per tube were frozen at -20ºC. 
PEI working solution (1mg/ml): 
In 50ml falcon tube, 1 tube of PEI stock solution (100mg/ml, 500ul) was diluted with Braun-
water to final volume of 50ml and stored at 4ºC. 
4.2.14 Production of the HBV particle 
HBV particles were obtained by co-transfection of HuH-7 cells with a mixture of a 1.1-fold 
over-length HBV plasmid (HBV L-, or HBV L-M-, or HBV L-M-S-) and a helper construct 
providing the L-protein. Medium was collected between days 3-8 (and days 8-13) post-
transfection.  
4.2.15 Purification and concentration of virus by PEG-precipitation 
Virions in the supernatant of transfected HuH-7 cells were precipitated overnight at 4ºC with 
6% polyethylene glycol 8000 (PEG 8000, Sigma) and subjected to a centrifugation (12,000 g, 60 
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min, 4ºC). After suspension in 1/50th to 1/100th of the volume of PBS/10% FCS, the 
preparation is centrifuged (8,000rpm, 5min) again and the supernatant is frozen at -20ºC. 
4.2.16 CsCl-gradient centrifugation and DNA dot-blot analysis 
2 ml cell culture supernatant or 30-50 µl concentrated virus were loaded onto a cesium chloride 
gradient ranging from 1.4 g/cm3 to 1.2 g/cm3. Fractions of ~200µl were collected from the 
bottom of the tube and spotted onto a nitrocellulose membrane. After denaturation the samples 
were hybridized overnight at 68ºC using a HBV specific 32P-labeled DNA probe. The blot was 
washed twice at 68ºC with SSC-buffer (150 mM NaCl, 15 mM sodium citrate, pH 7.0). Signals 
were quantified using a PhosphorImager and the Quantity One® software (Bio-Rad).  
4.2.17 Immunofluorescence analyses of HBcAg expression in infected cells 
11-13 days post-infection HepaRG cells or PHH were washed with PBS, fixed with 4% 
paraformaldehyde (20 minutes) and permeabilized with 0.25% (v/v) Triton-X-100 (30 minutes) 
in PBS. After removal of the detergent, the HBcAg or MRP2-specific polyclonal antibody was 
added (1:1000 dilution in PBS containing 5% skim milk powder). Following 2 h incubation at 
4ºC, cells were washed three times and incubated in the dark for 1 h at room temperature with 
the 1:500 diluted Alexa488-conjugated secondary Mouse-anti-Rabbit antibody (Invitrogen, 
Molecular Probes) in PBS containing 5% skim milk powder. After washing three times with PBS, 
cells were incubated for 30 min with 1 µg/ml DAPI. Cells were then washed twice with PBS. 
Images were acquired using the inverted fluorescence microscope Leica DM IRB. All images of 
one set of experiments were taken and handled under identical conditions. To quantify infection, 
positive cells in 4-8 fields under 100-fold magnification were counted. The counted numbers 
were converted to the whole well according the real area under the microscope. 
4.2.18 HBsAg and HBeAg measurement in the supernatants of infected cells 
The HBsAg and HBeAg were measured by the Abbott Axym test and performed by the 
Diagnostics Center of University of Heidelberg. 
4.2.19 Heparin binding assay  
The binding and elution of HBV particle are depicted in the Fig. 37. In short, 50ml of 
supernatant containing HBV particles was applied to the Heparin column (1ml) equilibrated with 
1×TN buffer, and then the column was wash with 50ml 1×TN buffer. Virus bound to the 
column was eluted at a stepwise concentration of 340nM TN buffer, 540nM TN buffer, and 2M 
TN buffer respectively. For each concentration, the eluate is collected in 4 tubes (1ml/tube). The 
OD260 and OD254 are measured by the AKTA system automatically.  
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1×TN buffer: 
50nM Tris, 150nM NaCl 
340nM TN buffer 
50nM Tris, 340nM NaCl 
540nM TN buffer 
50nM Tris, 540nM NaCl 
2M TN buffer 
50nM Tris, 2M NaCl 
4.2.20 Lentivirus production and transduction of HepaRG cells 
Lentivirus production was generated by the PEI-based co-transfection of 293T cells. In short, 4 
x 106 293T cells were seeded in 10-cm-diameter plates 1 day before transfection with 3 µg of 
envelope protein expression construct pczVSV-G242, 9 µg of HIV-Gag-Pol expression construct 
pCMV R8.74243, and 9 µg of the lentiviral vector pWPI244. The medium was replaced overnight 
after transfection. Supernatants containing the pseudoparticles were harvested 48 h later and 
filtered through 0.45µm filter. The pseudoparticles were concentrated by ultracentrifugation 
using a SW-28 rotor at 20,000 rpm, RT for 2 hours. The supernatant was aspirated and the 
precipitated pseudoparticles were dissolved in 1/50 of original volume.  
The HepaRG cells in 12-well-plate were transduced overnight with 100µl concentrated virus per 
well in the presence of 4% PEG. Then lentivirus pseudoparticles were removed, and HepaRG 
cells were washed once with PBS and further cultivated for 4 days prior to HBV infection. 
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Abbreviations 
 
ºC    degree Celsius 
µg    microgram 
µl    microlitre 
µM    micromolar 
 
aa    amino acid 
Ag    Antigen 
Ab    Antibody 
AGL    Antigenic loop 
 
b    base 
bp    base pairs 
 
C    HBV core 
cccDNA   covalently closed circular DNA 
CsCl    Caesium chloride 
CMV    Cytomegalovirus 
CYL-I    Cytosolic loop-I 
 
DAPI    4´6´- Diamidino-2´phenylindole-dihydrochloride 
dNTP    Deoxyribonucleoside triphosphate 
Delta (Δ)   Deletion 
DMEM   Dulbecco´s Modified Eagle Medium 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DR    Direct repeat 
ds    double-stranded 
DTT    Dithiothreitol 
 
E.coli    Escherichia coli 
EDTA    Ethylenediaminetetraacetic acid 
Enh    Enhancer 
ER    Endoplasmic reticulum 
ERGIC    ER Golgi intermediate compartments  
et al.    et alii, at aliae, et alia 
 
FCS    Fetal calf serum 
 
g    gram 
GAG    Glycosaminoglycan 
GE    Genome equivalents 
 
h    hour 
HB    Hepatitis B 
HBcAg    Hepatitis B core antigen 
HBeAg    Hepatitis B e antigen 
HBs    Hepatitis B surface protein 
HBsAg    Hepatitis B surface antigen 
HBV    Hepatitis B virus 
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HBx    Hepatitis B virus X protein 
HCC    Hepatoma cellular carcinoma 
Hsc or Hsp    Heat-shock cytoplasm or protein  
HCV    Hepatitis C virus 
HSPG    Heparan sulfate proteoglycans 
 
IF    Immunofluorescence 
 
Kb    kilo base pairs 
kD    kilo dalton 
 
L-protein    HBV large surface protein 
 
M-protein    HBV middle surface protein  
Mab     Monoclonal antibody  
MCS    Multiple cloning site 
 
MEIA     microparticle enzyme immunoassays 
mg    milligram 
min    minute 
ml    millilitre 
mM    millimolar 
mRNA    messenger RNA 
Myr    myristoyl 
 
N-    amino- 
nm    nanometer 
NP-40    Nonidet-40 
nt    nucleotide 
 
OD    Optical density 
ORF    Open reading frame 
 
P    HBV polymerase 
PAGE    Polyacrylamide gel electrophoresis 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PDI     Protein disulfide isomerase  
PEG    Polyethylene glycol 
PEI    Polyethylenimine 
PFA    Paraformaldehyde 
pgRNA   pregenomic RNA 
pH    pondus hydrogenii 
PHH    Primary human hepatocytes 
p.i.    post-infection 
p.t.    post-transfection 
PTH    Primary tupaia hepatocytes 
 
rcDNA   relaxed circular DNA 
RNA    Ribonucleic acid 
RNase    Ribonuclease 
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rpm    revolution per minute 
RT    Room temperature or Real-time 
 
S-protein    HBV small surface protein  
S/N    Signal-to-noise-ratio 
S/Co    Signal-to-control-ratio 
ss    single-stranded 
sec    seconds 
SDS    Sodium dodecyl sulfate 
SSC    Standard saline citrate 
SVPs     Subviral particles  
 
TBS    Tris buffered saline 
TEMED   N,N,N´,N´,-tetramethylethylenediamine 
temp    temperature 
TM    Transmembrane 
TP    Terminal protein 
Tris    Tris(hydroxylmethyl)-aminomethane 
 
U    Unit 
 
V    Volt 
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FIG. S1.  Schematic illustration of other mutant L proteins 
The listed mutant L proteins were characterized with respect to virus assembly and infectivity, but not described in 
the main text of the present PhD thesis. The L proteins from genotype D are shown in black bar, while those from 
woodchuck hepatitis virus (WHV) are shown in green bar. Note that the fusion peptide from Influenza virus was 
fused to the N-terminus of L protein (Flu24-L), as well as the fusion peptide of HIV (HIV23-L), palmitoylation 
motif of psd95 (psd95-L) and Gap43 (Gap43-L). The assembly and infectivity of virus with these L proteins are 
summarized at the right.  
 
 
 
 
 
FIG. S2. Assembly competence of a part of mutant L-proteins listed in FIG. S1 
HBV-DNA specific Dot-blot of fractions of an analytical CsCl density gradient was obtained from supernatants of 
transfected HuH-7 cells, which was transfected with a mixture of genomic construct (HBV L-) and helper construct 
(wt-L), or mutant L-protein expression construct. 
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FIG. S3. Dominant negative effect of mutant L protein on virus infectivity was not observed. 
A. Western blot of cellular extracts of HuH-7 cells 2 days post-transfection with the wild-type L expression 
constructs (wt-L), or mutant L protein devoid of myristoylation (G2A), with deleted putative fusion peptide 
(ΔTM1), with substituted prolines at aa 58-59 (PP58/59AA), with deletion in the essential binding site (Δ11-15), or 
with deletion Δ41-45. Markers with indicated molecular mass are shown in the right. 
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B1-5. Relative amount of HBsAg secreted from day 8-13 following infection of HepaRG cells by the virus bearing a 
mixture of wild-type and mutant L-proteins G2A (B1), ΔTM1 (B2), PP58/59AA (B3), Δ11-15 (B4), Δ41-45 (B5). 
For virus production, HuH-7 cells were transfected, in addition to genomic construct (HBV L-), with a mixture of 
mutant helper constructs and wild-type helper construct at different ratio resulting in percentage of mutants from 
100% to 0%. To test their sensitivity to the inhibitory peptide, virus inoculation was performed in the absence (black 
bars) or presence of 100 nM (white bars) HBVpreS/2-48myr.  
 
 
 
FIG. S4. Infectivity determinants in the same molecule of L protein can not be separated. 
A. Mixture of two assembly-competent L-proteins still allows virus production. HuH-7 cells wrer transfected with a 
mixture of the genomic construct HBV L-, and helper constructs expressing wide-type L-protein (wt-L), or helper 
construct expressing mutant L protein devoid of myristoylation (G2A), the deleted putative fusion peptide (ΔTM1), 
points mutation at aa 11-12 (LG11/12 RE), a deletion within the essential binding site (Δ11-15), deletions Δ41-45 
and Δ71-75, or an equal mixture of two mutant helper as indicated. HBV-DNA specific Dot-blot of fractions of an 
analytical CsCl density gradient was obtained from supernatants of HuH-7 cells and calculated for the relative 
assembly compared to wide-type L-protein. N.D., not determined. 
B. Infection of HepaRG-cells using concentrated virus preparation obtained from co-transfected HuH-7 cells as 
described in (A). HBsAg secreted between days 7-11 post-infection was determined (black bars).  
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FIG. S5. lipid-leakage assay of wild-type and mutant peptides 
A. Schematic illustration of the sequence of peptides used for the lipid-leakage assay. The letters in red indicate the 
amino acids that differ from the genotype D sequence. All the peptides are myristoylated (blue wave line) at the N-
terminus.  
B. 50µM of the various myristoylated peptides, a scrambled version of Myrcludex B (Scramblemyr), and a 
nonmyristoylated version of Myrcludex B (Myrcludex B Myr(-), all dissolved in Buffer A (5% Glycerol, 50mM KCl, 
and 12.5mM HEPES, 50% DMSO), were added to ~12mM liposome containing fluorescence dye (HPTS/DPX). 
The leakage was assayed by Fluoroskan Ascent FL (Thermo). The results are expressed as the percent of total lipid 
leakage that occurred when dodecylmaltoside was added to the liposomes. The control (no peptide) represents 
buffer A alone. 
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